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Over the past decade, microneedles of various geometries and materials have been 
developed as a minimally invasive alternative to painful hypodermic needles to deliver 
modern biotherapeutics such as proteins, peptides, DNA, and vaccines.  Previously, 
several in-vitro and in-vivo animal studies have been conducted to show that 
microneedles increase skin permeability to a wide range of macromolecules and 
hydrophilic molecules which cannot cross the skin using conventional transdermal 
patches.  However, only a limited number of studies have been performed to study 
microneedle-based drug delivery in human subjects.  Since the ultimate clinical 
application of microneedles cannot be realized until it is studied in human subjects, this 
thesis performed some of the first-in-humans microneedle studies to understand the 
applications of microneedle treatment in human subjects. 
This first aim of this thesis sought to characterize the skin repair responses to 
microneedle insertion by determining the microneedle and skin condition parameters that 
affect the duration of enhanced skin permeability using impedance spectroscopy.  The 
study demonstrated for the first time that skin occlusion significantly slowed down skin 
barrier recovery following microneedle treatment; however, the skin barrier rapidly 
resealed in the absence of occlusion.  This was because skin occlusion blocked the 
transdermal water gradient within the SC, which is the key signal necessary to facilitate 
skin barrier repair.  The study also revealed that microneedle geometry played a 
significant role in the skin resealing process in the presence of occlusion such that skin 
treated with longer, increased number, and larger cross-sectional area needles recovered 
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more slowly under the effect of occlusion.  Further, analysis of pain scores revealed that 
increasing the number of needles and needle cross-sectional area led to slower barrier 
recovery without significantly affecting pain.  This study also led to the development and 
validation of a pharmacokinetic model to predict transdermal drug delivery in-vivo using 
skin impedance measurements as the input without any fitted parameters.   
The second part of this thesis studied the effect of microneedle insertion and 
infusion parameters on the flow conductivity of skin.  The study showed for the first time 
that microneedle-based delivery within the dermis typically led to a decrease in flow 
conductivity with increasing fluid volume in-vivo.  This was due to fluid flow against the 
dense fibers within the dermis and also due to further compaction of this dense structure 
through compression at the needle tip.  Microneedle retraction, lower infusion flowrates, 
and the addition of hyaluronidase helped reduce the skin’s resistance to flow.  Further, 
analysis of pain scores during infusion demonstrated that microneedles can be used to 
deliver up to 800 µl of fluid at moderate to high flow rates with significantly less pain 
than hypodermic needle insertion.  Delivery of 1 mL of fluid can be attained with less 
pain than hypodermic needles at either low flow rates, shallow depths, or through the 
addition of hyaluronidase.       
The third aim of this thesis studied the efficacy of microneedles for systemic drug 
delivery effects by delivering insulin to Type 1 diabetes subjects and comparing results to 
a subcutaneous catheter control.  This study was carried out in three steps.  The study first 
determined the optimum microneedle insertion depth for effective insulin delivery by 
inserting microneedles to different depths within the skin ranging from 1 mm to 5 mm.  
The 1 mm depth led to the fastest insulin absorption and was then used to determine if 
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intradermal microneedle-based insulin delivery can be used to reduce postprandial 
glucose levels by delivering a bolus of insulin prior to consumption of a standardized 
meal.  Upon determining that insulin delivery at 1 mm was effective in reducing glucose 
levels, a more in-depth study involving additional subjects was performed at a depth of 
900 µm.  This phase of the study demonstrated that intradermal insulin delivery led to 
faster pharmacokinetics with higher peak insulin concentrations and faster times to reach 
these peaks while causing tighter glycaemic control.  This was due to the rapid absorption 
of insulin as a result of the microneedles targeting the rich capillary network of the 
papillary dermis.  The study also showed that microneedles caused less pain and irritation 
than catheters and were preferred by all study subjects.   
The last aim of this thesis studied the efficacy of microneedles for delivery of 
local therapeutics by delivering lidocaine for local anesthesia.  Lidocaine was delivered 
to the volar forearm skin and the back of the hand of healthy adult subjects to compare 
the pain and efficacy of microneedle injection with that of traditional hypodermic needle 
injection.  The study results were the first to demonstrate that microneedle-based 
lidocaine delivery was less painful than and as effective as hypodermic needles in terms 
of anesthesia onset time, area and depth of analgesia, and lack of pain associated with an 
intravenous catheter insertion.  Further, greater than 77% of the subjects preferred 
microneedle treatment over hypodermic needles and greater than 82% of the subjects 
considered microneedles to be not painful.   
Overall, these results are among the first to demonstrate the clinical application of 





provides key results necessary to facilitate the transfer of microneedles from the 
laboratory to clinical practice. 
 
 
CHAPTER 1: INTRODUCTION 
 
Drugs are conventionally delivered to the body either orally via pills or by means 
of injections using hypodermic needles.  While these methods have historically been 
effective, they each have their own advantages and limitations.  Oral delivery is painless, 
however, many modern therapeutics such as proteins, peptides, and DNA based 
compounds cannot be delivered orally as they lose their activity either by enzymatic 
degradation in the gastrointestinal tract (GI) or by first-pass effects of the liver or they are 
poorly absorbed across the intestinal epithelium leading to low bioavailability (Swarbrick 
and Boylan 2002).  These modern drugs are therefore delivered by means of injections 
using hypodermic needles which can effectively deliver drugs without losing activity.  
However, hypodermic needles require administration expertise and are often painful and 
cause fear and anxiety among many people leading to poor patient compliance (Hamilton 
1995; Nir, Paz et al. 2003; Deacon and Abramowitz 2006).  Further, hypodermic needles 
are generally used to deliver a large bolus of drug to the body and do not allow for 
sustained drug delivery.   
Transdermal drug delivery, which refers to the penetration of drugs across the 
skin, is an attractive alternative to deliver these modern biotherapeutics, as it is painless, 
can be self-administered, avoids degradation in the GI tract and first-pass effects of the 
liver, and can allow for sustained drug delivery over extended periods of time (Prausnitz 
and Langer 2008).  Additionally, the large surface area of the skin makes it an appealing 
route for drug delivery (Prausnitz 2001).  Transdermal patches have been developed to 
deliver drugs across the skin; however they can only be applied to a limited number of 
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drugs that are small enough and lipophilic enough to permeate through outermost barrier 
layer of the skin at therapeutic rates.  Consequently, micron-dimension needles called 
microneedles, which are long enough to pass the skin’s barrier, but short enough to avoid 
stimulating nerve endings have been developed to increase skin permeability to large and 
hydrophilic molecules while minimizing pain.  
Over the past decade, microneedles of various materials, geometries, and delivery 
mechanisms have been developed (Prausnitz, Gill et al. 2008).  Several studies have been 
conducted in in-vitro skin models and in-vivo in animals to show that microneedles 
enhance skin permeability to a large number of drugs.  However, only a limited amount 
of research has been conducted in human subjects and several key questions regarding 
the safety, efficacy, and patient acceptance of microneedles in clinical applications still 
remain to be answered.  An ideal microneedle drug delivery system would be one that: i) 
is safe by maintaining skin permeability only during the desired period of drug delivery, 
ii) can create sustained or bolus delivery profiles, iii) can deliver therapeutic 
volumes/doses of drug quickly with minimal discomfort, iv) has rapidly responsive 
pharmacokinetics and pharmacodynamics, v) causes minimal pain and irritation, and vi) 
is simple, inexpensive, and well-accepted by patients.  This thesis seeks to answer some 
of the questions pertaining to the safety, efficacy, and usability of microneedles for 
clinical applications in human subjects. 
Therefore, the objective of this thesis was to perform the first-in-humans 
microneedle studies to: a) characterize skin repair responses to solid microneedle 
insertion to determine the extent of increased skin permeability coupled with predictions 
of pharmacokinetics of drug delivered through premeabilized skin, b) determine the 
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effect of hollow microneedle-based infusion parameters on flow conductivity of skin and 
pain and thereby identify barriers to fluid flow into the skin from hollow microneedles, c) 
assess the safety and efficacy of systemic therapeutic effects through measurement of 
pharmacokinetic parameters, pain, irritation, and user preference for microneedle-based 
insulin delivery in type 1 diabetes subjects, and d) assess the safety and efficacy of local 




CHAPTER 2: BACKGROUND 
 
2.1. Skin Anatomy 
Human skin is a complex, multilayered tissue that serves the function of 
preventing water loss from the body and protecting the body against microorganisms and 
other exogenous materials by acting as a permeability barrier to the environment 
(Schaefer and Redelmeier 1996).  The skin is the largest functional organ in the body and 
its structure can be categorized into four main layers: the stratum corneum (SC), the 
viable epidermis (the stratum corneum and viable epidermis together make up the 
epidermis), the dermis, and the hypodermis (or subcutaneous fat layer) (Williams 2003).   
 
Figure 2.1: Structure of human skin (http://en.wikipedia.org/wiki/Skin). 
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The outermost superficial layer of the skin is called the stratum corneum (SC) and 
is between 10-20 μm thick.  Although the SC is the thinnest layer of the skin, it is this 
outermost layer that forms the main skin barrier and is responsible for preventing 
molecules from entering and leaving the body through the skin.  The stratum corneum is 
a thin two-compartment membrane consisting of dead, polyhedral, keratinized cells 
without any nuclei called corneocytes embedded in a lipid matrix.  The corneocytes are 
approximately 40 µm in diameter and 0.5 µm thick (Schaefer and Redelmeier 1996).  The 
intercellular lipid matrix consists of ceramides, free fatty acids, cholesterol, and 
cholesterol sulphate and is the only continuous medium in the stratum corneum.  The 
most important feature of these lipids is that they are structured into ordered lipid bilayers 
(Guy and Hadgraft 2003).  In fact, the SC is commonly described as a “brick and mortar” 
model in which 15-20 corneocyte layers are embedded in a mortar of more than 100 lipid 
bilayers (Williams 2003).  The corneocytes disrupt the continuous intercellular lipid 
phase and create a tortuous diffusional pathway by increasing the intercellular path length 
by 50 to 100 fold (Schaefer and Redelmeier 1996).  It is this unique ordered organization 
of the hydrophilic keratin cells within the hydrophobic, lipid environment that makes the 
stratum corneum an extremely efficient biological barrier to foreign molecules, including 
drugs delivered via transdermal delivery systems.  The stratum corneum has an acidic pH 
which helps provide antimicrobial resistance  and in addition to proteins (70% - alpha and 
beta keratin) and lipids (15%), it also contains water (15%) (Fluhr and Elias 2002). 
Below the stratum corneum lies the viable epidermis which has a thickness 
ranging between 50 and 100 μm.  The stratum corneum and the viable epidermis together 
form the epidermis.  The epidermis consists of 70% water and keratinizing epithelial cells 
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responsible for synthesis of the SC.  The epidermis does not contain any blood vessels 
and hence molecules permeating across the epidermis must cross the dermal-epidermal 
layer to enter the body’s systemic circulation.  Melanocytes, Langerhans cells, and 
Merkel cells are also present in this layer (Williams 2003).   
Directly below the epidermis lies a thicker region called the dermis.  The dermis 
is a non-homogeneous, anisotropic, viscoelastic layer (Grebenyuk 1994).  This thick layer 
(1 - 2 mm) forms the bulk of the skin and consists of a vast network of fibrous, 
filamentous, and amorphous connective tissue.  The dermis can be sub-divided into two 
layers: the superficial papillary dermis where collagen fibers are packed in thin bundles 
the deeper, thicker, and denser reticular dermis formed by an entangled mass of collagen 
bundles (Irion 2002).  The papillary dermis is highly vascularized and consists of a rich 
bed of blood capillaries and lymphatic vessels which are found immediately below the 
epidermis (Monteiro-Riviere 1991; Pettis, Harvey et al. 2002).  The reticular dermis is 
relatively less vascularized.  The overall vasculature nature of the dermis offers a rich 
blood flow of approximately 0.05 mL/min/mg which is effective for the removal of 
molecules (including drugs) that have passed the outer layers of the skin, allowing for 
transport of drug molecules from the dermal-epidermal layer to the systemic circulation 
(Williams 2003).  The lymphatic system also reaches the dermal-epidermal layers and 
can also help remove drug molecules that have passed the upper skin layers (Pettis, 







Figure 2.2: Vasculature network in the skin (modified from Gray’s Anatomy of the 
Human Body, Fig 942: http://www.bartleby.com/107/234.html). 
The connective tissue in the dermis is primarily made up collagenous fibers which 
form a scaffold running through the dermis.  Elastic connective tissue is also present and 
provides elasticity for the shape of the skin and is also associated with hair follicles and 
vascular networks (Schaefer and Redelmeier 1996).  Several proteins such as elastin and 
fibrillin are associated with these fibers.  All these structures prevent tissue failure by 
withstanding deformation and dissipating energy.  As mentioned previously, the skin is 
viscoelastic in nature.  This is predominantly due to the dermis.  The typical stress-strain 
curve for human skin represents a biphasic response that consists of linear low- and high- 
strain regions (Seehra and Silver 2006).  In the low strain region, the skin behaves 
elastically and this behaviour is dominated by elastic fibers which act to recover small 
strains in the dense collagen network.  In the high-strain region, as the tissue is strained, 
the collagen fibrils become aligned and absorb and store the strain energy.  The high-
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strain response includes a viscous component associated with energy dissipation of the 
applied load through viscous sliding of collagen fibrils in the extracellular matrix (Seehra 
and Silver 2006).  The elastic component is due to the axial stretching of the collagen 
structure (a triple helix) and energy storage, which is important in ensuring shape 
recovery after skin deformation (Seehra and Silver 2006).    
Proteoglycans (PG), which are large brush-shaped macromolecules that are 
constructed of carbohydrates that are often sulfated, known as glycosaminoglycans 
(GAGs) attached to a protein core are also present in the dermis.  These structures bind 
up to 1000 times their weight in water and are responsible for the water-retaining 
capacity of the dermis.  The collagen fibers and proteoglycans (including GAGs) in the 
dermis are responsible for the resistance of the dermis to fluid flow (Swartz and Fleury 
2007).  All these connective tissue structures in the dermis determine the tensile strength 
and elasticity of the skin and provide physical support for the extensive nerve and 
vascular networks in the skin.  Fibroblasts, endothelial cells, mast cells, and sensory 
nerve endings are also present in this layer (Schaefer and Redelmeier 1996). 
The hypodermis lies beneath the dermis and is made up of a network of 
adipocytes.  The hypodermis typically has a thickness on the order of a few millimeters 
and plays an important role in energy storage and metabolism and also provides 
insulation and protection from injury.  The hypodermis also contains an extensive 
circulatory network (Schaefer and Redelmeier 1996) as well as nerve fibers.  
2.2. Skin Repair 
As indicated above, the SC contains about 15% water, while the underlying 
epidermis contains 70% water leading to a water gradient across the stratum corneum 
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from 70% at the deepest SC layers to ambient humidity at the outer surface of the SC 
(Wertz and Michniak 2004).  Although the SC is an excellent water barrier, it is not 
entirely impermeable and under normal conditions water from the deeper hydrated skin 
layers diffuses at a slow rate through the SC and evaporates at the surface.  This outward 
diffusion of water through the skin is called transepidermal water loss (TEWL) (Levin 
and Maibach 2005).  Any breach in the stratum corneum barrier leads to a significant 
increase in TEWL as the water now diffuses through the barrier perturbation instead of 
following the tortuous SC intracellular pathway (Figure 2.3).  This increased TEWL flux 
is the main signal for recovery of the SC barrier structure and function (Grubauer, Elias et 
al. 1989).           
 
Figure 2.3: TEWL across intact skin is slow and requires diffusion across the 
tortuous intercellular pathway.  A breach in the stratum corneum increases TEWL 
(modified from http://www.pg.com/science/skincare/Skin_tws_toc.htm). 
Upon disruption of the stratum corneum barrier, the TEWL rises and triggers 
barrier recovery.  The first step in the skin repair response is the rapid secretion of 
organelles called lamellar bodies which are rich in polar lipids and catabolic enzymes.  
These epidermal lamellar bodies serve as carriers of precursors of the stratum corneum 
lipids.  The increased lamellar body secretion leads to an upregulation of skin lipid 
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enzymes leading to increased synthesis of the SC lipids (cholesterol, ceramides, and fatty 
acids) from the lamellar body polar lipids.  The re-accumulated lipids are then organized 
into ordered lipid bilayers, thereby restoring the SC barrier function (Elias and Feingold 
2006).  The skin repair process continues with a burst in DNA synthesis which is also 
necessary for normalizing the skin barrier function (Proksch, Feingold et al. 1991).  The 
degree of lipid and DNA synthesis depends on the degree of barrier perturbation (i.e: 
greater the damage, greater the synthesis).  
2.2.1. Effect of Occlusion  
 Occlusion refers to covering of the skin by a membrane that is impermeable to air 
or moisture.  As described above, disruption of the SC barrier leads to an increase in 
TEWL.  However, if an occlusive membrane is placed on the damaged skin surface, then 
the membrane acts as an artificial barrier and the recovery of the SC is retarded as the 
TEWL signal for barrier recovery is blocked.  This consequently hinders lamellar body 
secretion and lipid and DNA synthesis (Grubauer, Elias et al. 1989; Proksch, Feingold et 
al. 1991; Menon, Feingold et al. 1992).  Further, the decrease in transepidermal water 
loss leads to an increase in SC hydration, thereby swelling the corneocytes, promoting 
uptake of water into the intercellular lipid domains and subsequently disrupting lipid 
order (Warner, Boissy et al. 1999).  The swollen corneocytes expand until they 
interconnect forming a continuous pore pathway which can enhance skin permeability 
(Elias, Tsai et al. 2002).         
2.3. Transdermal Drug Delivery Systems 
Since the approval of the first transdermal drug delivery patch system 30 years 
ago, transdermal delivery has proven to be a successful and painless delivery route for 
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local and systemic drug effects.  However, today, there are only a handful of such 
conventional transdermal patch systems available on the market.  This is because 
transdermal patches require drug molecules to pass through the stratum corneum barrier 
by passively diffusing through the tortuous intercellular lipid pathway between the SC 
corneocytes before entering the body.  This pathway, however, only allows drugs with 
low molecular mass (<500 Da), high lipophilicity (oil soluble), and small dosage 
requirements (daily dose ≤ 20 mg) to permeate through the SC barrier (Finnin and 
Morgan 1999; Prausnitz, Mitragotri et al. 2004).  Therefore, there is a need for 
transdermal delivery systems that have the ability to increase skin permeability to macro 
and hydrophilic molecules.  Consequently, several chemical and physical methods have 
been developed to increase skin permeability by reversibly disrupting or reorganizing the 
stratum corneum structure to allow for increased transport of large molecules across the 
skin in an effective and minimally invasive manner. 
  Chemical enhancers use surfactants, fatty acids, water, or solvents to increase 
skin permeability (Barry 2001; Williams and Barry 2004).  These enhancers work by 
disrupting the bilayer structure of the SC by either increasing hydration of the 
intracellular keratin, inserting amphiphilic molecules into the layers to disrupt the ordered 
molecular packing or by extracting intracellular lipids to created nano-scale defects in the 
stratum corneum (Prausnitz and Langer 2008).   
A physical method of enhancing the rate of transdermal drug delivery is 
iontophoresis.  Iontophoresis uses an electric field to move charged or uncharged 
molecules across the skin by electrophoresis, electro-osmosis, or transiently increased 
skin permeability.  This process has the ability to increase transdermal delivery rates for 
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large and hydrophilic molecules in a minimally invasive manner (Nair, Pillai et al. 1999; 
Pillai, Nair et al. 1999; Prausnitz, Mitragotri et al. 2004).  Another physical method of 
increasing skin permeability is electroporation which applies short, high voltage pulses to 
create nanometer sized disruptions in the skin allowing hydrophilic and macromolecules 
to permeate the skin (Prausnitz, Edelman et al. 1995; Prausnitz 2001).  Application of 
low frequency ultrasound by means of a process called sonophoresis has also been found 
to premeabilize skin to a large number of drugs due to cavitation and formation of 
acoustic micro-jets that impact the stratum corneum and disrupt the lipid bilayers 
(Mitragotri and Kost 2000; Prausnitz, Mitragotri et al. 2004).  Thermal ablation, whereby 
micron-sized holes are generated in the skin by the application of electrical energy which 
is converted to thermal energy has also demonstrated increased skin permeability to a 
number of large molecules (Smith and Tomlinson 2008).  Application of a high-
frequency alternating current through densely spaced micro-electrodes placed on the skin 
surface also create permeable micro-channels in the skin by means of radiofrequency 
ablation (Banga 1998; Banga 2009).  A mechanical method of increasing skin 
permeability includes micro-dermabrasion which uses a stream of fine aluminum-oxide 
crystals to disrupt and remove the stratum corneum (Barry 2001).  Jet injectors are 
another mechanical system which puncture the skin without the use of needles by firing 
liquid or solid particles across the skin at a very high velocity (Arora, Prausnitz et al. 
2008).  This system allows large quantities of drugs to be administered rapidly without 
depending on diffusion across the SC.   
While all of these methods overcome the limitation of conventional transdermal 
patches by breaching the skin’s barrier to allow for increased permeability to 
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macromolecules, each of them has its own limitations which hinder its clinical 
application.  Chemical enhancers, although painless to apply are known to cause skin 
irritation and skin toxicity (Prausnitz, Mitragotri et al. 2004) leading to safety concerns.  
Electrical transdermal delivery devices are minimally invasive, however, they all require 
a power source which makes the device cumbersome, bulky and expensive (Prausnitz, 
Gill et al. 2008).  Further, most of these devices require special training to administer  
and poorly designed iontophoresis systems have been known to cause skin irritation and 
burns (Houck and Sethna 2005; Zempsky 2008).  Further, while these systems reversibly 
disrupt the stratum corneum barrier and increase permeability, in some cases, the barrier 
typically takes on the order of several hours or days to recover, thereby creating risk for 
entry of unwanted foreign molecules into the body long after drug delivery has been 
completed (Farinha, Kellogg et al. 2006).  Micro-dermabrasion also employs an 
expensive bulky device and needs to be performed carefully as excessive abrasion may 
damage the skin.  Jet injectors can allow for bolus delivery of large drug doses, however 
the high drug velocity can cause pain and bruising and the device cannot be used for 
sustained drug delivery (Bremseth and Pass 2001).  
 Therefore, there remains a need for an ideal transdermal drug delivery system that 
a) is safe by maintaining skin permeability only during the desired period of drug 
delivery, b) can create sustained or bolus delivery profiles, c) can deliver therapeutic 
volumes/doses of drug quickly with minimal discomfort, d) has rapidly responsive 
pharmacokinetics and pharmacodynamics, e) causes minimal pain and irritation, and f) is 
simple, inexpensive, and self-administrable.  
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Consequently, micron dimension needles called microneedles have been 
developed to reversibly increase skin permeability by creating micron-sized channels in 
the skin allowing for increased transdermal drug transport of small and large drug 
molecules in a minimally invasive manner (Prausnitz 2004).  These microneedles are 
long enough to breach the skin’s barrier to allow for drug transport, yet are short enough 
to avoid stimulating the nerves, thereby reducing pain.  Additionally, microneedles do not 
require any power supply and are relatively simple to use.   
2.4. Microneedles   
 The concept of microneedles was first proposed in the 1970s (Gerstel and Place 
1976) to provide a minimally invasive route for transporting drugs into the skin by 
combining the benefits of hypodermic needle injections and transdermal patches while 
eliminating the shortcomings associated with both techniques.  However, this concept 
was not realized in practice until more recently when the microelectronics industry 
provided the micro-electronic mechanical system (MEMS) tools required to make 
structures of micron sized dimensions (Prausnitz 2004).  Microneedles are typically 
hundreds of microns long, 1 to 50 μm wide at the tip, and approximately 50 - 300 μm at 
the base.   They can be solid or hollow and can be fabricated as single needles or multi-
needle arrays (Figure 2.4) (Prausnitz 2005).   
 Over the past decade, microneedles of various geometries and materials have been 
developed.  Depending on the microneedle design, microneedles can be applied by four 
different delivery strategies (Prausnitz, Gill et al. 2008):  
a) “Poke and patch” – this was the first microneedle concept to be developed and 
involves inserting (poking) an array of solid microneedles into the skin to create 
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transport pathways followed by the application of a drug loaded transdermal patch 
over the channels.  The creation of these micron-dimension channels enhances 
delivery of large and hydrophilic molecules which would not be able to traverse an 
intact SC barrier via passive diffusion. 
b) “Poke and flow” – this method is analogous to hypodermic delivery, however, instead 
of inserting needles deep into the subcutaneous or intramuscular region, this method 
uses hollow microneedles to deliver liquid drug formulations to the dermal capillaries 
via pressure driven convection. 
c) “Coat and poke” – this method involves coating drug molecules onto the 
microneedles.  The coated needles are inserted into the skin and the drug coating is 
dissolved off the needles into the skin. 
d) “Poke and release” – this delivery method involves fabrication of biodegradable 
polymer microneedle structures with drug encapsulated inside the needle.  The 
needles are then inserted into the skin and the polymer either degrades or dissolves, 
releasing the encapsulated drug into the skin.  This technique generates no 
biohazardous sharp waste allowing for elimination of contamination due to needle-
sticks and potential needle reuse.  Depending on the type of polymer used, the 




Figure 2.4: Solid Microneedles: a) solid silicon microneedles (150 µm tall) (Henry, 
McAllister et al. 1998); b) solid microneedles of a microprojection array (300 µm 
tall) etched from a titanium sheet (Matriano, Cormier et al. 2002); c) solid 
microneedles of a microenhancer array (200 µm tall) etched from a silicon wafer 
(Mikszta, Alarcon et al. 2002); d) stainless steel microneedle coated with Vitamin B2 
(750 µm tall) (Gill 2007).  Hollow Microneedles: e) in-plane hollow single needle with 
multiple ports (30 µm2 ports) (Brazzle, Mohanty et al. 1999); f) Hollow silicon 
microneedles (200 µm tall) (Stoeber and Liepmann 2000b); g) Hollow metal 
microneedles (500 µm tall) (Davis, Prausnitz et al. 2003); h) Hollow silicon 
microneedles (350 µm tall) (Gardeniers, Luttge et al. 2003).  Polymer Microneedles: 
i) solid polyglycolic acid (PGA) biodegradable microneedles (600 µm tall) (Park, 
Allen et al. 2005); j) array of polyvinyl pyrrolidone (PVP) microneedles (750 µm 
tall) encapsulated with sulforhodamine (Sullivan, Murthy et al. 2008); k) array of 
200 poly-lactide-co-glycolide (PLGA) microneedles (Park, Allen et al. 2006); l) 
bevel-tip PLGA microneedles (600 µm) encapsulating calcein within their tips 




2.4.1. In-Vitro Microneedle Delivery 
 The initial microneedle studies were carried out in-vitro in animal and human 
cadaver models.  The first studies to determine that microneedles can be used to increase 
skin permeability of macromolecules were carried out using solid silicon microneedles by 
Henry et al. (Henry, McAllister et al. 1998) and McAllister et al. (McAllister, Wang et al. 
2003).  Using the poke and patch approach they showed that microneedles increased the 
permeability of human cadaver skin to calcein, insulin, bovine serum, albumin, and latex 
nanospheres as large as 10 nm in diameter by several orders of magnitude, in some cases 
as high as 10,000-fold.  Other studies using the same approach have also been carried out 
to show increased permeability of human skin in-vitro to lipid-polycation plasmid DNA 
using silicon microneedles (Chabri, Bouris et al. 2004) and to BSA and calcein using 
polyglycolic acid (PGA) polymer needles (Park, Allen et al. 2005).  Increased 
permeability of rat skin to calcein was demonstrated using silicon microneedles (Teo, 
Shearwood et al. 2005).  Polycarbonate microneedles were also used to deliver calcein to 
rat cadaver skin and results showed that longer needles and increased needle density led 
to increased permeability (Oh, Park et al. 2008). 
Hollow microneedles of various lengths ranging from 600 to 800 µm have been 
studied to demonstrate the distribution of calcein and fluorescently labeled insulin within 
the epidermis and dermis in-vitro in hairless rat skin (Wang, Cornwell et al. 2006).  
Further, 200 µm long hollow microneedles have been shown to deliverer blue ink and 
fluorescent lucifer yellow dye to a depth of 100 µm under the skin (~ dermal-epidermal 
junction) of chicken thigh (Stoeber and Liepmann 2000a; Stoeber and Liepmann 2000b).  
Hollow microneedles have also been inserted into human cadaver sclera to deliver 
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nanoparticles on the order of 280 nm (Jiang, Moore et al. 2009).  Hollow microneedle 
studies in human cadaver tissues have demonstrated that the primary resistance to fluid 
flow to skin via microneedles resides within the skin and not the microneedles.  These 
studies have shown than insertion of hollow microneedles into the skin or sclera followed 
by retraction leads to an increase in fluid flow into tissue as microneedle insertion causes 
tissue compaction while retraction allows the skin to recoil to its original state (Wang, 
Cornwell et al. 2006; Martanto, Moore et al. 2006a; Jiang, Moore et al. 2009).    Further, 
addition of drug spreading enzymes such as hyaluronidase to the drug formulation has 
also demonstrated an increase in fluid flow into tissue through hollow microneedles 
(Martanto, Moore et al. 2006a; Jiang, Moore et al. 2009). 
Coated microneedles have also been studied in human cadaver sclera to show 
rapid delivery of sulforhodamine and BSA in less than 30 seconds (Jiang, Gill et al. 
2007).  Further, insertion of microneedles coated with vitamin B, calcein, and 1 µm 
barium-sulfate microparticles into porcine cadaver skin has shown rapid dissolution of 
the drug from the needle into the dermis within a matter of seconds (Gill and Prausnitz 
2007).  A variation of the coat and poke method whereby the needle base substrate is 
coated with drug matrix instead of the needles themselves has demonstrated controlled 
delivery of calcein and BSA from a chitosan coated substrate reservoir in rat skin (Xie, 
Xu et al. 2005). 
Poly-lactide-co-glycolide (PLGA) microneedles (750 µm long) using the poke 
and release approach have been shown to deliver calcein just below the dermal-epidermal 
junction in a controlled release manner to human cadaver skin (Park, Allen et al. 2006).  
Depending on the encapsulation formulation, these needles could control delivery times 
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ranging from hours to months.  Further, carboxymethylcellulose (CMC) microneedles 
demonstrated delivery of sulforhodamine to porcine dermis in both a bolus release 
(minutes) and sustained release (hours) manner by encapsulating just the needles and 
both the needles and substrate with the model drug respectively (Lee, Park et al. 2008).  
Polyvinylpyrrolidone (PVP) microneedles have also shown to rapidly deliver BSA into 
porcine cadaver skin on the order of a minute whereas PVP copolymerized with 
methacrylic acid can lead to slow delivery over a couple of hours (Sullivan, Murthy et al. 
2008).   
2.4.2. In-Vivo Microneedle Delivery 
2.4.2.1. Animals 
Over the past decade, microneedles have been studied extensively in-vivo in 
animals for delivery of peptides, proteins, genetic material, and vaccines among many 
other molecules.  Solid microneedles have been used to deliver peptides like insulin to 
diabetic hairless rats by inserting a microneedle array into the rat skin at a high velocity 
followed by deposition of a solution of insulin on top of the array.  Delivery over a period 
of four hours caused blood glucose levels to drop as much as 80% (Martanto, Davis et al. 
2004).  Hollow microneedles have also shown reduction in plasma glucose levels during 
basal insulin delivery in rats using silicon and glass microneedles (Gardeniers, Luttge et 
al. 2003; McAllister, Wang et al. 2003; Wang, Cornwell et al. 2006; Nordquist, Roxhed 
et al. 2007). Rapidly dissolving dextrin-based insulin loaded microneedles also led to a 
reduction in blood glucose levels in mice (Ito, Hagiwara et al. 2006).  The same dextrin 
microneedles have been used to deliver proteins such as erythropoietin, in mice and a 
polysaccharide drug, viz. low molecular weight heparin in rats (Ito, Yoshimitsu et al. 
19 
 
2006; Ito, Murakami et al. 2008).  Self dissolving chondroitin sulfate microneedles 
encapsulated with insulin have also been shown to reduce blood glucose levels in dogs 
(Ito, Ohashi et al. 2008).  CMC microneedles too have demonstrated successful delivery 
of peptides through administration of human growth hormone to rats (data not published).  
Further, peptide delivery was accomplished via desmopressin-coated microneedles which 
were inserted into hairless guinea pig skin and showed bioavailability as high as 85% 
(Cormier, Johnson et al. 2004).   
Small molecules such as diclofenac and pilocarpine have been delivered via 
hollow microneedles to rat skin (Gardeniers, Luttge et al. 2003) and through coated 
microneedles to rabbit eyes, respectively (Jiang, Gill et al. 2007).  Lin et al. (Lin, Cormier 
et al. 2001) successfully delivered genetic material (oligonucleotides) in hairless guinea 
pigs by poking the skin with solid microneedles followed by covering the skin with an 
oligonucleotide loaded gel. 
Microneedles have also been used for vaccination in animals and have shown 
dose-sparing of vaccine and an immune response that is at least as good as conventional 
intramuscular or subcutaneous vaccination.  This is because microneedles target the 
highly immunogenic dendritic cells in the dermis and epidermis.  Studies have 
demonstrated solid microneedle-based delivery of vaccines against hepatitis B, anthrax, 
and Japanese encephalitis in animals leading to a strong immune response (Mikszta, 
Alarcon et al. 2002; Dean, Alarcon et al. 2005; Mikszta, Dekker et al. 2006).  
Microneedles coated with ovalbumin, a model antigen also led to strong immune 
response and suggested dose-sparing in hairless guinea pigs (Matriano, Cormier et al. 
2002; Widera, Johnson et al. 2006).  More recently, microneedles coated with different 
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strains of inactivated influenza virus demonstrated complete protection of mice against 
the virus (Koutsonanos, del Pilar Martin et al. 2009; Zhu, Zarnitsyn et al. 2009).  Hollow 
microneedles also showed dose-sparing and strong immune response in rats using three 
different types of influenza vaccines (Alarcon, Hartley et al. 2007).  These hollow 
needles were also used to vaccinate mice and rabbits against anthrax and non-human 
primates against Japanese encephalitis respectively (Dean, Alarcon et al. 2005; Mikszta, 
Sullivan et al. 2005).        
In-vivo animal studies have also been carried out to demonstrate the increased 
permeability of skin after microneedle treatment as characterized by transepidermal water 
loss.  Solid microneedle treatment of hairless guinea pig skin showed that microneedles 
enhanced skin permeability over a 48 h time period (Banks, Gill et al. 2005). Further, in 
another study, treatment of skin with hollow microneedles showed that transepidermal 
water loss increased immediately after needle insertion, but then returned to normal 
within a few minutes (Gardeniers, Luttge et al. 2003).       
2.4.2.2. Humans 
 While extensive studies have been carried out using microneedles in living 
animals, only a few studies have been carried out in human subjects.  Coated 
microneedles developed by a company called Zosano Pharmaceuticals have been used to 
successfully deliver parathyroid hormone and desmopressin to human subjects 
(Padmanabhan, Phipps et al. 2008).  Hollow microneedles (200 µm long) have been used 
to deliver very small volumes (1 µL) of methyl nicotinate to human subjects.  More 
recently, 1.5 mm long hollow microneedles developed by Becton Dickinson have been 
used for influenza vaccination and led to a stronger immune response than intramuscular 
21 
 
injection in elderly subjects (Holland, Booy et al. 2008) and a comparable immune 
response in younger subjects (Beran, Ambrozaitis et al. 2009).  The same needles have 
also been used to deliver sterile saline to human subjects and confirmed fluid delivery in 
the dermis with less insertion pain than hypodermic needles (Laurent, Bonnet et al. 
2007).  Influenza vaccine delivery has also been carried out in human subjects by using 
arrays containing four hollow microneedles (450 µm long) developed by Nanopass (Van 
Damme, Oosterhuis-Kafeja et al. 2009).  Biodegradable, 500 µm long maltose 
microneedles encapsulated with ascorbate-2-glycoside have been inserted in the skin of 
human subjects and found to be dissolved in the epidermis and dermis within 5 min with 
no adverse skin reactions and without causing pain on insertion (Miyano, Tobinaga et al. 
2005).  Other studies have also evaluated pain associated with microneedle insertion.  
Kaushik et al., Gill et al., and Haq et al. demonstrated that pain caused by inserting solid 
microneedles into skin was significantly less than that of a conventional hypodermic 
needle (Kaushik, Hord et al. 2001; Gill, Denson et al. 2008; Haq, Smith et al. 2009).  Few 
studies have also been carried out in human subjects where transepidermal water loss was 
used to demonstrate that microneedle insertion leads to an increase in skin permeability 
(Mikszta, Alarcon et al. 2002; Bal, Caussin et al. 2008; Haq, Smith et al. 2009).  Lastly, 
microneedles have been used to extract interstitial fluid from the volar forearm skin of 
human subjects in a painless manner for the purpose of glucose monitoring (Wang, 
Cornwell et al. 2005).   
2.5. Skin Electrical Impedance 
Electrical impedance is the resistance of a material to the flow of an alternating 
current.  The skin’s electrical impedance is therefore defined as the skin’s opposition to 
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flow of alternating current.  Skin impedance is generally modeled as an equivalent circuit 
consisting of two parallel resistor/capacitors in series.  One parallel RC combination 
represents the stratum corneum, while the other represents the deeper tissue layers 
(Yamamoto and Yamamoto 1976a; Burnette and DeNuzzio 1997).  The skin’s 
capacitance is mainly due to the dielectric properties of the lipid-protein components of 
the epidermis while the skin’s resistance is associated primarily with the stratum corneum 
layer (Burnette and DeNuzzio 1997).  The high electrical resistance of the stratum 
corneum is attributed to the multilamellar structure of the lipids between the corenocytes 
(Pliquett and Prausnitz 2000).  In fact, the stratum corneum is the predominant 
contributor to the skin’s resistance (Yamamoto and Yamamoto 1976b).  Although the SC 
is in series with the viable epidermis and dermis, these deeper layers do not act as a 
barrier to electric current and their resistance is negligible (Yamamoto and Yamamoto 
1976a; Pliquett and Prausnitz 2000).  This has been demonstrated through studies which 
showed that removal or puncturing of the stratum corneum leads to a significant decrease 
in skin impedance, ultimately approaching a very low constant value beyond which 
further skin removal or puncturing does not affect resistance (Lawler, Davis et al. 1960; 
Edelberg 1971; Yamamoto and Yamamoto 1976a).  Studies have also demonstrated that 
the resistance in the SC is not homogenous; the resistance is highest in the uppermost 
layers of the SC and decreases as one moves lower into the stratum corneum (Burnette 
and DeNuzzio 1997).  As a result, skin electrical impedance is a good indicator of the 
skin barrier integrity.  Consequently, since skin permeability depends on the integrity of 
the stratum corneum, skin electrical impedance is a good indicator of skin permeability.  
In-vitro studies have shown that there is a strong linear relationship between skin 
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impedance and skin permeability, with a decrease in impedance corresponding to an 
increase in permeability (Karande, Jain et al. 2005).       
 Disruption of the SC barrier and/or an increase in skin hydration leads to a 
decrease in skin’s electrical impedance.  As described previously, any breach in the skin 
barrier leads to diffusion of water from the deeper skin layers across the stratum 
corneum, thereby increasing the water content of the SC.  Occlusion too increases the 
hydration of the SC.  This increased water content leads to an increase in the dielectric 
constant of the SC, allowing ions to move more freely, thereby reducing the skin’s 
resistance to current flow (Burnette and DeNuzzio 1997).  Additionally, the keratin 
protein chains in the SC have a dipole moment; therefore an increase in hydration causes 
the keratin to become more flexible and responsive to an electric field (Burnette and 
DeNuzzio 1997) ultimately leading to reduction in skin impedance. 
2.6. Single-Compartment Pharmacokinetic Model 
Compartmental analysis is used to determine what happens to a drug as a function 
of time once it has been delivered to the body. The primary assumption behind this type 
of analysis is that the human body can be divided into one or more compartments where 
the drug resides in a dynamic state for a period of time.  A compartment is a hypothetical 
space, bound by an unspecified membrane across which drugs are transferred and it is an 
open system where drug passes freely into and out of the system (Allen, Popovich et al. 
2005).  In-vivo absorption of drugs across the skin is generally modeled using single-
compartment pharmacokinetics (Roberts and Anissimov 2005). This model depicts the 
body as one compartment having a certain volume of distribution (Vd).  Vd is a theoretical 
volume in which the drug must be distributed to achieve the desired concentration of drug 
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measured in blood or plasma.  This volume of distribution is a constant that is determined 
by the drug properties as well as factors such as age and state of disease.  This model 
assumes that the drug is confined to the blood (or plasma) and then eliminated (Allen, 




Figure 2.5: Single-compartment pharmacokinetic system (Fisher and Peattie 2007). 
For transdermal systems, the drug is absorbed into the compartment at a certain 




a−=       (2.1) 
where ka is the absorption rate constant and A is the drug present at the absorption site 
which disappears with time and depends on the initial dose delivered and the volume of 




el=       (2.2) 
where kel is the elimination rate constant, E is the eliminated drug and C is the 
concentration of the drug in the body (compartment).  The drug concentration in the 




ela −=       (2.3) 
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These three differential equations define single-compartment pharmacokinetics and can 
be used to calculate pharmacokinetic parameters such as time to maximum concentration 
of drug in body, tmax; the peak drug concentration, Cmax, and the area under the 
plasma/blood concentration versus time curve, AUC, which represents the total amount 
of drug absorbed in the body.   
2.7. Diabetes and Insulin Delivery 
Diabetes Mellitus is the fourth leading cause of death by disease in the world.  
With an estimated 246 million current cases of diabetes worldwide and a forecasted 
increase to almost 380 million cases by 2025, it is becoming one of the most prevalent 
non-communicable diseases in the world (International Diabetes Foundation).  Diabetes 
if not managed effectively can be fatal.  Consequently, a significant amount of money is 
being spent to manage this disease.  It is estimated that the annual healthcare costs 
associated with treating and preventing diabetes and its complications worldwide were at 
least US$ 232 billion in 2007 (Diabetes Atlas – Economic Impacts).  Moreover, 
intangible costs such as reduced quality of life and reduced life expectancy are 
immeasurable and significant.   
Diabetes is a metabolic disease that affects how the body uses glucose (blood 
sugar).  Glucose is the main source of energy for the cells that make up muscles and other 
tissues.  Food is one of the major sources of glucose.  During digestion, sugar (glucose) is 
absorbed into the bloodstream.  In healthy patients, glucose then enters the cells with the 
help of insulin.  Insulin is a hormone secreted by the pancreas and acts as a key to unlock 
cells, allowing glucose to enter.  As glucose enters the cells, blood glucose levels drop 
and consequently insulin secretion from the pancreas also drops.  Diabetes can be 
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classified into two categories: type 1 diabetes, whereby the body’s own immune system 
attacks the pancreas making it lose its ability to produce insulin, and type 2 diabetes, 
which is caused by insulin resistance and subsequent insulin deficiency.  If the body does 
not produce/absorb enough insulin, the blood sugar levels continue to rise and can be 
fatal.  As a result, diabetes is generally characterized by a rise in blood glucose levels 
known as hyperglycaemia which is associated with long-term damage, dysfunction, and 
failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels 
(American Diabetes Association, 2003). 
      Type 1 diabetes affects 5-10% of all diabetes patients and is typically diagnosed in 
children and adolescents.  These patients are dependent on insulin and require daily 
delivery of external insulin in order to survive.  Diabetes management involves tight 
control of blood glucose levels as close as possible to levels found in normal subjects 
(between 80 – 120 mg/dL before a meal).  Since insulin cannot be administered orally 
due to degradation and loss of activity in the gastrointestinal tract, these patients self-
administer insulin subcutaneously several times a day using hypodermic needle in order 
to control blood glucose levels.  However, the kinetics of the injected insulin are far from 
the natural rise and fall of insulin levels within the body and hence, inaccurate dosing can 
often lead to hypo- or hyper-glycaemic conditions (Tyagi 2002).  In order to more closely 
mimic the natural insulin secretion behaviour, insulin pumps have been developed which 
allow for flow of insulin into the patient’s body at set basal rates throughout the day and 
bolus injections for meal time requirements using a subcutaneous catheter (Webb 2006).  
Although this method provides some time controlled release of insulin, the device is 
fairly bulky and inconvenient, and the insertion of subcutaneous catheters is quite painful 
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resulting in omission of insulin doses, anxiety, and poor patient compliance, especially 
among young patients which can lead to serious complications (Mollema, Snoek et al. 
2001; Hanas 2004).  Moreover, the pharmacokinetics of the insulin itself is far from 
ideal, as the rate of insulin absorption is slow and it takes several minutes before the drug 
begins to take effect.  As a result, patients have minimal flexibility in their meal-time 
lifestyle.   
Several insulin analogues have been developed to improve insulin 
pharmacokinetics; however, there still remains room for improved analogues that have 
improved pharmacokinetics and pharmacodynamics.  With regards to insulin delivery 
devices, jet injectors are currently available; however, they are associated with pain and 
are not commonly recommended, except for patients who fear needles or who have 
severe lipoatrophy (Cefalu 2004; Warrell, Cox et al. 2005).  Exubera, a form of inhalable 
insulin marketed by Pfizer was introduced in 2006 as the first insulin delivery route 
alternative to subcutaneous insulin since 1922.  However, it was withdrawn the following 
year as it had low bioavailability, high cost, a bulky design, and unknown health risks 
(Bailey and Barnett 2007; Barnett 2008).  Other methods such as buccal, nasal, oral, and 
other transdermal methods such as iontophoresis, thermal and radio-frequency ablation, 
and sonophoresis are still being studied, however with limited success (Cefalu 2004).   
Therefore, in order to improve diabetes management so as to increase patient 
compliance, reduce complications, and enhance quality of life for diabetes patients there 





2.8. Lidocaine Delivery 
  Lidocaine is an amino amide type local anesthetic commonly used in topical, 
infiltration, nerve block, ophthalmic, epidural, and intravenous (IV) regional anesthesia.  
By blocking the fast sodium channels in the cell membrane, lidocaine alters the 
depolarization in neurons.  With sufficient blockade, the ionic fluxes required for the 
initiation and conduction of impulses are inhibited and the cell membrane will not 
depolarize, thereby, not transmitting an action potential, leading to its anesthetic effects.  
Lidocaine is generally used in the form of lidocaine hydrochloride and is available in 
several forms such as injected local anesthetic, dermal patch, oral gel or liquid, and 
topical gel or liquid (Lidocaine Hydrochloride Package Insert, 2001).   
One of the most common applications of lidocaine is for regional anesthesia 
during needle insertion for venipuncture or intravenous cannulation, as this process can 
be painful, uncomfortable, and frightening, especially for children and can often lead to 
needle phobia (Lysakowski, Dumont et al. 2003; Migdal, Chudzynska-Pomianowska et 
al. 2005).  In a study performed by Cummings et al. (Cummings, Reid et al. 1996), 
placement of IV lines was ranked as the second highest source of worst pain in children 
only after disease-related pain.  Painless topical anesthetics such as eutectic mixture of 
local anesthetics (EMLA) have been shown to provide effective local anesthesia for 
venipuncture and intravenous catheterization, however, effective analgesia requires 
application of the topical formulation for 30 to 90 minutes prior to needle insertion, 
thereby limiting its usefulness in busy ambulatory health care settings (Lander, Hodgins 
et al. 1996; Eichenfield, Funk et al. 2002).  Consequently, physicians continue to use 
hypodermic needles to inject lidocaine prior to IV placement due to its rapid onset; 
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however, though quite rapid, this procedure is painful as compared to EMLA.  As a 
result, several alternative transdermal delivery systems are being studied for lidocaine 
delivery for local dermal anesthesia.  Needle free jet injectors have been used in clinical 
applications for pre IV placement treatment, however, the jet injection procedure itself is 
painful and the procedure has also been found to be cost prohibitive (Lysakowski, 
Dumont et al. 2003).  Lidocaine delivery using iontophoresis, sonoporation, and 
electroporation have been found to provide effective topical anesthesia of the skin and 
underlying tissue for pain free venipuncture and IV placement within 5-15 minutes of 
treatment in children (Zempsky, Anand et al. 1998; Wallace, Ridgeway et al. 2001; Katz, 
Shapiro et al. 2004).  Devices using these methods have been marketed, however, most of 
them have had poor patient/physician uptake and some have subsequently been 
withdrawn due to poor sales.  Just earlier this year, Zingo, a new lidocaine jet-injection 
system marketed by Anesiva was discontinued (Anesiva Annual Report, 2008) and 
previously a sonoporation device company, Sontra, also suffered poor sales.  
Iontophoresis devices such as LidoSite developed by Vyteris too have suffered poor 
market acceptance causing the company to de-emphasize its focus on iontophoresis based 
lidocaine delivery (Vyteris Annual Report, 2008).  This is presumably due to the cost, 
complexity, and slower onset of these systems in comparison to conventional hypodermic 
needle-based lidocaine delivery.  Therefore, there continues to remain a need for a 




CHAPTER 3: METHODS 
 
3.1. Microneedle Fabrication 
3.1.1. Solid Microneedles 
Solid microneedles were fabricated by laser cutting stainless steel sheets (Trinity 
Brand Industries, SS 304, 75 μm and 125 μm thick; McMaster-Carr, Atlanta, GA) using 
previously published methods (Martanto, Davis et al. 2004; Gill and Prausnitz 2007).  
The microneedles designs were first drawn according to their geometry specifications in 
AutoCAD (Autodesk, Cupertino, CA) and then cut in-plane using an infrared laser 
(Resonetics Maestro, Nashua, NH).  The arrays were then cleaned, bent out of plane at 90 
degrees, and electropolished as described previously (Gill and Prausnitz 2007) followed 
by sterilization in a steam autoclave (Steris Amsco Renaissance 3033 Prevac Steam 
Sterilizer; Steris Corporation, Mentor, OH).  The microneedle arrays had an overall 
footprint size of 12 mm by 12 mm.  Figure 3.1 shows an example of a solid microneedles 
used in this thesis.  
 
Figure 3.1: Solid stainless steel microneedles.  a) Brightfield micrograph of a 50 




3.1.2. Hollow Microneedles 
Hollow microneedles (Figure 3.2a) were fabricated by pulling fire-polished type I 
borosilicate glass pipettes (BF150-86-15, Sutter Instrument, Novato, CA) with a 
micropipette puller (P-97, Sutter Instrument).  Programmable puller parameters of Pull = 
40, Velocity = 10, Heat = 580, Time = 150, and P = 500 allowed reproducible production 
of microneedles with tip properties strong enough to insert into skin without breakage.  
The pulled needles were then beveled at a 30° angle using a beveler (BV-10 beveler, 
104D fine bevel plate, Sutter Instrument) producing hollow microneedles with an oval-
shaped opening.  Due to this oval shape, the effective radius of the needle opening was 
determined by averaging the lengths of the long and short axes of the needle tip opening.  
The effective tip radii of the microneedles used in this thesis were between 60 and 80 µm.  
The microneedles were then cleaned in an ultrasonic deionized water bath (SW-34, 
Sonicwise Ultrasonics, San Diego, CA) for 2 min by bubbling air through the needles 
dipped in water via an air filled syringe (10 mL, Becton Dickinson, Franklin Lakes, NJ) 
and tubing (2C5685, Baxter, Deerfield, IL) connected to the non-tip needle end.  The 
needles were placed in an autoclavable micropipette storage bell jar (World Precision 
Instruments, Sarasota, FL) and dried for 2 h in an oven at 180°C (VC-300, Grieve Corp., 
Round Lake, IL) followed by steam sterilization in an autoclave (Scientific Series 3021-




Figure 3.2: a) Hollow borosilicate glass microneedle, b) custom rotary microneedle 
insertion device. 
3.2. Hollow Microneedle Insertion Device 
To insert the hollow microneedles into the skin of human subjects safely and 
accurately, a custom rotary device was fabricated by modifying previously used designs 
(Wang, Cornwell et al. 2005).  As seen in Figure 3.2b, the device consisted of 4 parts 
positioned concentrically within each other so as to allow the glass microneedle to pass 
through.  The rectangular block (piece 1) allowed the user to hold and stabilize the device 
on the skin’s surface.  The ball-shaped end of piece 2 helped minimize skin deflection 
during microneedle insertion.  Only the microneedle length protruding beyond the 
convex-surface was inserted into skin.  Piece 3 was threaded into piece 2 and these parts 
together served as the depth-controlling structures.  The threads were calibrated such that 
each 360° turn of piece 3 moved the microneedle tip 800 µm in its axial direction.  
Graded markings on pieces 2 and 3 allowed the microneedle to be precisely “drilled” into 
33 
 
the skin at the desired depth with ±10 µm accuracy. The fourth and final piece served as a 
set-screw that helped keep the needle firmly within the device.  A rubber gasket (Pipette 
seal PS-15, Warner Instruments, Hamden, CT) was placed between pieces 1 and 2 to 
ensure the needle was secured tightly within the device.  The non-tip end of the needle 
extended beyond piece 1 and was connected to tubing.  The microneedle was inserted 
into skin at a 90° angle by placing the convex end of the device on the skin followed by 
carefully inserting the microneedle to the desired depth into the skin.   
3.3. Assessment of Pain 
All experiments in this thesis involved asking study subjects to assess the pain 
associated with microneedle insertion and fluid infusion. These pain scores were 
measured using a Visual Analog Scale (VAS) consisting of a 100 mm ruler with “No 
Pain” written on the left end and “Worst Imaginable Pain” on the right end.  There were 
no other markings visible to the subject.  In order to measure pain, subjects were asked to 
slide a marker along the ruler to correspond with his or her pain.  An un-blinded observer 
recorded the pain score in millimeters by reading a number corresponding to the marker 
position on the opposite side of the ruler. 
3.4. Resealing of Human Skin Barrier In-Vivo 
3.4.1. Study Subjects 
Ten healthy adult human subjects (3 female, 7 male, age: 24-52) with no history 
of dermatological disease were recruited to participate in this study.  Both the left and 
right volar forearms of all subjects were used in the study.  Subjects were asked to refrain 
from application of any topical formulations or soaps on their arms, as well as to avoid 
any vigorous physical activity or extreme temperature showers one day prior to and 
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throughout the duration of the experiment.  In order to obtain hourly skin impedance data 
over a period of 48 hours after treatment, subjects were divided into two groups of five 
individuals each.  The first group provided data for time points 1-11 and 23-35 h post 
treatment and the second group generated data for time-points 12-22 and 36-48 h post 
treatment.  Both groups also provided data for time-points -1, -0.5, and 0 (immediately 
after treatment) h. Subjects remained in the study room throughout each data collection 
period.   Prior to commencing skin impedance data collection on each study day, subjects 
were asked to rest in the controlled environment study room for 1 h in order to acclimate 
to the experimental conditions of 40% relative humidity and room temperature of 21oC.  
The study was approved by the Georgia Tech Institutional Review Board and all subjects 
provided informed consent prior to participation.  The experiments were conducted in 
accordance with the Declaration of Helsinki protocol.     
3.4.2. Experimental Design 
Five different solid microneedle geometries with varying microneedle length, 
number of needles, and base cross-sectional area were fabricated (Table 3.1). 
Table 3.1: Parameters of the five different microneedle geometries and two other 
experimental controls studied 
 
 








A 750 75 200 50 
B 750 75 200 10 
C 500 75 200 50 
D 1500 75 200 10 
E 750 125 500 50 
F Hypodermic Needle (26 Gauge) 








A total of 11 sites (left arm: 6 and right arm: 5) were identified on the volar 
forearms of all ten subjects and were outlined with a pen.  The six sites on the left arm 
received treatment with microneedles having geometries A, B, and C, three of which 
were occluded and the remaining three were non-occluded.  Of the five sites on the right 
arm, four received occlusive and non-occlusive treatments with microneedle geometries 
D and E.  At all sites, the microneedles were inserted into the skin manually by pressing 
the array into the skin for approximately 15-20 s using the thumb of a study investigator.  
The application took place such that the microneedles were inserted perpendicular to the 
surface of the skin.  In the occasional event that the microneedles did not successfully 
insert into the skin as characterized by high impedance measurements after insertion, the 
sites were then treated as no-treatment, negative control sites (G).   
The last site on the right arm received non-occlusive treatment using a 26-gauge 
hypodermic needle (treatment F) inserted 5 mm deep into the skin (Becton Dickinson, 
Franklin Lakes, NJ) and served as the positive control.  This site was studied only in the 
absence of occlusion, because hypodermic needle treated sites are traditionally left un-
occluded in clinical practice.  To control the insertion depth, the protective needle cap 
covering the hypodermic needle was cut such that only 5 mm of the hypodermic needle 
was protruding from the cap.   
The location and order of treatments on the marked skin sites were not 
randomized and remained consistent among all subjects.  Further, neither the 
investigators nor the subjects were blinded to the treatments and all personnel were aware 
of the treatment being administered and its corresponding location during the study.   The 
treatment sites were arranged such that the reference electrode was at the center of the 
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volar forearm surrounded by the sites with approximately 5 mm spacing between the 
reference and the treatment electrodes.  Figure 3.3 shows the experimental set-up on the 
left volar forearm of a subject.   
 
Figure 3.3: Experimental set-up of the left volar forearm of a human subject: a 
large, highly conductive, gelled reference electrode surrounded by dry Ag/AgCl 
measurement electrodes placed on treatment sites.  Impedance measurements were 
made by periodically connecting reference and measurement electrodes to an 
impedance meter by applying low frequency alternating current. 
3.4.3. Experimental Procedure 
Prior to commencing the study, all subjects were allowed to acclimate to the study 
environment conditions for a period of 1 h, after which the treatment sites were gently 
wiped with 70% isopropyl alcohol swabs (BD Alcohol Swabs; Becton Dickinson).  The 
experimental measurement procedure then commenced with a baseline pre-treatment skin 
impedance recording of the t = -1 h reading for all sites by placing the reference and 
treatment electrodes on their respective sites.  Each reading required approximately 30 s 
to obtain.  After data collection, the reference and non-occluded site electrodes were 
removed.  The occluded sites remained covered with the measurement electrode (25 mm 
x 25 mm); an occlusive tape (3M Blenderm Surgical Tape; 3M Healthcare, St. Paul, MN) 
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was added to further occlude the sites.  Pre-treatment skin impedance measurements were 
repeated 30 min later at t = -0.5 h.   
At t = 0 h, the occlusive coverings were removed and all sites were administered 
their respective treatments.  Subjects were asked to rate the pain they felt during insertion 
using the VAS pain scale.  Electrodes were immediately placed on the sites and 
impedance measurements were recorded (the occluded sites were covered again).  
Measurements were taken on the two subject groups to generate impedance data up to 48 
h post treatment.  After the 42nd hour reading, all occlusive dressings were removed and 
all sites remained non-occluded for the last 6 h.   At the end of each study day, the 
occluded sites were further covered with a waterproof dressing (Nexcare Absolute 
Waterproof Premium Adhesive Pad, 3M Healthcare) and with an occlusive film of 
polyvinylidene chloride (Saran Wrap; SC Johnson, Racine, WI) which was secured with 
waterproof tape (Nexcare Absolute Waterproof First Aid Tape; 3M Healthcare) to ensure 
complete occlusion when subjects went home for the night.      
3.4.4. Electrodes and Impedance Measurement 
Ag/AgCl dry electrodes (Thought Technology T-3404; 25 mm x 25 mm total 
area; 10 mm active electrode diameter; Stens Corporation, San Rafael, CA) were used as 
the measurement electrodes for the treatment sites.  A large electrode with a highly 
conductive gel (Superior Silver Electrode with PermaGel, 70 mm total and active 
electrode diameter; Tyco Healthcare Uni-Patch, Wabasha, MN) was used as the reference 
electrode to keep the impedance contribution of the reference site at a negligibly low 
value.  Impedance measurements were made by connecting lead wires to the reference 
and measurement electrodes, the opposite ends of which were connected to an impedance 
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meter (EIM-105 Prep-Check Electrode Impedance Meter; General Devices, Ridgefield, 
NJ) applying a low frequency (30 Hz) alternating current modified with a 200 kΩ resistor 
(Ack Electronics, Atlanta, GA) in parallel to allow for measurement of skin impedance 
values greater than 200 kΩ.  Due to the parallel resistor modification, the impedance 















1        (3.1) 
where Rmeter is the meter readout, Rp is the resistance of the resistor in parallel as 
measured by a multimeter.  
3.4.5. Statistical Methods 
One- and two-way repeated measures ANOVA were performed using NCSS 2007 
(NCSS, Kaysville, UT).  Analysis of the occluded and non-occluded data over all time 
points and for all needle geometries was performed using the general linear model 
(GLM) ANOVA using Minitab 15 (Minitab Inc., State College, PA).  Tukey’s post-hoc 
pairwise comparisons were performed to compare which factor levels led to significant 
differences.  Comparisons of goodness of fit between experimental naltrexone delivery 
concentrations (Appendix B) and impedance-based predicted concentrations were 
performed using the χ2 test with 12 degrees of freedom (12 experimental measurement 





3.5. Flow Conductivity in Human Skin During Microneedle Infusion 
3.5.1. Study Subjects 
Ten healthy adult subjects (1 female, 9 male) were recruited to participate in this 
study.  Subjects with diseased or abnormal skin and/or known hypersensitivity to 
hyaluronidase enzyme were not included in the study.  The study was approved by the 
Georgia Institute of Technology and Emory University Institutional Review Boards and 
all subjects provided informed consent prior to participation.  The study was carried out 
in accordance with the Declaration of Helsinki protocol and was performed at Emory 
University under the supervision of a physician.   
3.5.2. Experimental Design 
This was a non-randomized, single-blinded study.  A total of 9 sites were 
identified on the volar forearms of subjects (left: 5, right: 4) and were marked as T1 
thorough T9.  Sites T1-T4 were infused with sterile saline at a flow rate of 0.3 mL/min 
using hollow microneedles (described in section 3.1.2) at various depths ranging from 
500 µm (intradermal) to 4 mm (subcutaneous).  Site T5 was treated with a 26-gauge 
intradermal bevel hypodermic needle (Becton Dickinson) and was inserted into the skin 
using the standard Mantoux technique for intradermal delivery of sterile saline at 0.3 
mL/min.  For site T6, the hollow microneedle was first inserted to a depth of 1 mm into 
the skin and then retracted back to 500 µm after approximately 5 seconds and then 
infusion was carried out at that depth.  Sites T7 and T8 involved microneedles inserted 
750 μm into the skin followed by infusion of sterile saline at flow rates of 1 mL/min 
(fast) and 0.1 mL/min (slow), respectively.  The last site T9 involved microneedle-based 
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delivery of hyaluronidase into the skin at 750 µm and 0.3 mL/min.  Table 3.2 summarizes 
all 9 treatment sites from this study.     
Table 3.2: Experimental conditions for the 9 treatment sites 























) 0.1 (low)  T8     
0.3 (medium) T1 T2 T3 T4 T5 T6 
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Hyaluronidase 
(0.3 mL/min) 
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3.5.3. Experimental Set-up 
Figure 3.4 depicts the experimental apparatus for this experiment.  A syringe 
pump (NE-1000, New Era Systems, Farmingdale, NY) housing a 10 mL syringe (Becton 
Dickinson) was connected to the hollow microneedle by means of flexible infusion 
tubing (Mallinckrodt - three way stopcock with 12 in pressure tube, Tyco Healthcare, 
Pleasanton, CA and 2C5685, Baxter, Deerfield, IL).  A digital manometer (DigiMano, 
Netech, Hicksville, NY) was placed in-line to measure the pressure associated with 
infusion.  The hollow microneedle was housed in the custom rotary drilling device 
described in section 3.2.  Needle insertion and retraction were controlled via the graded 





Figure 3.4: Experimental apparatus set-up: an in-line manometer was placed 
between the microneedle and syringe to measure the pressure during fluid infusion 
into skin. 
A digital video-camera (PV-GS380 MiniDV Camcorder, Panasonic, Secaucus, 
NJ) was used to capture continuous readings on the manometer and the movements of the 
syringe plunger.  The video-camera data was converted to 1-second interval image files 
by using the batch capture feature in Adobe Premiere Elements 4.0 (Adobe, San Jose, 
CA).  The pressure readings were obtained for every second from the corresponding 
captured image files and the volume delivered was determined by measuring the 
displacement of the plunger every 200 µL in pixels (Adobe Photoshop CS3, Adobe).    
3.5.4. Injection Solutions 
Sterile saline (0.9% sodium chloride injection, USP, Hospira, Lake Forest, IL) 
was used for the saline delivery procedures in this study.  Hyaluronidase delivery was 
achieved by using Hylenex recombinant solution (Baxter, Deerfield, IL).  
3.5.5. Experimental Procedure 
After obtaining informed consent and ensuring subjects met the study 
inclusion/exclusion criteria, the subject was seated and asked to place his/her arms 
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beneath a curtain barrier such that the subject was unable to see the experimental 
procedure.  The subject’s forearms were wiped with 70% isopropyl alcohol (Becton 
Dickinson) swabs followed by marking of an outline of the treatment sites with a fine 
black marker using a custom made stencil to ensure consistent spacing and location of the 
treatment sites among subjects.  The skin sites were then imaged using an ultrasound skin 
imaging device that allowed visualization of the different layers of the skin in a non-
invasive manner (DermaScan C, Cortex Technology, Denmark).  The sites were once 
again wiped with isopropanol swabs ensuring that the marker outline was not erased.  
The subject was then informed that the first treatment procedure was about to begin.  
Treatments were carried out in a non-randomized order from T1 to T9.  The 
needle/microneedle was inserted into the skin and the subject was asked to indicate the 
pain associated with needle insertion by using the VAS pain scale.  The pain score was 
recorded and the scale marker was moved back to the zero position by the study 
investigator.  The syringe pump was then turned on and infusion began as per the flow 
rate corresponding to the treatment site.  Continuous pressure and volume measurements 
were taken via continuous video imaging of the manometer and syringe.  Upon infusion 
of 0.2 mL of fluid, the subject was again asked to rate the pain associated with infusion 
using the VAS scale.  Keeping the VAS marker in the same position as the 0.2 mL score, 
the subject was asked to slide the maker in either direction upon infusion of 0.4, 0.6, 0.8, 
and 1 mL respectively.  Upon delivery of 1 mL of fluid, the pump was stopped.  The 
needle was slowly removed from the skin and then the subject was asked to rate the 
overall delivery procedure as causing “no pain”, “no pain to mild pain”, “mild pain”, 
“mild to moderate pain”, “moderate pain”, “moderate to severe pain”, “severe pain” or 
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“worst possible pain”.  The treatment site skin layers were re-imaged using the ultrasound 
Dermascan device.  The treatment procedure was then repeated for the remaining sites at 
their corresponding depths and flow rates using the appropriate injection solution. 
3.5.6. Statistical Methods 
Comparisons between two treatment conditions were carried out using Student’s 
t-test.  Comparisons between three or more conditions were carried out using one- and 
two- way ANOVAs for one and two factors respectively.  Tukey’s post-hoc pairwise 
comparisons were performed to compare which factors levels led to significant 
differences.  In all cases p < 0.05 was considered significant.  NCSS 2007 (NCSS), 
Minitab (Minitab Inc.), and Microsoft Excel 2007 were used to perform the analyses. 
3.6. Insulin Delivery to Type 1 Diabetes Subjects Using Hollow Microneedles 
3.6.1. Study Subjects 
Five subjects with type 1 diabetes (1 female, 4 male; age 11-44), who were 
managed with an insulin pump and were in good glycaemic control were recruited to 
participate in this study.  In order to be included in the study, subjects were required to 
have type 1 diabetes for at least 2 years, be using a conventional Food and Drug 
Administration-approved insulin pump with lispro insulin for the past year, have mean 
hemoglobin A1c levels ≤8% for the past year and a body mass index within the 85th 
percentile for their age.  Subjects were excluded if they had type 2 diabetes, acanthosis 
nigricans, a clinically significant major organ system disease, were on glucocorticoid 
therapy, had an insulin requirement of ≥150 U/day, an illness on the day of the study, or 




Table 3.3: Demographics of study subjects 
Parameter Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Age (years) 43 38 11 19 18 
Race Caucasian Caucasian Caucasian Caucasian Caucasian
Gender Female Male Male Male Male 
Mean HbA1ca (%) 6.5 6.2 6.9 6.3 6.9 
Weight (kg) 63.5 78.0 45.2 80.8 72.6 
BMI (kg/m2) 23.3 25.5 19.7 26.6 21.8 
Time since diagnosis (years) 30.0 28.5 5.5 10.75 14.5 
Duration of pump use (years) 12.2 7.5 3.9 7.4 5.0 
Length of pump catheter (mm) 9.0 9.0 9.0 9.0 9.0 
Mean insulin per day (units) 40.0 45.0 36.0 80.0 52.0 
ICR (units/g) 1:7.5 1:10 1:7.5 1:5 1:7.5 
BMI, body mass index; ICR, insulin to carbohydrate ratio. 
aMean hemoglobin A1c over the past year. 
 
This study was performed in the Diabetes Clinic at the Emory Children’s Center 
at Emory University (Atlanta, GA) in accordance with the Declaration of Helsinki 
protocol.  The study was approved by the Institutional Review Board at Emory 
University.  All subjects provided informed consent (or written assent for subjects under 
age 18 along with parental consent) to participate in the study. 
3.6.2. Microneedle Insertion 
Hollow microneedles with a bevel angle of 30° and effective tip radii between 60 
and 80 µm were fabricated and sterilized as described in section 3.1.2.  The microneedles 
were inserted at a 90° angle into the abdominal skin at various depths ranging from 900 
µm to 5 mm using the custom-made rotary drilling device described in section 3.2.  The 
microneedle was connected to a 3-mL syringe (Becton Dickinson) by means of a flexible 
intravenous extension set tubing (2C5685, Baxter).  The syringe was further connected to 
a syringe pump (NE-1000, New Era Systems) that controlled the insulin delivery flow 
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rate at 1 mL/min.  The microneedles were removed from the skin immediately after 
insulin delivery was completed. 
3.6.3. Insulin 
Humalog insulin (lispro, Eli Lilly, Indianapolis, IN) was used in this study.  The 
control treatments used a 100-U insulin formulation, whereas the microneedle treatments 
used a 50-U insulin, which was prepared by diluting 100-U insulin with sterile diluent for 
Humalog (Eli Lilly). 
3.6.4. Experimental Design 
 The study was an open-label, within-subjects, controlled design.  This study was 
conducted in three phases.  The first phase was carried out in subject 1 in the absence of a 
meal to determine the optimum microneedle insertion depth for intradermal insulin 
delivery.  The second phase was performed on subject 2 using the optimum depth 
obtained from Phase 1 and included consumption of a standardized meal immediately 
after insulin administration.  Unequal insulin doses were given for the microneedle and 
control treatments as post-prandial (after a meal) insulin bioavailability following 
intradermal-microneedle insertion was initially unknown.  Guided by the results of phase 
2, the third phase was carried out in all 5 subjects and included consumption of a meal 
after insulin administration and equal insulin doses for both microneedle and control 
treatments.  The protocols for each phase are described as follows. 
3.6.5. Phase 1: Effect of Microneedle Insertion Depth  
This phase was conducted to determine the minimum microneedle insertion depth 
for effective bolus insulin delivery through a microneedle device in fasting subjects.  The 
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study was carried out in Subject 1 and included four study visits.  The first visit served as 
the control visit (subcutaneous insulin catheter: 9 mm) and the subsequent three visits 
served as the study visits (microneedle: 5 mm, 3.5 mm, and 1 mm insertion depths, 
respectively).  Prior to each visit, the subject underwent overnight fasting for a minimum 
of 10 h.  In an effort to minimize the amount of insulin on board, subjects turned their 
pumps off 2 h prior to insulin delivery.  Capillary glucose measurements were then taken 
every 30 min using a glucose meter (FreeStyle Lite™, Abbott Laboratories, Abbott Park, 
IL) until blood glucose levels remained stable or were at the onset of rising.  An 
intravenous catheter was then placed in the subject’s antecubital fossa, and a 10-mL 
blood sample was drawn.  The specimen was collected in a sterile vacuum blood 
collection tube (BD Vacutainer Plus plastic serum tube 367820, Becton Dickinson) 
followed by centrifugation at 1,300 g (Vanguard V6500, Hamilton Bell, Montvale, NJ), 
separation, and immediate freezing at –4°C.  A capillary glucose measurement was also 
taken at this time. 
The abdominal insulin administration site was then wiped with 70% isopropyl 
alcohol (Becton Dickinson).  This was followed by administration of an insulin bolus into 
the subject’s abdomen either by inserting a subcutaneous insulin catheter (9 mm, 
Paradigm Quick-set, Medtronic MiniMed, Northridge, CA) connected to a conventional 
insulin pump (Paradigm, Medtronic MiniMed) in the case of the control treatment or 
through a microneedle connected to a programmable syringe pump at the rate of 1 
mL/min for the study treatment.  The insulin dose was determined based on the subject’s 
blood glucose level, individual insulin requirement, and type of delivery device. After 
insulin delivery, the pumps were immediately shut off, and the subject received no basal 
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insulin during the experiment.  Capillary glucose level measurements and blood draws 
were collected periodically at 30 min, 45 min, 60 min, 75 min, 90 min, and every 30 min 
thereafter until blood glucose levels returned to normal.  All samples were assayed for 
plasma glucose and free insulin concentrations (Esoterix, Calabasas Hills, CA). 
The first phase of the study did not involve the consumption of any food after 
insulin delivery, and the subject fasted throughout the study.  If at any time the subject 
developed severe hypo-glycaemia (capillary glucose <70 mg/dL) or severe hyper-
glycaemia (capillary glucose >300 mg/dL), felt ill, or desired to withdraw from testing, 
the study was discontinued.  The subject was asked to qualitatively describe and compare 
the pain associated for each of the four delivery procedures. 
3.6.6. Phase 2: Effect of Microneedle-Based Insulin Delivery on Postprandial Glucose 
Levels (unequal control and microneedle insulin doses) 
 This phase was carried out in Subject 2 and involved three study visits: the first 
served as the control visit (subcutaneous insulin catheter: 9 mm) and the last two as the 
study visits (microneedle: 1 mm).  The protocol for this study was identical to that in 
phase 1; however, the subject consumed a standardized mixed meal comprising 75 g of 
carbohydrates, 12 g of protein, and 14 g of fat immediately following the insulin bolus.  
Capillary glucose levels and blood draws were collected according to the same schedule 
as phase 1.  The subject was asked to qualitatively describe and compare the pain 
associated with both the delivery procedures.  The insulin delivery sites were imaged 
(PowerShot SD400, Canon, Tokyo, Japan) periodically before and after the insulin bolus 
for the control and first microneedle visit.  Figure 3.5 shows a hollow microneedle next to 




Figure 3.5: A 1-mm hollow microneedle in a holder (above) compared to a 9-mm 
infusion catheter (below). 
3.6.7. Phase 3: Effect of Microneedle-Based Insulin Delivery on Postprandial Glucose 
Levels (equal control and microneedle insulin doses) 
 This phase was carried out in all five subjects and consisted of two visits per 
subject.  The first visit was the control visit where a bolus dose of U-100 insulin based on 
the subject’s glucose level and insulin-to-carbohydrate ratio was administered to the 
subject’s abdomen using a 9-mm catheter and the insulin pump.  During the second visit, 
the same insulin dose was administered using U-50 insulin and a 900-µm long 
microneedle connected to a syringe pump set at 1 mL/min.   
 Prior to each visit, subjects underwent overnight fasting and were required to turn 
off their insulin pumps 45 min before the start of the study.   At the start of the study, a 
blood draw was taken from the antecubital fossa and a capillary blood measurement was 
also made.  This was followed by insulin bolus administration to the abdomen skin by 
one of the two treatment methods and immediate consumption of the same standardized 
meal as in phase 2.  Capillary glucose measurements and venous blood draws were taken 
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periodically every 15 min for the first 2 hours and every 30 min thereafter up to a total of 
3.5 h or until the subject became hypo- or hyper-glycaemic as described above.   
3.6.8. Pain Scores and Skin Irritation 
Subjects were asked to rate the pain associated with microneedle and catheter 
insertion and insulin infusion using the VAS pain scale.  Subjects were also asked to give 
their treatment preference among the two delivery procedures.  Erythema and edema 
scores were recorded using the Draize Dermal Irritation Scoring System (Table 3.4) at 
every blood collection time point (Bonnette, Rodabaugh et al. 2002).      
Table 3.4: Draize dermal irritation scoring system for erythema and edema 
Score Erythema Description Edema Description 
0 • No erythema • No edema 
1 • Very slight erythema (barely perceptible) • Very slight edema (barely perceptible) 
2 • Well-defined erythema • Slight edema (edges of area well defined by definite raising) 
3 • Moderate to severe erythema • Moderate edema (raised ~ 1 mm) 
4 • Severe erythema (beet-redness) to slight, eschar formation 
• Severe edema (raised more than 1 mm 
and extending beyond the area of 
exposure) 
 
3.6.9. Calculation of Pharmacokinetic Parameters 
 Phase 3 pharmacokinetic (PK) parameters tmax and Cmax were directly determined 
from the plasma free insulin level assay data.  The area under the insulin curves were 
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where C0 is the initial plasma free insulin concentration at t = 0, tn corresponds to a 
particular blood collection time point and tn-1 corresponds to the time point immediately 
before it.  Similarly, Cn corresponds to the plasma concentration at tn and Cn-1 to the 
concentration at tn-1. 
 Using the above PK parameters and the single-compartment model described in 
section 2.6, the absorption (ka) and elimination (kel) rate constants were calculated using 
the following method.  The solution to the differential equation (equation 2.3) describing 
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where A0 is given by the insulin dose delivered divided by the volume of distribution of 
insulin (A0 = Dose/Vdist).  The time when the maximum insulin concentration occurs in 
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Using the above three equations, the experimental plasma free insulin concentrations, and 




3.6.10. Statistical Methods 
All phase 3 pharmacokinetic parameters, rate constants, and pain scores are 
reported as mean ± SD.  Statistical significance comparisons for phase 3 results were 
performed using a two-tailed Student’s t-test with p < 0.05 being considered significant.  
Microsoft Excel 2007 was used to perform all t-tests.   
3.7. Local Anesthesia Using Hollow Microneedles in Human Subjects 
3.7.1. Study Subjects 
Fifteen healthy adult human subjects (11 male, 4 female; age: 22-56) participated 
in this study.  Subjects having diseased or abnormal skin, known diseases affecting nerve 
function or perception of pain, allergies to lidocaine, and poorly accessible veins on the 
dorsum (back) of their hand were excluded from the study.  The study was approved by 
the Emory University Institutional Review Board and all subjects provided informed 
consent prior to participation.  The study was carried out in accordance with the 
Declaration of Helsinki protocol.  The study was conducted at Emory University under 
the supervision of a physician.   
3.7.2. Endpoints 
The following end points were measured: a) pain associated with microneedle and 
hypodermic needle-based lidocaine injection, b) area of skin numbness at t = 0, 7.5, and 
15 min after lidocaine injection, c) depth of skin numbness at t = 0, 7.5, and 15 min after 
lidocaine injection,  d) efficacy of injection based on pain associated with administration 
of an intravenous catheter (IV) immediately after lidocaine delivery, e) onset of 
anesthesia based on results from b, c, and d, and f) preferred treatment method among 
microneedle and hypodermic needle injection. 
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3.7.3. Pain Scores 
Pain scores were measured to assess the pain associated with microneedle and 
hypodermic needle-based lidocaine injection and to determine the efficacy of lidocaine 
anesthesia by measuring pain associated with administration of the IV catheter.  Pain 
scores were measured using the VAS pain scale.  Immediately after lidocaine injection 
and after IV insertion, subjects were asked to slide a marker along the VAS ruler to 
correspond with his or her pain as described in section 3.3. 
3.7.4. Lidocaine 
A 2% preservative-free injectable lidocaine hydrochloride solution (Hospira) was 
used for all injection procedures in this study. 
3.7.5. Microneedle Fabrication and Injection 
Hollow microneedles with a bevel angle of 30o and tip radii between 60 and 80 
μm were fabricated as described in section 3.1.2.  The microneedles were inserted at a 
90o angle into the skin to a depth of 500 μm using the custom rotary drilling device.  The 
microneedle was connected to a 3-mL syringe (Becton Dickinson) by means of a flexible 
IV extension set tubing (2C5685, Baxter).  The syringe was further connected to a 
syringe pump (NE-1000, New Era Systems) which controlled the lidocaine delivery flow 
rate at 300 μl/min.  The microneedles were removed from the skin immediately after 
infusion.    
3.7.6. Hypodermic Needle Injection 
A 26-gauge 3/8 inch intradermal bevel needle (Becton Dickinson) connected to a 
1 mL syringe (Becton Dickinson) was used as the positive control lidocaine injection 
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method.  The needle was inserted at a small angle (Mantoux method), almost parallel to 
the skin, into the intradermal space by an experienced anesthesiology personnel and 
lidocaine was injected within a period of approximately 3-5 s.  Figure 3.6 shows a hollow 
microneedle compared to a 26-gauge hypodermic needle. 
 
Figure 3.6: The bevel opening of a 26-gauge intradermal bevel hypodermic needle 
(top) compared to the entire length of a 500 μm long microneedle (bottom).  As seen 
in the image, the entire microneedle (bevel + shaft) is short enough to sit inside the 
bevel of the hypodermic needle. 
3.7.7. Study Design 
This study was a randomized, within subjects, controlled, single-blinded design 
and was carried out in two phases.  One phase was carried out on the forearm while the 
other was carried out on the dorsum (back) of the hand.  The forearm phase was carried 
out to assess the pain associated with microneedle-based injection and to determine the 
efficacy of injection by measuring the area and depth of numbness.  The phase on the 
dorsum of the hand was carried out to further assess the pain associated with 
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microneedle-based injection and to determine the efficacy of injection by assessing pain 
associated with subsequent intravenous catheter insertion.  All subjects received 
treatments with both devices on their forearms and on the dorsum of their hands and each 
subject served as his or her own control.  The sequence of these two phases (forearm or 
dorsum) was randomized among subjects.  The study was controlled using hypodermic 
needle-based lidocaine injection.  Within each phase, the procedure sequence (i.e.: 
microneedle or hypodermic needle) and the treatment forearm/hand (i.e.: left or right) 
was also randomized among subjects.  The subjects were blinded throughout the study by 
placing their arms under a curtain barrier. 
3.7.8. Forearm Protocol 
The volar forearm insertion site was identified and marked 7 cm from the 
midpoint of the antecubital fossa.  The site was then wiped with 70% isopropanol swabs 
(Becton Dickinson) followed by injection of 200 μl of lidocaine using a microneedle or 
hypodermic needle as per the randomization schedule.  The subject was asked to rate the 
pain associated with injection using the VAS scale.  The subject was then asked if he/she 
considered the procedure to be painful.  The area of numbness was then measured via a 
pin-prick test by gently tapping the blunt stylet of a 25-gauge 3.5 inch spinal needle 
(Becton Dickinson) on the skin starting from the insertion point and extending radially 












Figure 3.7: Schematic of the volar forearm insertion site and measurement map.  
Position C depicts the injection site located 7 cm from the middle of antecubital 
fossa.  The area of numbness was measured by conducting a pin-prick test starting 
from position C and extending radially outward towards the top, bottom, left, and 
right.  The depth of numbness was measured by inserting a 26-gauge 3/8 inch needle 
into the skin at point C until the subject indicated presence of sensation. 
The depth of numbness was measured by inserting a 26-gauge 3/8 inch (Becton 
Dickinson) hypodermic needle into the skin at the site of lidocaine injection until the 
subject indicated that he/she felt a sensation (up to a maximum of 9.5 mm).  The 
procedure took approximately 2 min to complete and was carried out immediately after 
lidocaine injection (t = 0 min) and again at 7.5 min and 15 min after injection.  The 
lidocaine injection followed by pain and efficacy assessment was then repeated on the 
opposite forearm using the other injection method.  At the end of both treatment 
procedures, subjects were asked to rank their preference between the microneedle and 





3.7.9. Dorsum of Hand Protocol 
A site near a vein accessible for venipuncture was identified and wiped with 
isopropanol swabs.  Lidocaine (100 μl) was then injected using a microneedle or a 
hypodermic needle as per the randomization schedule to generate a skin wheal.  The 
subject was then asked to rate the pain associated with lidocaine injection using the VAS 
scale and indicate if the procedure was painful.  A 22-gauge IV catheter (Optiva, Smiths 
Medical, Carlsbad, CA) was then inserted through the wheal into the vein until a small 
amount of blood was drawn, upon which the IV catheter was immediately removed.  The 
site was wiped with an isopropanol swab and covered with an adhesive bandage.  The 
subject was asked to rate the pain of inserting the IV catheter and indicate if the 
procedure was painful.  The procedure was then repeated on the opposite hand using the 
other injection method.  At the end of both treatments, the subject was asked to indicate 
the preferred treatment method between the first and second treatment. 
3.7.10. Local Skin Reaction 
Immediately following lidocaine delivery and 1 h post delivery, the injection sites 
were visually examined for skin irritation (not using the Dermal Draize scale). 
3.7.11. Statistical Methods 
All data are expressed as mean ± SD.  VAS pain scores between hypodermic and 
microneedle-based lidocaine delivery were compared using Student’s t-test.  Venous 
cannulation pain scores following the two treatment methods were also compared via 
Student’s t-test.  In all cases, p-value < 0.05 was considered significant.  Differences in 
the radii of numbness (top, bottom, left, and right) for the two treatment methods over all 
three time points were compared using a repeated measures three-way ANOVA.  The 
57 
 
total area and depth measurements for the two devices were compared over the three time 
points using a repeated measures two-way ANOVA.  All comparisons were performed 




CHAPTER 4: RESULTS & DISCUSSION 
 
4.1. Resealing of Human Skin Barrier In-Vivo 
4.1.1. Introduction 
As described in chapter 2, microneedles can be fabricated as single or multi-
needle arrays having hollow channels or solid structures that can be coated with or 
encapsulate with drug.  Hollow microneedles actively deliver drug to the dermis through 
convective flow, similar to the mechanism of a hypodermic needle.  Solid microneedles 
also deliver drug actively by either inserting drug-coated needles or drug-encapsulated 
needles into the skin.  In each of these active delivery cases, from a safety standpoint it is 
desirable for the micro-channels to close soon after needle removal to prevent permeation 
of undesired toxic substances or pathogenic microbes that may lead to infection at the 
treatment site. 
Solid microneedles can also deliver drugs via passive diffusion by creating micro-
channels to increase skin permeability followed by the application of a drug-loaded patch 
on top of the channels (Henry, McAllister et al. 1998; Wermeling, Banks et al. 2008).  To 
achieve sustained delivery, from an efficacy standpoint, it is desirable for these micro-
pathways to stay open as long as the drug patch is on the skin.  However, it is also desired 
for the holes to close immediately after patch removal to prevent site infection.     
To achieve prolonged drug delivery using solid microneedles, it is essential to 
determine the extent and duration of the skin’s increased permeability because as with 
any skin wounds or abrasions, the holes created in the skin reseal over time due to the 
skin’s natural repair mechanisms.  Upon disruption of the stratum corneum barrier, 
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lamellar body secretion is immediately initiated followed by synthesis of lipids, which 
are necessary to restore and maintain the SC barrier (Grubauer, Elias et al. 1989; Menon, 
Feingold et al. 1992).  Because the kinetics of SC repair depend on the degree of barrier 
perturbation (Schaefer and Redelmeier 1996), it is also important to study SC repair 
following treatment with microneedles of various geometries.  Further, because the 
presence of a drug-loaded patch on the treatment site covers (occludes) the skin, it is also 
necessary to study the effect of occlusion on skin resealing after microneedle treatment. 
Previous in-vivo studies performed in hairless guinea pigs have shown that 
microneedles enhanced skin permeability over a 48 h time period as characterized by 
transepidermal water loss (Banks, Gill et al. 2005).  Other studies have also been carried 
out in human subjects using transepidermal water loss to show that microneedle insertion 
leads to an increase in skin permeability, but the kinetics of repair were not examined 
(Bal, Caussin et al. 2008; Haq, Smith et al. 2009).  Thus, no kinetic studies have been 
performed to determine the “window” of increased permeability following microneedle 
treatment and how it can be modulated.     
In this chapter, we perform the first human experiments to analyze the recovery of 
skin’s barrier properties after microneedle insertion and determine the duration of 
increased skin permeability as a function of microneedle geometry and skin occlusion.  
We also study the role of occlusion to influence the expected safety and efficacy of 
microneedle treatment as well as the relationship between pain and skin recovery time.  
Lastly, we use the results from this study to develop a model to predict the transdermal 
drug delivery of a drug (naltrexone) in-vivo and compare the prediction to experimental 
observations.   
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Several non-invasive biophysical tools such as transepidermal water loss, infrared 
spectroscopy and electrical impedance spectroscopy have been evaluated to determine the 
in-vivo integrity of the SC barrier and the permeability of the skin (Curdy, Naik et al. 
2004; Fluhr, Elsner et al. 2005).  While TEWL is the most commonly used evaluation 
tool, this method requires areas studied under occlusion to be un-occluded during the 
measurement procedure.  Because this study specifically tested the effects of occlusion, 
we employed electrical impedance spectroscopy as our measurement tool so as to allow 
the occluded treatment sites to remain occluded throughout the experimental period.   
The skin’s electrical resistance lies predominantly in the stratum corneum and any 
break in the integrity of the barrier leads to a decrease in skin impedance (Yamamoto and 
Yamamoto 1976a; Yamamoto and Yamamoto 1976b), thereby making impedance 
spectroscopy a useful tool to determine skin barrier integrity after microneedle insertion.  
Previous studies have demonstrated that there is a strong correlation between skin 
impedance and skin permeability with a decrease in skin impedance corresponding to an 
increase in skin permeability (Karande, Jain et al. 2005).  Additionally, impedance 
spectroscopy is a non-invasive and safe measurement tool that is often used in 
dermatology for the assessment of skin diseases and in the cosmetic industry to study the 
effect of cosmetics on skin (Burnette and DeNuzzio 1997).    
Microneedles are known to increase skin permeability to a wide range of 
molecules by creating microchannels in the skin.  In this study, we quantify that effect 
using impedance spectroscopy and determine the lifetime of transdermal transport 
pathways by testing the hypothesis that increasing microneedle length, number, and base 
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cross-sectional area in conjunction with occlusion leads to an increase in skin resealing 
time that can exceed one day.   
4.1.2. Effect of Microneedle Design on Initial Skin Impedance Drop 
As described in section 3.4, the left and right volar forearms of 10 healthy adult 
human subjects were used in this study.  Five different microneedle geometries (Table 
3.1) with varying length, number, thickness, and width (Designs A-E) were studied under 
occlusive (impermeable to air and moisture) and non-occlusive conditions and compared 
to positive (F, hypodermic needle) and negative (G, no treatment) controls.  A total of 11 
sites (5 occluded, 6 non-occluded) were identified and marked.  Figure 3.1 shows a 
microneedle array used in this study and Figure 3.3 depicts the treatment sites on the arm.  
Pre-treatment impedance measurements were taken at the beginning of the study, after 
which the marked sites on each subject were administered their respective treatments at 
time t = 0 h, followed by hourly skin impedance measurements.  The impedance values 
were then normalized with respect to their corresponding positive control hypodermic 
needle (F) impedance to account for inter-subject variability.  
To determine the effect of microneedle design on the initial drop in skin 
impedance as compared to that caused by a 26-gauge hypodermic needle, the average 
normalized skin impedance Znorm for each of the treatment conditions (A-G) at time t = 0 
h was analyzed (Figure 4.1).  The impedance values for the microneedle (A-E) and 
hypodermic needle (F) sites were all significantly lower than that of the no treatment 
control (G) (repeated measures one-way ANOVA; p < 0.05), however, there were no 
significant differences among treatments A-F (repeated measures one-way ANOVA; p > 
0.05).  Since in-vivo intact human skin is generally characterized by relatively high 
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impedance and the skin’s electrical resistance is attributed primarily to the stratum 
corneum, these low impedances indicate that the SC barrier was compromised with 
increased permeability to drug molecules.  Further, though we anticipated that more 
needles and needles with larger cross-sectional area would make more/bigger holes, 
which would lead to lower initial impedance at t = 0 h, comparisons between geometries 
A and B, and A and E revealed no significant difference in initial impedances.  However, 

















Figure 4.1: Comparison of normalized (relative to hypodermic needle (F) positive 
control) average skin impedance (Znorm) values at time = 0 h (immediately after 
treatment) for the different treatment conditions.  A significant reduction in skin 
resistance upon treatment with microneedles (A-E) and hypodermic needle (F) was 
observed in comparison to the intact skin negative control (G).  There was no 
significant difference among treatments A-F. Graphs expressed as mean ± SD. 
4.1.3. Kinetics of Skin Barrier Recovery: Effect of Occlusion 
To determine the duration of the increased skin permeability caused by 
microneedles, skin impedance profiles for all microneedle geometries were measured and 
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analyzed in the presence and absence of occlusion over a 48 h experimental study period.  
The impedance data for each subject were normalized with respect to their corresponding 
t = 0 positive control (F) and the average normalized impedance was plotted over time for 
both the occluded and non-occluded cases as shown in Figure 4.2.  From these data, the 
kinetics of skin resealing can be determined as a function of microneedle geometry and 
skin occlusion.       
Analysis of the effect of occlusion on skin resealing was performed in two ways.  
First, the impedance profiles for the occluded and non-occluded sites were compared up 
to the 42 h time point (at which point occlusion was removed from all occluded sites).  
As can be seen from Figure 4.2, the impedance values for both the occluded and non-
occluded cases dropped significantly from their pre-treatment values immediately after 
needle insertion and then increased over time indicating skin barrier recovery.  However, 
the speed of this recovery depended on the occlusive condition of the skin and on 
microneedle design.  Comparison of the occluded and non-occluded cases over all time-
points indicated that skin recovery was significantly faster in the absence of occlusion 
(GLM ANOVA followed by Tukey’s post-hoc pairwise comparison; p < 0.05).   
Second, the data for the occluded sites (Figure 4.2a) were analyzed before and 
after removal of occlusion at the 42nd hour.  This evaluation revealed that upon removal 
of occlusion after the 42nd hour, the skin impedance immediately increased within one 
hour (two-way ANOVA followed by Tukey’s post-hoc pairwise comparison; p < 0.05), 






































Figure 4.2: Normalized (relative to hypodermic needle (F) positive control 
impedance at t = 0) average skin impedance (Znorm) profile over the course of a 48 h 
time period for different skin treatments (Table 3.1).  Profile (a) under occlusion 
and (b) without occlusion.  Occlusion led to a slower recovery of skin impedance on 
the order of several hours to days for all treatment conditions when compared to 
non-occluded sites.  Upon removal of occlusion, skin impedance rapidly increased.  
Graphs expressed as mean ± SD; n = 5 for t > 0, n = 10 for t ≤ 0. 
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We hypothesize that this slow barrier recovery under occlusion is due to the 
reduced transepidermal water loss under occlusive skin conditions. Previous studies have 
shown that stratum corneum barrier repair is regulated by the formation of a water 
gradient in the skin caused by increased transepidermal water loss through the 
compromised skin barrier (Grubauer et al. 1989).  Occluding the skin with a vapour 
impermeable membrane introduces an artificial skin barrier and eliminates this gradient.  
As a result, the secretion of lamellar bodies and lipid synthesis, which are essential to 
repair and regulate the SC barrier, are significantly retarded, leading to prolonged barrier 
recovery (Grubauer, Elias et al. 1989; Menon, Feingold et al. 1992).  Additionally, under 
occlusion, the skin becomes significantly hydrated.  Hydration is the primary variable 
influencing the skin’s impedance, with increased SC hydration leading to a reduction in 
skin impedance (Burnette and DeNuzzio 1997; Curdy, Naik et al. 2004).   
This switch-like behaviour where microneedle-generated channels remain open 
under occlusion but close rapidly after removal of occlusion gives insight into the safety 
and efficacy of solid microneedle-based passive-delivery systems described earlier.   This 
finding suggests that a drug-loaded occlusive patch can be applied to the skin 
immediately after solid microneedle treatment to enable prolonged drug delivery, 
followed by rapid skin resealing and termination of delivery upon patch removal.  
Additionally, the fast resealing of microneedle holes in the absence of occlusion reduces 
the chance of infection at the insertion site, which should increase safety of non-occlusive 




Figure 4.2a also shows that the no-treatment negative control line (G) gradually 
decreased during the first 10 to 12 h and then remained relatively constant for the 
remainder of the study until occlusion was removed.  This reduction in impedance was 
due to the increased hydration of the skin under occlusion as described above. The non-
occluded negative control on the other hand did not show this reduction in impedance, 
but rather, showed an erratic noisy behaviour (Figure 4.2b).  This was also true for the 
non-occluded treated sites once they recovered (A-F).  While the underlying reason for 
the erratic behaviour is not known, this could be due to a measurement artifact.  For intact 
skin with high impedance, even a small change in the barrier or its hydration can have a 
large effect on the impedance values.  In contrast, compromised skin with low impedance 
is relatively insensitive to such small changes.     
4.1.4. Kinetics of Skin Barrier Recovery: Effect of Microneedle Design 
This study also hypothesized that increasing microneedle length, number, 
thickness, and width leads to an increase in skin barrier recovery time.  In order to test 
this hypothesis and to determine the time for the channels created by microneedles to 
recover, the impedance profiles for each treatment type were compared with that of the 
no-treatment negative control (G).  The skin resealing time (Table 4.1) was determined as 
the time at which there was no significant difference between the treatment and negative 
control sites shown in Figure 4.2.  This comparison controlled for the effects of hydration 





Table 4.1: Skin resealing time and pain as a function of needle design and skin 
occlusion 
 Time (h)a 
Design Occluded Non-Occluded 
A 30 2 
B 3 2 
C 22 2 
D 18 2 
E 40 2 
F n/a 2  
aTime to achieve non-significant difference of skin impedance from negative control. 
 
Analysis of the occluded data revealed that the window of increased permeability 
showed strong dependence on microneedle geometry (Table 4.1).  The non-occluded data 
on the other hand revealed that for all needle treatment conditions (A-F), the skin 
impedance increased rapidly and within 2 h of treatment, skin was resealed with no 
dependence on needle geometry. 
To further elucidate the effect of microneedle geometry parameters on skin 
resealing under occlusion, we compared the resealing times based on changes in length, 
number, and cross-sectional area of microneedles as seen in Figure 4.3.  Doubling the 
microneedle length while keeping other parameters constant led to a 6-fold increase in 
skin recovery time as revealed by comparison of geometries B (750 μm length) and D 
(1500 μm length).  Further, comparing geometries C (500 μm length) and A (750 μm 
length) indicated that a 50% increase in microneedle length, while holding other 
parameters constant, led to approximately 35% increase in skin resealing time.  Both 
these comparisons confirmed the hypothesis that increasing microneedle length increases 
skin barrier recovery time under the effect of occlusion. 
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The number of microneedles also affected skin resealing time with a 5-fold 
increase in number of needles corresponding to a 10-fold increase in barrier recovery 
time demonstrated by comparing geometries B (10-needle array) and A (50-needle array) 
(Figure 4.3).  Further, a 4-fold increase in cross-sectional area led to a 33% increase in 
recovery time as revealed by comparing geometries A (w = 200 μm, t = 75 μm) and E (w 
= 500 μm, t = 125 μm).  Under occlusion, microneedles with geometry E had the longest 
skin resealing time of 40 h.  These results validated that increasing microneedle number 






















50 needles; wide base
Figure 4.3: Comparison of skin barrier recovery time under occlusion based on 
microneedle length, number of microneedles, and cross-sectional area.  Geometry E 
with 50 microneedles having length 750 µm, width 500 µm, and thickness 125 µm 
had the slowest recovery at 40 h under occlusion. 
In the small array (10 needles), increasing needle length (geometry B vs. D) and 
increasing number of needles (geometry B vs. A) both dramatically increased recovery 
time.  In the large array (50 needles), increasing needle length (geometry C vs. A) and 
increasing needle cross-sectional area (geometry A vs. E) both had much smaller effects 
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on recovery time. This suggests that very minor injury from a small number of short 
needles (geometry B) can be quickly repaired, but injury beyond some threshold 
exceeded by increasing needle length and/or number of needles significantly slows the 
repair process from a few hours to on the order of one day. 
4.1.5. Relationship Between Microneedle Design, Recovery Time, and Pain 
Overall, under occlusion, skin recovery depended on microneedle length, number, 
and cross-sectional area with length and number having the most sensitive effects.  While 
these parameters have strong effects in increasing skin recovery time, they also have a 
significant effect on pain.  We therefore hypothesized that microneedles causing 
increased recovery time also cause increased pain, because both are secondary measures 
of tissue injury.  To test this hypothesis, we asked the subjects to report the VAS pain 
scores felt during each microneedle insertion.  The pain scores for each subject were then 
normalized with respect to their corresponding hypodermic needle positive control (F) 
(Figure 4.4).  All pain scores with the exception of geometry D were significantly 
different from the hypodermic needle F.  Increasing the base cross-sectional area (A to E) 




























Figure 4.4: Normalized VAS insertion pain scores (with respect to hypodermic 
needle (F) positive control) for the 5 microneedle geometries as a function of 
recovery time under occlusion. VAS scores expressed as mean ± SD of occluded and 
non-occluded treatments, since pain was measured irrespective of skin condition; 
i.e. n = 20 for A-E and n = 10 for F. 
Overall, all microneedle geometries with the exception of D were significantly 
less painful than the hypodermic needle control, F (one-way ANOVA followed by 
Tukey’s post-hoc pairwise comparison; p < 0.05), and all microneedle geometries with 
the exception of D were not significantly different from each other (one-way ANOVA 
followed by Tukey’s post-hoc pairwise comparison, p > 0.05).  This finding is consistent 
with previous measurements of pain caused by microneedles, which showed that 
microneedle length is the most important factor (Gill, Denson et al. 2008).  This finding 
also indicates that although varying microneedle length, number and area all affected skin 
resealing time, only microneedle length affected pain, over the range of parameters 
considered.  These observations are inconsistent with our proposed hypothesis and 
suggest that aspects of tissue injury caused by microneedles that affect pain are different 
from those which affect resealing time.  This could be explained because pain is 
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influenced by a direct interaction between microneedles and sensory nerve fibers, 
whereas resealing time is influenced by damage to the stratum corneum, which is devoid 
of nerves.  The finding that skin resealing time and pain are not directly coupled presents 
opportunities for design of microneedle devices that cause prolonged skin permeability 
(under occlusion), but still cause little or no pain. It appears that using larger numbers of 
needles with larger cross-sectional area, rather than long needles, can accomplish this 
goal (e.g., geometry E).   
4.1.6. Skin Impedance to Predict Transdermal Drug Delivery 
In order to determine if the skin impedance results in this study can be used to 
predict transdermal drug delivery following microneedle-based poke and patch treatment, 
we compared our data to a study carried out in collaboration with the University of 
Kentucky to deliver naltrexone to human subjects after treatment with the same 
microneedles used in this study (Appendix B).  Two microneedle arrays with geometry A 
were inserted four times each into the forearm of six healthy subjects to create a total of 
400 micro-channels per subject.  A naltrexone gel patch was then placed over the treated 
area and covered by an occlusive dressing for 72 h.  Data from that study show that 
plasma naltrexone concentration increased over the first few hours and then held 
relatively steady for the remaining 72 h study (Figure B.1).  As a first comparison, our 
study found that the resealing time for microneedle geometry A was 30 h, which 
contrasts with the finding shown in Appendix B that naltrexone concentration remained 
elevated for at least 72 h.  This result, however, can be explained by the fact the 
naltrexone study inserted arrays of microneedle geometry A a total of 8 times into the 
skin (i.e., 400 micro-channels), whereas our prediction of skin resealing is based on a 
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single insertion (i.e., 50 micro-channels).  Given the strong dependence of skin resealing 
on the number of microneedles seen when comparing a 10-needle array to a 50-needle 
array, increasing from 50 needles to, effectively, 400 needles could further increase 
resealing time.  In addition, our impedance data measured the time taken for the SC 
barrier to repair, whereas the naltrexone delivery study measured the kinetics of plasma 
naltrexone levels.  Plasma drug levels are influenced not only by SC permeability, but 
also by drug diffusion through the skin and into the bloodstream and by drug elimination 
from the bloodstream, which in the case of naltrexone has a half-life of 4.4 h, and from a 
possible drug depot within the skin often associated with transdermal delivery. 
To provide a more detailed comparison between the naltrexone data and our 
predictions of drug delivery based on skin impedance measurements, we developed a 
single-compartment pharmacokinetic model to predict plasma naltrexone concentration 
over time.  In order to do this, we first sought to estimate a relationship between the 
permeable area of skin available for drug transport after microneedle treatment and skin 
impedance.  To do this, we assumed that the channels created by microneedles have a 





       
(4.1) 
where Apermeable is the total permeable area of all micro-channels created by an array, ρ is 
the electrical resistivity of interstitial fluid in the skin (~78 Ω-cm (Trajanoskil, Schaupp 
et al. 1996)), L is the length of the diffusional pathways in the stratum corneum (~15 μm, 
which is the average thickness of the SC (Prausnitz and Langer 2008)), and Z is the 
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absolute skin impedance measured during the study.  We then determined a relationship 
between flux across skin and skin impedance using Fick’s first law of diffusion according 
to which the theoretical transdermal flux (JTheoretical) of a drug-loaded patch across skin 
treated with microneedles can be described as:  
patchplTheoretica CKJ Δ=       (4.2) 
where ΔCpatch is the difference in drug concentration in the patch and in the body (~160 
mg/mL (Appendix B)), and Kp is the permeability of skin treated with microneedles 
defined by:  
L
DfK p ×=       (McAllister, Wang et al. 2003)   (4.3)   
In this equation, D is the diffusion coefficient for naltrexone at infinite dilution in water 
as determined via Stokes-Einstein equation (= 4.6× 10-6 cm2/sec, using a molecular 
diameter of 9.15 A for naltrexone (Iyer, Barr et al. 2007)), L is the length of the micro-
channel created by the microneedle in the stratum corneum, and f is the fractional skin 
area containing holes from microneedles and can be expressed as Apermeable/AMN-array, 
where Apermeable is given by equation 4.1 developed above and AMN-array is the area of the 
microneedle array for which impedance measurements were taken.  Using these relations, 
the theoretical transdermal flux (JTheoretical) of a drug loaded patch across skin treated with 
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Using the above relation, we developed a single compartment pharmacokinetic 
















      (4.5) 
where N is the area of microneedles arrays in the clinical naltrexone study divided by the 
area of arrays in this impedance study (i.e. 8/1), Vdist is the apparent volume of 
distribution for naltrexone (~1350 L (Pagliaro and Pagliaro 1998)), Z(t) is the absolute 
skin impedance measured in this study, and Cl is the total body clearance of naltrexone 
(~3.5 L/min (Pagliaro and Pagliaro 1998)).  This equation indicates that the rate of 
change of the naltrexone plasma concentration is equal to the rate of absorption of 
naltrexone (first term on right hand side of equation) minus the rate of elimination 
(second term on right hand side of equation).  The absorption term containing impedance 
was obtained by multiplying the Flux (equation 4.4) by the area of the arrays used in the 
naltrexone study and dividing by the volume of distribution.  The elimination term was 
simply defined as the elimination rate constant (kel = Cl/Vdist) multiplied by the 
naltrexone concentration as commonly used in pharmacokinetic analysis (Davidian and 
Giltinan 1995).  Therefore, all parameters in this model are based on properties of the 
drug and skin and the model does not contain any fitted parameters.  Figure 4.5 shows a 
plot of the experimental (from Appendix B) and predicted (from equation 4.5) plasma 


































Figure 4.5: Plasma concentrations of naltrexone from (○) experimental study 
involving delivery of naltrexone to human subjects, and from ( ) theoretical 
prediction using equation 4.5 for 30 h.  The predicted data are in agreement with 
the experimental results.  Experimental data are expressed as mean ± SD n = 6. 
As seen in the figure, both graphs saw an initial increase in naltrexone 
concentrations and then remained relatively steady.  The concentration profile plotted for 
the experimental data is an average of the six subjects who participated in the study and 
hence the peak concentration and the time to peak concentration in this graph are not 
representative of the true peak values.  The real peak concentration from the naltrexone 
delivery experiment was found to be 4.5 ± 2.5 ng/mL and the time to this peak was 8.8 ± 
7.6 h.  The predicted naltrexone profile led to a peak concentration of 3 ng/mL at 13 h.  A 
χ2 test to compare the experimental plasma concentrations of naltrexone and the predicted 
concentrations from Equation 4.5 revealed that the predicted data is in agreement with the 
experimental observations (χ2 = 5.16 < χ2critical value = 21.06).  These results indicate that 
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skin impedance can be used to predict drug concentrations in the body after microneedle-
based delivery to within the accuracy of the experimental data. 
4.1.7. Conclusions 
This study validated the hypothesis that increasing microneedle length, number, 
and cross-sectional area in conjunction with occlusion leads to an increase in skin 
resealing time that can exceed one day.  Results indicated that occlusion significantly 
retards skin barrier recovery after microneedle treatment.  However, skin rapidly reseals 
in the absence of occlusion.  The study also revealed that the initial degree of skin 
permeabilization created by microneedles is relatively insensitive to the length, number, 
or cross-sectional area of the microneedles.  However, these parameters do play a 
significant role in the SC resealing process.  Longer, increased number, and larger cross-
sectional area needles recovered more slowly under the effect of occlusion.  Analysis of 
pain scores demonstrated that only increasing microneedle length increased pain, which 
suggests that the duration of increased skin permeability can be extended without 
increasing pain through increasing the number of microneedles rather than their length.  
Overall, this study demonstrated that microneedles can be used to increase skin 
permeability over timescales ranging from as little as 2 h to as long as 40 h.  This study 
also validated that skin impedance measurements can be used to predict transdermal flux 
in-vivo.   
The findings of this study have implications for both passive and active 
microneedle delivery systems.  From an efficacy standpoint, piercing skin with 
microneedles can provide increased skin permeability to facilitate drug delivery from a 
transdermal patch over a period of almost 2 days.  However, increased skin permeability 
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can be quickly reversed in the absence of occlusion due to the rapid skin resealing that 
occurs under these conditions.  This simple dependence of skin permeability on skin 
occlusion provides an inherent safety feature that allows skin to reseal rapidly after 
removal of microneedles at the end of an active delivery process (e.g. injection) or after 
patch removal at the end of passive drug delivery through long-lived micro-channels. 
4.2. Flow Conductivity in Human Skin During Microneedle Infusion 
4.2.1. Introduction 
Hollow microneedles of various geometries and materials have been fabricated as 
a less painful and potentially more effective alternative to hypodermic needles for 
delivering liquid drug formulations into the skin by targeting the dermal capillaries for 
systemic uptake and the dermal dendritic cells for vaccine delivery.  However, to date, 
arrays of microneedles have been shown to deliver only 1 µl (Sivamani, Stoeber et al. 
2005) of fluid into the skin of human subjects without significant pain while single 
microneedles have been used to deliver 120 µl (Laurent, Bonnet et al. 2007).  This is due 
to the resistance to fluid flow offered by the dense dermal structure. 
Previous studies have demonstrated that the low flow conductivity of skin to 
microneedle-based delivery is due to the skin itself as a result of compression of the 
dermal structures and not the microneedles alone (Sivamani, Stoeber et al. 2005; 
Martanto, Moore et al. 2006b).  The dermis is a dense matrix consisting of a continuous 
phase (e.g. water, electrolytes) within a network of coarse fixed elements such collagen 
fibrils and elastin, as well as fibrous molecules such as GAGs, and PG core proteins that 
are imobilized by collagen mesh.  All these materials together offer dermal resistance to 
fluid flow (Levick 1987; Swartz and Fleury 2007).  However, the extent of this dermal 
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resistance to microneedle-based fluid delivery, the parameters effecting it, and its effect 
on pain have not been studied in human subjects. 
Further, the skin has a vast network of nerves, which can potentially be stimulated 
by fluid injection. Several cutaneous branches of spinal and cranial nerves pass through 
the subcutaneous space into the dermis, where the axons spread to form three horizontal 
plexuses (Kiernan and Barr 2008).  The papillary plexus lies in the papillary layer, just 
below the epidermis (at the dermal-epidermal junction) and consists of Merkel receptors 
and Meissner’s corpuscles which are usually sensitive to touch and pressure (Kandel, 
Schwartz et al. 2000); the dermal plexus lies within the dense reticular dermis, and the 
subcutneous plexus lies in the hypodermis (Kiernan and Barr 2008).  Several free nerve 
endings which are sensitive to pain lie in the subcutaneous tissues and the dermis and a 
few extend to the cells of the epidermis.  The free nerve endings in the dermis run parallel 
to the skin’s surface whereas the nerve endings near the epidermis typically lie 
perpendicular to the skin’s surface (Palastanga, Field et al. 2006).  The subcutaneous and 
dermal layers also contain several additional nerve corpuscles and receptors with larger 
receptive fields.  Pain associated with hypodermic needle injection is typically stimulated 
by deeper nerve receptors instead of superficial receptors (Gajraj, Pennant et al. 1994).        
In order to use hollow microneedles for clinical applications it is essential to 
understand the parameters affecting the skin’s flow conductivity.  It is also important to 
understand the effect of these parameters on patient pain perception.  Th objective of this 
study was to determine the effect of the following parameters: microneedle insertion 
depth, needle retraction, infusion flow rate, and the presence of hyaluronidase (an agent 
responsible for breaking down the dense dermal matrix) on flow conductivity of skin to 
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microneedle-based fluid delivery as well on associated pain.  The resulting data were 
used to determine optimum delivery characteristics for practical clinical applications. 
4.2.2. Flow Conductivity 
 The flow conductivity of skin was determined by measuring the pressure 
associated with fluid delivery into skin through microneedles since pressure is inversely 
related to flow conductivity of tissue (Levick 1987; Jackson, Hussain et al. 2006).  
4.2.2.1. Effect of Depth 
To determine the pressures associated with microneedle-based fluid delivery in 
skin and to validate the hypothesis that the dermis offers resistance to fluid flow through 
microneedles in-vivo, saline was delivered to skin through microneedles inserted at 90o 
into the dermis at 500 µm (T1)1, 750 µm (T2), and 1 mm (T3) and into the subcutaneous 
space at 4 mm (T4).  A hypodermic needle (T5) was also inserted into the dermis almost 
parallel to the skin’s surface using the Mantoux technique (Laurent, Bonnet et al. 2007).  
Figure 4.6 depicts the pressure versus volume profile at a constant delivery flow rate of 
0.3 mL/min.  As seen in Figure 4.6, intradermal microneedle delivery (T1-T3) led to an 
increase in pressure as more saline volume was delivered into the skin.  Pressures reached 
as high as 3000 mmHg upon delivery of the entire 1 mL dose.  There were no significant 
differences (one-way ANOVA; p > 0.05) in pressures at any of the volumes between the 
three intradermal depths indicating that regardless of the insertion depth, the dermal 
resistance is the same at a given flow rate.   
 
                                                 




















Figure 4.6: Effect of needle insertion depth on skin resistance to flow. Microneedles 
were inserted into the dermis at ( ) T1 = 500 µm, ( ) T2 = 750 µm, and ( ) T3 = 1 
mm.  A microneedle was inserted into the subcutaneous space at ( ) T4 = 4 mm.  A 
hypodermic needle ( ) T5, was also inserted intradermally.  All infusions were 
performed at the medium flow rate of 0.3 mL/min.  Data are expressed as mean 
values ± SD, n = 10. 
Insertion of microneedles into the hypodermis at 4 mm (T4) led to an initial 
increase in pressure up to ~ 600 µl after which the pressures appeared to somewhat 
stabilize (Student’s t-test; p > 0.05) and then decline (Student’s t-test; p > 0.05 for 
comparison between 0.9 and 1 mL) leading to a significant difference in pressures 
between sites T1-T3 and T4 during the last 300 µl (one-way ANOVA, Tukey’s post-hoc 
comparison; p < 0.05).  This stabilization in infusion pressure during subcutaneous 
delivery is due to the loose tissue network of the subcutaneous space and due to the large 
volume of interstitial fluid available in the hypodermis. This observation of stabilization 
of pressures during subcutaneous delivery confirmed the hypothesis that the dermis offers 
resistance to fluid flow through microneedles.  However, as seen in Figure 4.6, it was 
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also noted that delivery into the dermis via a hypodermic needle (Mantoux method) did 
not lead to high pressures as seen in T1-T3, but rather a slight increase in pressure to ~ 
300 mmHg until delivery of 300 µl, beyond which the pressures remained constant (one-
way ANOVA; p > 0.05).  The pressure for T5 was significantly less than that of T1-T3 
throughout the infusion procedure except the first 300 µl (one-way ANOVA; p > 0.05 for 
volumes ≤ 300 µl).  This observation appears to contradict the hypothesis that the dermis 
offers high resistance to fluid flow.  However, it must be noted that hypodermic needle 
(T5) insertion and flow occurred at an orientation almost parallel to the skin whereas 
microneedle insertion and flow occurred perpendicular to the skin surface.  The dermal 
fibers are generally aligned parallel to the skin’s surface and fluid flow in the same 
orientation as the fibers offers significantly less resistance than flow perpendicular to the 
dermal fibers (Swartz and Fleury 2007).  Therefore, hypodermic needle-based fluid flow 
which was almost in the same orientation as the dermal fibers experienced significantly 
less resistance to flow.  On the other hand, hollow microneedle-based infusion occurred 
perpendicular to the fiber orientation and hence these fibers offered higher resistance to 
flow.  Additionally, the vertical microneedle insertion led to compression and compaction 
of the dense coiled fibers in the dermis.  This compaction led to a decrease in hydration 
(due to pushing away of interstitial fluid between the dermal components) and tissue 
porosity which caused an increase in pressure and flow resistance (Levick 1987; Bert and 
Reed 1998; Martanto, Moore et al. 2006a).  On the other hand, the hypodermic needle did 
not lead to this tissue compression.  Figure 4.6 also showed that the pressures appeared to 
increase gradually first and then increased more quickly after approximately 500 µl.  We 
hypothesize that this is due to the following flow pattern: when fluid flows out of the 
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needle bevel, it first accesses the fiber layers near the micron-sized needle opening and 
flows along these tightly packed layers, leading to increasing pressures.  Since the tissue 
beneath the needle tip is compacted due to compression from the needle, the fluid then 
accesses the fiber layers located above the bevel opening towards the less dense papillary 
dermis leading to stretching of the skin and an increase in fluid pressures.  Flow into 
these layers located at the level of the needle tip and above is likely able to stretch the 
skin enough due to its viscoelastic nature to accommodate 500 µl of fluid while leading 
to increased pressures and the formation of a skin wheal (as will be seen later in this 
chapter).  At this point, the coiled collagen fibers are likely stretched significantly and in 
order to allow more fluid to flow into the skin, the fluid now has to access the deeper, 
compressed, dense, reticular dermis layers below the needle tip, which leads to a more 
rapid increase in pressure.   
Overall, the results from this graph demonstrated that the skin’s structure offers 
increased resistance to flow for microneedles inserted vertically into the skin’s surface 
due to flow against dermal fibers and compaction of the dermal structures.              
4.2.2.2. Effect of Retraction 
 Previous in-vitro studies have shown that microneedle insertion into the dermis 
followed by retraction increases flow conductivity of skin, with almost complete needle 
retraction leading to a significant increase in flow due to de-compression of the dermal 
tissue components that were compacted during perpendicular needle insertion (Martanto, 
Moore et al. 2006a; Martanto, Moore et al. 2006b).  However, since these studies were 
performed in-vitro where skin elasticity and tension conditions were far from that of 
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living human tissue and since only micro-liter quantities of fluid were delivered, the true 


















Figure 4.7: Effect of needle retraction on skin resistance to flow. Microneedles were 
inserted into the dermis at ( ) T1 = 500 µm, ( ) T3 = 1 mm, and at 1 mm followed 
by retraction back to 500 µm, ( ).  A hypodermic needle ( ) T5, was also inserted 
intradermally.  All infusions were performed at the medium flow rate of 0.3 
mL/min.  Data are expressed as mean values ± SD, n = 10. 
In this study, saline was infused at a rate of 0.3 mL/min through a single 
microneedle that was inserted 1 mm into the dermis for approximately 5 seconds and then 
retracted to 500 µm.  Figure 4.7, shows that the infusion pressure for the retracted needle 
(T6) increased up to a volume of 600 µl beyond which the pressure increased very 
gradually and started to stabilize (one-way ANOVA; p > 0.05).  Delivery of 1 mL with 
retraction required pressures less than half of that required to deliver to 500 µm (T1) or 1 
mm (T3) in the absence of retraction.  A two-way ANOVA revealed that the pressures for 
T1, T3, and T6 were comparable up to 600 µl beyond which the T6 values were 
significantly lower than that of T1 and T3 indicating retraction began to play a significant 
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role at this point.  We hypothesize that this behaviour of flow conductivity is likely due to 
initial flow of fluid into the pathway created by retraction (<< 10 µl), followed by flow 
into the less dense papillary dermis and then the more dense reticular dermis leading to 
an increase in pressure and formation of a skin wheal (as seen later in this chapter).  As 
more fluid was infused and the pressure continued to increase, the retraction pathway 
likely expanded leading to tissue damage and ultimate reduction of pressures due to flow 
into the damaged dermis and possibly into the deeper dermis.  This hypothesis of tissue 
damage and flow to the deeper dermis is further confirmed by the results of the infusion 
pain scores as seen later in this chapter.  An additional reason for the lower later 
pressures seen by retraction as compared to T1 to T3 could be the one described by 
previous in-vitro studies (Martanto, Moore et al. 2006a; Martanto, Moore et al. 2006b), 
that microneedle insertion followed by retraction reduced compression of the dermis at 
the needle tip and hence did not lead to as high pressures as without retraction.  It should, 
however, be noted that although retraction reduced infusion pressures (compared to T3) 
due to likely reduction in tissue compaction, the pressure was still higher than that of 
hypodermic needles.  This is presumably due to the delivery of fluid perpendicular to the 
fibers via vertically inserted microneedles as described previously.  Additionally, while 
tissue compression might have been reduced due to retraction, it may not have been 
completely eliminated.  Overall, while all three microneedle conditions (T1, T3, T6) 
allowed delivery of 1 mL of fluid into the skin, the later low pressures seen by T6 
indicate that retraction increases flow conductivity of skin which is consistent with the 




4.2.2.3. Effect of Infusion Flowrate 
 To determine the effect of infusion rate on flow conductivity, saline was delivered 
into the dermis at a depth of 750 µm at three different flow rates of 0.1 mL/min (T8 = 
low), 0.3 mL/min (T2 = medium), and 1 mL/min (T7 = fast).  As seen in Figure 4.8, the 
slow flow rate saw an increase in pressures until 700 µl was infused after which the 
pressures started to stabilize (one-way ANOVA; p > 0.05).  This is presumably due to the 
fact that at this point as more saline was infused, the saline depot created near the needle 
tip would slowly clear from the insertion site creating space for more saline to enter with 
minimal additional resistance.  The stabilization of pressure beyond this point indicates 
that the rate of saline clearance from the needle tip region was the same as the infusion 
flow rate of 0.1 mL/min (steady-state) and more saline could continue to be delivered at 


















Figure 4.8: Effect of infusion flowrate on skin resistance to flow. Microneedles were 
inserted into the dermis at 750 µm and saline was infused at rates of ( ) T8 = 0.1 
mL/min, ( ) T2 = 0.3 mL/min, and ( ) T7 = 1 mL/min.  Data are expressed as 
mean values ± SD, n = 10. 
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 Infusion at the medium flow rate (T2) led to an initial gradual increase in pressure 
up to approximately 500 µl beyond which the pressure continued to increase in a slightly 
more rapid manner as described previously.  On the other hand, infusion at the faster flow 
rate saw higher pressures than T2 and T8 (beyond 400 µl, one-way ANOVA, Tukey’s 
post-hoc comparison; p < 0.05) that appeared to increase more rapidly than the low and 
medium flow rates.  However, as the pressures continued to rise, upon reaching almost 
4000 mmHg (at 900 µl), the pressure appeared to decrease, however, the difference was 
not significant (Student’s t-test; p > 0.05).  We hypothesize that this might be due to 
tissue damage in the deeper dermis caused by the high fluid pressure within the skin.  
Most subjects reported a sharp piercing pain at this high pressure (discussed later in this 
chapter) which further validates our hypothesis that tissue damage may have occurred.  
Overall, an increase in flow rate led to an increase in skin flow resistance for undamaged 
skin while a decrease in flow rate led to stabilization of skin flow resistance at higher 
volumes.   
4.2.2.4. Effect of Hyaluronidase 
 To further test the hypothesis that the dermis offers resistance to fluid flow, 
hyaluronidase, an enzyme which is known to reduce skin’s flow resistance by breaking 
down glycosaminoglycans within collagen fibrils (Levick 1987) was delivered via 
microneedles at 0.3 mL/min and compared to saline delivery at the same conditions.  The 
pressure associated with hyaluronidase delivery increased up to 600 µl beyond which the 
pressures started to stabilize (one-way ANOVA; p > 0.05), while the saline delivery 
pressures continued to rise.  This reduction in pressure shows that the dermal structural 
components consisting of proteoglycans and glycosaminoglycans are a contributing 
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factor to skin’s resistance to flow as their subsequent degradation by the infusion of 


















Figure 4.9: Effect of hyaluronidase on skin resistance to flow. Microneedles were 
inserted into the dermis at 750 µm and ( ) saline, T2 and ( ) hyaluronidase, T9 
were infused at a rate of 0.3 mL/min.  Data are expressed as mean values ± SD, n = 
10. 
4.2.3. Microneedle Insertion Pain 
 Analysis of pain scores was performed for microneedle insertion and fluid 
infusion.  First, to determine the pain associated with microneedle insertion, retraction, 
and hypodermic needle insertion, subjects were asked to rate the pain they felt using the 
VAS scale.  Figure 4.10 shows that all microneedle-based intradermal insertions, 
including needle insertion followed by retraction, were less painful than the hypodermic 
intradermal needle control insertion (one-way ANOVA, Tukey’s post-hoc comparison; p 
< 0.05).  These hollow microneedle results are consistent with previous solid microneedle 
pain study results (Kaushik, Hord et al. 2001; Gill, Denson et al. 2008; Haq, Smith et al. 
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2009).  While previous studies compared results to hypodermic needles inserted 
vertically into the subcutaneous space where it is expected that needle insertion will 
cause pain due to the stimulation of nerve bundles in the subcutaneous region; the results 
in this study show that microneedles are also less painful than hypodermic needles 
inserted intradermally using the Mantoux method.  This is likely due to the fact that the 
hypodermic needle was inserted into the skin at an acute (almost parallel) angle to a 
length of almost 3 mm, thereby leading to piercing of a larger tissue area and 
consequently increasing the chances of encountering dermal nerve endings.  Additionally, 
due to lack of a depth control mechanism for the Mantoux technique, the intradermal 
insertion of hypodermic needles could still reach the deeper dermis and further stimulate 
the free nerve endings located in the deeper nerve plexus.  Moreover, the microneedles 
used in this study were thinner than the 26-gauge intradermal hypodermic needle and 
hence had a lower chance of stimulating dermal nerve endings (Arendt-Nielsen, Egekvist 
et al. 2006).  The 4 mm subcutaneous microneedle insertion was as painful as the 
hypodermic needle insertion (Student’s t-test; p > 0.05).  This is presumably due to 





















Figure 4.10: Absolute microneedle insertion pain scores on a 100 mm VAS scale for 
the five microneedle depths and the 26-gauge intradermal needle.  Data are 
expressed as mean ± SD and n = 10 for all cases, except 750 µm where pain scores 
from T2, T7-T9 were averaged and n = 40 in this case. * p < 0.05. 
4.2.4. Fluid Infusion Pain 
 Analysis of pain associated with fluid infusion was performed to determine which 
study parameters led to more painful delivery and thereby determine parameters to 
minimize pain.  The pain scores were also used to interpret the flow conductivity data as 
changes in pain sensation during infusion may help understand what is happening in the 
skin.  In order to do this, subjects were asked to rate the pain they felt during infusion at 
200 µl intervals.  The pain scores were normalized relative to the hypodermic needle 
insertion scores and plotted as a function of volume.   
4.2.4.1. Effect of Depth 
 The effect of needle depth of infusion pain was studied at a constant flow rate of 
0.3 mL/min (Figure 4.11).  The pain for the shallowest insertion depth site, T1 at 500 µm 
was not affected by an increase in volume delivered (or infusion pressure).  The pain for 
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T1 remained almost constant throughout the 1 mL delivery (one-way ANOVA; p > 0.05).  
Upon delivery of the final 200 µl, the pain slightly increased, however, it was not 
significant from the previous 800 µl.  This is presumably due to the fact the fluid 
remained in the upper dermal layers and in spite of the high infusion pressure, did not 
flow deep enough to contact the deeper dermal free nerve endings.  The slight (but non-
significant) increase during the last 200 µl indicates that further fluid delivery may lead 
to further increase in pain at volumes greater than 1 mL.  Comparison of the T1 infusion 
pain scores at all volumes with the T1 insertion scores revealed no significant difference 
(one-way ANOVA; p > 0.05).   
 The pain scores for T2 (750 µm) and T3 (1 mm) infusion increased gradually over 
the infusion procedure, however, the increase was not significant until the last 200 µl 
(one-way ANOVA, Tukey’s post-hoc comparison; p < 0.05).  This increase in pain after 
delivery of 800 µl could be due to fluid flowing into the deeper dermis under high 
pressure experienced by T2 and T3 at these volumes, subsequently stimulating the dermal 
pain receptors in the dermal plexus.  While T1 also experiences similar pressures, it is 
likely that the 250 µm difference in depth between T1 and T2 was enough to prevent 
fluid from flowing deep enough to cause pain.  This pain could also be due to large 
spreading of fluid within the dermis itself thereby increasing the chances of encountering 
nerves.  The increased pain during the last 200 µl (for T2 and T3) was described by 
subjects as slight burning which confirms that mechanical receptors in the dermis were 
stimulated as they are responsible for eliciting burning sensation (Rook, Burns et al. 
2004).  Comparison of the T2 and T3 infusion pain scores with their respective insertion 
scores revealed no significant difference until the last pain measurement (one-way 
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ANOVA; p > 0.05 till 800 µl).  Further, there was no significant difference between the 
pain scores for T1, T2, and T3 during the entire infusion process (two-way ANOVA; p > 
0.05) indicating that increasing or decreasing microneedle depth within the dermis did 
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Figure 4.11: Normalized (relative to hypodermic needle insertion) pain scores over 
the 1 mL infusion process to determine the effect of microneedle depth on infusion 
pain. T1 = 500 µm, T2 = 750 µm, T3 = 1 mm, T4 = 4 mm (subcutaneous), and T5 = 
hypodermic needle (intradermal).  All infusions took place at the medium flow rate 
of 0.3 mL/min and delivered saline.  Data are expressed as mean ± SD and n = 10 for 
all sites.    
 Subcutaneous delivery through the 4 mm microneedle (T4) led to pain scores that 
were as high as the 4 mm insertion pain throughout the 1 mL infusion (one-way 
ANOVA; p > 0.05).  This is possibly due to the needle being in contact with the 
subcutaneous nerves during the entire infusion process and also due to flow of fluid in to 
the hypodermis where nerve fibers and corpuscles with large receptive fields are present.  
Further, even though subjects were asked to not consider the insertion pain in the infusion 
scores, it is possible that some of this high infusion pain is attributed to residual pain 
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from the needle insertion procedure itself.  Overall, there was no effect of volume on the 
pain associated with infusion through microneedle site T4 (one-way ANOVA; p > 0.05). 
 Intradermal delivery through the hypodermic needle (T5) led to pain scores lower 
than the needle insertion itself for the first 400 µl (one-way ANOVA, Tukey’s post-hoc 
comparison; p < 0.05).  During infusion of the remaining 600 µl, the pain scores 
continued to increase with volume and were as painful as the hypodermic needle 
insertion itself (one-way ANOVA, p > 0.05).  This is probably due to spreading of saline 
within the dermis leading to an increased probability of contacting nerves and also due to 
flow into the deeper dermis, and possibly even the hypodermis to some extent, thereby 
causing stimulation of the nerves in these regions and subsequent increase in pain over 
time.  Further, the hypodermic needle infusion pain scores were relatively higher than 
that of intradermal microneedle infusions (T1-T3) during the first 400 µl (but not always 
significantly different).  The hypodermic injection pain scores were significantly higher 
for the next 400 µl (two-way ANOVA, Tukey’s post-hoc comparison; p < 0.05), and then 
the pain scores were comparable for the last 200 µl (two-way ANOVA; p > 0.05).   
4.2.4.2. Effect of Retraction 
Although retraction led to a significant increase in flow conductivity, retraction 
also led to a significant increase in pain upon delivery of 600 µl and beyond (one-way 
ANOVA, p < 0.05).  This 600 µl volume is also the point beyond which the delivery 
pressures started to stabilize (as seen in Figure 4.7).  This is probably because during the 
initial part of the infusion, fluid was delivered into the small tear created by the needle 
retraction (<< 10 µl) followed by flow to the papillary dermis above the needle tip and 
the reticular dermis near the needle tip leading to stretching of the skin and an increase in 
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pressure.  As the infusion pressure continued to the rise, the fluid continued to flow into 
the tear created by the needle retraction causing expansion of this region and possibly 
leading to tissue damage, thereby causing pain.  Further, since the pain score for T6 at 
600 µl is comparable with that at 1 ml for the 1 mm infusion, it is also likely that some of 
the fluid might have flown deeper into the dermis which may also be the cause of pain.  
Further, the retraction infusion pain scores were comparable with the pain scores 
associated with needle insertion and retraction procedure for the first 400 µl (one-way 
ANOVA; p > 0.05) after which the infusion pain scores were significantly higher for the 
remainder of the infusion (Tukey’s post-hoc comparsion; p < 0.05).  The retraction 
delivery pain scores were significantly higher than the T1 and T3 scores for the 600 µl 





















Figure 4.12: Normalized (relative to hypodermic needle insertion) pain scores over 
the 1 mL infusion process to determine the effect of retraction on pain.  T1 = 500 
µm, T2 = 750 µm, T6 = 1 mm insertion followed by retraction to 500 µm.  All 
infusions took place at the medium flow rate of 0.3 mL/min and delivered saline.    
Data are expressed as mean ± SD and n = 10 for all sites.   
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4.2.4.3. Effect of Infusion Flowrate 
The lowest flow rate, T8 = 0.1 mL/min led to minimal pain scores (Figure 4.13) 
which increased slightly during the infusion process, however, the difference was not 
significant (one-way ANOVA; p > 0.05).  These pain scores were also similar to the 
corresponding T8 insertion pain scores which were significantly less than that of 
hypodermic needles.  This low pain throughout the 1 mL saline infusion is presumably 
due to the clearance of saline from the delivery site leading to low pressures which did 
not lead to saline flow to the deeper dermis.  As described previously, the medium flow 
rate (T2) saw an increase in pain during the last 200 µl, presumably due to flow of fluid 
into the deeper dermis, thereby contacting free nerve endings in the dermal nerve plexus 
or due to spreading of fluid within the dermis increasing the possibility of encountering 
nerves.  The high flow rate of 1 mL/min (T7) also saw an increase in pain scores with 
increasing volume; however, the pain was not significant until the last 200 µl.  During the 
last 200 µl, the pain was also significantly higher than the needle insertion pain (one-way 
ANOVA, Tukey’s post-hoc comparison; p < 0.05).  As seen in (Figure 4.8) previously, 
the flow conductivity also appeared to slightly decrease towards the end of infusion.  This 
is likely due to tissue damage caused by the high fluid pressure and also due to the 
subsequent flow of saline into the deeper dermis.  Further, (70%) of subjects reported a 
sharp piercing sensation during infusion of the last 200 µl during T7 delivery indicating 
that there was likely damage to the skin structure leading to this pain.  Comparisons of 
pain scores among the three different flow rates revealed no significant differences until 
the last 200 µl at which point the pain associated with low flow rate delivery was 
significantly less than that of the high flow rate (two-way ANOVA, Tukey’s post-hoc 
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comparison; p < 0.05).  Therefore increasing infusion flow rate did not have a significant 





















Figure 4.13: Normalized (relative to hypodermic needle insertion) pain scores over 
the 1 mL infusion process to determine the effect of infusion flow rate on pain.  T8 = 
0.1 mL/min (low flow rate), T2 = 0.3 mL/min (medium flow rate), T7 = 1 mL/min 
(fast flow rate).  All infusions took place at the depth of 750 µm and delivered saline.    
Data are expressed as mean ± SD and n = 10 for all sites.    
4.2.4.4. Effect of Hyaluronidase 
As seen from Figure 4.14, the VAS pain scores for hyaluronidase, T9, remained 
constant throughout the delivery procedure (one-way ANOVA; p > 0.05).  This is 
because the hyaluronidase broke down the dense dermal tissue structure which could 
allow the fluid to access a larger volume of skin and thereby reduced the need to form 
micro-cracks in the tissue which could be painful.  Comparisons of pain scores for the 
saline (T2) and hyaluronidase (T9) infusion procedures indicated similar pain scores, 
except for the final measurement point where the saline delivery was more painful than 
hyaluronidase (two-way ANOVA, Tukey’s post-hoc comparison; p < 0.05).  The T9 
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infusion and needle insertion pain scores were comparable at all volumes (one-way 






















Figure 4.14: Normalized (relative to hypodermic needle insertion) pain scores over 
the 1 mL infusion process to determine the effect of hyaluronidase on pain.  T8 = 
hyaluronidase, T2 = saline.  All infusions took place at the depth of 750 µm and a 
flow rate of 0.3 mL/min.  Data are expressed as mean ± SD and n = 10 for all sites.    
4.2.5. Pain and Pressure Relation 
As seen from the analysis of pain scores, the pain values typically increased with 
volume towards the end of the infusion process.  However, as seen in Figure 4.15, which 
shows a scatter plot representation of the normalized VAS pain scores versus pressure; 
pain scores did not always increase with pressure.  As seen from this figure and from the 
infusion pain analysis described above, only sites T2 (750 µm depth), T3 (1 mm depth), 
and T7 (high flow rate, 1 mL/min) saw a significant increase in pain scores with 




























T1 T2 T3 T4 T5 T6 T7 T8 T9
Figure 4.15: Scatter plot representation of the normalized VAS scores for all 
experimental conditions as a function of pressure. T1 ( ) = 500 µm, 0.3 mL/min; T2 
= ( ) 750 µm depth, 0.3 mL/min; T3 ( ) = 1 mm depth, 0.3 mL/min; T4 ( ) = 4 
mm depth, 0.3 mL/min; T5 ( ) = 26-gauge intradermal hypodermic needle, 0.3 
mL/min; T6 ( ) = 1 mm insertion, 500 µm retraction, 0.3 mL/min; T7 ( ) = 750 
µm depth, 1 mL/min; T8 ( ) = 750 µm depth, 0.1 mL/min; T9 ( ) = hyaluronidase, 
750 µm depth, 0.3 mL/min.   Data are expressed as mean for n = 10.  
To determine the pressure levels that caused pain to increase significantly, the 
normalized VAS scores were plotted for these 3 sites over the pressure ranges measured 
(Figure 4.16).  Pain scores for sites T2 and T3 significantly increased above 3000 mmHg 
and those for T7 increased significantly above 3500 mmHg (two-way ANOVA, Tukey’s 
post-hoc comparison; p < 0.05).  This could be attributed to either extreme stretching of 
the skin under high pressures, thereby leading to pain or due to flow of saline into the 
deeper dermis under high pressure thereby stimulating nerves or also due to subsequent 
























Figure 4.16: Normalized pain scores (relative to hypodermic needle insertion) as a 
function of pressure for sites T2 (saline, 750 µm, 0.3 mL/min), T3 (saline, 1 mm, 0.3 
mL/min), and T7 (saline, 750 µm, 1 mL/min).  
4.2.6. Overall Perception of Pain 
Upon completion of infusion for each treatment site, subjects were asked to rate 
their perception of pain for the overall infusion procedure ranging from no pain to worst 
possible pain.  Figure 4.17, shows the results from this survey.  More than 75% of the 
subjects rated all microneedle treatment sites, including the 4 mm subcutaneous insertion 
as being no more than mildly painful whereas only 36% rated hypodermic needles this 
way.  Further, approximately 25% of the subjects rated the shallow (T1 = 500 µm), slow 
(T8 = 0.1 mL/min), and hyaluronidase (T9) delivery procedures to be not painful at all.  
Moreover, almost 10% of subjects considered the subcutaneous 4 mm delivery (T4) and 
the hypodermic needle intradermal delivery (T5) to be severely painful.  No intradermal 


























Figure 4.17: Overall perception of pain for the 9 treatment sites.  Subjects were 
asked to rate the overall pain (insertion and infusion) for each treatment site as no 
pain, no pain to mild pain, mild pain, mild to moderate pain, moderate pain, 
moderate to severe pain, severe pain, and worst possible pain. n = 10 for each 
treatment site.  
4.2.7. Skin Observation 
 Lastly, all skin sites were visually examined and imaged by photography and 
ultrasound echography before and after treatment as seen in Figure 4.18.  Visual 
observation immediately after infusion revealed that all sites with the exception of 
subcutaneous injection via T4 were characterized by skin the formation of a characteristic 
skin wheal or bleb (raised skin surface due to stretching of the skin) indicating that all or 
part of the fluid delivered was within the dermis.  Formation of such a bleb is a well 
known characteristic of intradermal injections and is expected during microneedle 
delivery (Springhouse 2005).  Raised local blanching was also seen at the injection site.  
The bleb completely subsided within 2 h for all treatment sites.  While most microneedle 
site blebs had similar characteristics and measured approximately 1.5 cm in diameter, the 
hyaluronidase bleb appeared slightly less raised and more dispersed laterally (~1.8 cm 
diameter).  This could be due to the fact the hyaluronidase is a spreading agent and hence 
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flowed more readily within the skin due to breakdown of the dermal matrix.  Further, the 
4 mm subcutaneous microneedle injection did not produce any bleb either since no saline 
was deposited within the dermis.  All 9 treatment sites experienced slight erythema which 
was mostly resolved within 2 h and completely resolved in 24 h.  The hypodermic needle 
site also experienced punctate redness at the needle insertion site which resolved within 
24-48 h.   
 Figure 4.18 also shows ultrasound echographs to supplement the skin 
photographs.  The ultrasound image depicts the different layers of the skin as different 
echogenic layers.  The thin bright white line at the topmost part of the image depicts the 
epidermis; the green layer (with red and yellow areas) below it is the dermis.  The black 
area below the dermis is the hypodermis.  Comparison of before and after echographs for 
all intradermal microneedle sites (T1-T3, T6-T9) show a thicker dermis and curved skin 
structure after infusion.  The thicker dermis is due to the swelling of skin as a result of 
fluid injection within the dermis and the curved structure represents the curvature of the 
bleb.  The subcutaneous delivery site does not show these characteristics further 
confirming that fluid was delivered to the hypodermis, as expected.  Further, most 
intradermal images also show a thin dark region between the epidermis and dermis after 
infusion (illustrated by red arrows in Figure 4.18).  We hypothesize that this dark space 
may represent saline that is present in the dermal/epidermal junction and the papillary 
dermis.  Further, dark spaces are also seen within the dermis after infusion for all 
intradermal delivery sites.  It is likely that these regions also represent the saline 
delivered to the dermis.  The dark spaces for the T1 to T3 echographs (yellow arrows) 





evidence that this region could represent the saline.  The insertion/retraction site, T6 also 
shows a dark space beginning at approximately 500 µm and continuing throughout the 
thickness of the dermis which could possibly be along the saline flow channel/tissue 
damage region.  The T7 site shows several small dark spaces between the green color 
representing the dermis beginning at 750 µm.  The slow flow rate site, T8 indicated 
swelling as seen by the thicker green dermal layer, however, does not show any dark 
deeper regions.  This is presumably because the pressures for T8 were not high enough to 
push fluid deeper into the dermis.  The hyaluronidase site, T9 has a low-echogenic (less 
density of brightness, i.e: less yellow and red) dermis as compared to the before image 
and also compared to after images of saline infusion sites.  Several dark spaces are seen 
among the green region (orange arrow).  These dark regions could represent spaces filled 
with either interstitial fluid or excess hyaluronidase after the breakdown of the dense 
dermal matrix. 










Figure 4.18: Before and after photographs (immediately after) and echographs (~ 5 min after) of skin sites.  The bright white 
line on the top of the echograph represents the epidermis; the green layer below it depicts the dermis; the black region below 
the dermis is the hypodermis.  Red arrows indicates dark space between epidermis and dermis which may possibly depict 
saline.  Yellow arrows indicate possible saline depots/pathways.  The orange arrow indicates low echogenic regions after 





 Therefore, in conclusion, this experiment studied the effect of microneedle and 
infusion parameters on flow conductivity of skin and associated pain for the first time.  
Microneedle-based delivery within the dermis led to an increase in infusion pressures due 
to the high resistance offered by the skin.  Microneedle retraction and low infusion flow 
rates helped reduce the skin resistance to allow fluid to be delivered at low pressures.  
Further, the addition of hyaluronidase led to breakdown of the dermal components, 
thereby increasing flow conductivity.  The pain analysis from this study helped interpret 
the flow data to understand the possible flow of fluid within the skin and also helped 
determine the parameters causing pain. Pain scores indicated that microneedles can be 
used to deliver liquid drugs up to 800 µl in volume regardless of insertion depth (without 
retraction) and flow rate without significant increase in pain from that of the needle 
insertion itself.  This is practical for clinical purposes, since most intradermal applications 
are indicated to deliver of no more than 500 µl of bolus drug due to the low volume 
capacity of the dermis as compared to the hypodermis (Washington, Washington et al. 
2001; Lynn and Evans-Smith 2003).  In the unusual event that intradermal delivery of 
larger volumes is required, shallow insertion depth, low infusion flow rates, and the 






4.3. Insulin Delivery to Type 1 Diabetes Subjects using Hollow Microneedles2 
4.3.1. Introduction 
Insulin was first administered in 1922 by intramuscular injection.  However, it 
was rapidly determined that subcutaneous insulin delivery had similar efficacy to 
intramuscular injections but was significantly less traumatic (Cefalu 2004).  
Subcutaneous administration was subsequently established as the new delivery standard.  
Insulin is currently delivered through the subcutaneous route by means of hypodermic 
needles, insulin pens, and catheters connected to insulin pumps. However, these 
treatment methods are inconvenient and painful and often lead to poor patient 
compliance, especially among children and adolescents with type 1 diabetes.  These 
patients have a tendency to omit their insulin injections because of fear, pain, anxiety, 
and inconvenience associated with subcutaneous needles and catheters (Hanas and 
Ludvigsson 1997; Zambanini, Newson et al. 1999; Mollema, Snoek et al. 2001; Hanas 
2004), leading to poor diabetes management.  
It has been 87 years since insulin was first given to individuals with diabetes, yet 
subcutaneous administration continues to remain the prevalent means of insulin delivery.  
In order to improve patient compliance, there is a need for new and improved delivery 
systems.  Intradermal insulin delivery is an attractive administration route because it is 
less invasive than subcutaneous delivery.  Additionally, the presence of a rich capillary 
bed in the dermis may allow for rapid uptake of drugs delivered intradermally.  Previous 
studies have shown that intradermal delivery can accelerate the pharmacokinetics of 
                                                 
2 This work was published in part as Gupta, J., Felner, EI, and Prausnitz, M.R. “Minimally invasive insulin 





proteins (Guy 2007).  The pharmacokinetics and pharmacodynamics of intradermal 
insulin, however, have not been studied.  Additionally, current intradermal systems 
involve use of the Mantoux technique where a hypodermic needle is carefully inserted at 
an angle into the skin so as to reach the dermis.  This method is unreliable as it is difficult 
to correctly place the needle within the dermis and requires medical personnel to 
administer the injection (Mikszta and Laurent 2008).  Hence, patients cannot self-
administer using this method.  
 Inhaled insulin is another alternative to subcutaneous insulin delivery, and is 
noninvasive and can eliminate the pain and apprehension associated with injections.  
However, introduction of the first Food and Drug Administration approved inhalable 
insulin, Exubera (Pfizer, New York, NY), failed to achieve patient and physician 
acceptance for various reasons such as low bioavailability, high cost, cumbersome device 
design, side effects, and unknown health risks (Bailey and Barnett 2007; Barnett 2008).   
Moreover, it requires continued delivery of basal insulin through traditional subcutaneous 
methods.  Several other novel and minimally invasive delivery methods such as oral, 
buccal, transdermal, and nasal systems are being investigated to determine effectiveness 
and increased patient compliance; however, these technologies are mostly still in 
preclinical development.  Hollow microneedles have the potential to serve as a minimally 
invasive intradermal insulin delivery system to increase patient compliance.  These 
microneedles can reduce the pain, apprehension, and inconvenience associated with 
insulin delivery because they are long enough to breach the skin’s barrier and allow for 





This chapter presents the first proof-of-principle study showing delivery of insulin 
through a microneedle device in human subjects with type 1 diabetes.  To first determine 
the ideal microneedle insertion depth and then evaluate the effect of insulin delivery 
through a microneedle, the study was carried out in three phases.  In the first phase, the 
minimum microneedle insertion depth was determined based on the pharmacodynamic 
response to insulin delivery at different microneedle insertion depths within the skin.  In 
the second phase, the minimum depth was used to determine the efficacy of hollow 
microneedle insulin delivery in reducing postprandial glucose levels.  In the third phase, 
the pharmacokinetics, pharmacodynamics, and pain associated with microneedle-based 
insulin delivery were compared to that of conventional insulin catheter-based delivery. 
4.3.2. Phase 1: Effect of Microneedle Insertion Depth  
To determine the minimum transdermal insertion depth of microneedles for 
effective insulin delivery, we initially administered 10 units of 100-U Humalog insulin to 
Subject 1 using a conventional 9 mm catheter.  As expected, plasma free insulin levels 
rose, reaching a peak at tmax = 1 h (Figure 4.19a), and plasma glucose levels decreased 
correspondingly (Figure 4.19b).  At the next two study visits, the subject received a bolus 
of 10 and 15 units of 50-U humalog at microneedle insertion depths of 5 mm and 3.5 
mm, respectively.  Although at both of these depths, tmax occurred at 30 min after bolus 
delivery, both plasma insulin concentration values were lower than that of the catheter. 
The plasma glucose levels decreased correspondingly, however, at slower rates than in 
the case of the standard catheter.  We then used the microneedle to deliver 15 units of 50-




insulin levels with a peak at tmax = 30 min.  Plasma glucose levels declined very rapidly, 
























10 U: Control Catheter 9 mm
10 U: Microneedle 5 mm
15 U: Microneedle 3.5 mm
























10 U: Control Catheter 9 mm
10 U: Microneedle 5 mm
15 U: Microneedle 3.5 mm
15 U: Microneedle 1 mm
b
Figure 4.19: Microneedle-based insulin delivery at 1, 3.5, and 5 mm insertion depths 
in comparison to 9-mm catheter control (Phase 1). a) Plasma free insulin level and 
b) corresponding plasma glucose level response. Microneedle-based insulin delivery 
at 1 mm led to high insulin absorption and rapid glucose level reduction. 
A comparison of the area under the insulin curves (AUICs) for the first hour after 
delivery (Figure 4.20a) indicated that the 1-mm microneedle led to higher insulin 
absorption than the other study and control treatments.  Further, comparison of the 
change in plasma glucose levels over the first hour after insulin delivery (Figure 4.20b) 
revealed that the shallow 1-mm microneedle delivery was most effective in reducing 




four delivery conditions were available only for the first hour (as a result of stopping 



















































Figure 4.20: Microneedle-based insulin delivery results for Phase 1. a) AUIC for 0-1 
h and b) change in plasma glucose levels from 0 to 1 h.  Within 1 h of insulin bolus, 
the 1-mm microneedle (MN) delivery case led to an AUIC more than twice that of 
the catheter control and produced a higher change in plasma glucose levels. 
This phase revealed that the 1 mm microneedle depth had the fastest 
pharmacokinetics and pharmacodynamics.  We hypothesize that this is due to the fact that 
the microneedle targeted the papillary dermal region, which has a rich capillary network 
(Lawrence, Bell et al. 2006).  It is this heavily vascularized area that likely permits 
effective insulin uptake and systemic absorption.  Although this result could also be 
attributed to the fact that the experiment at 1 mm involved 50% more insulin than the 9-
mm catheter case, the increase in AUIC and change in plasma glucose levels are both 
more than doubled at 1 mm, which suggests that there may be increased efficacy.  
Moreover, subcutaneous delivery at 3.5 mm also used a 50% higher insulin dose than the 
control but had a lower AUIC than both the 1-mm microneedle and the 9-mm control, 
which also suggests increased efficacy and is consistent with our hypothesis that uptake 




3.5-mm and 5-mm deliveries had lower insulin peaks and slower glucose response 
compared to the 9-mm catheter, which may be due to the fact that the microneedle was 
not deep enough in the hypodermis for effective systemic delivery.  This explanation is 
consistent with Subject 1’s observation from her daily experience that she typically has 
poor absorption in the upper hypodermis and generally requires long infusion sets (> 9 
mm) for effective delivery.   
Overall, this phase of the study led to establishment of the 1-mm microneedle 
depth as not only the minimum, but also the optimum, transdermal depth for effective 
insulin delivery among the three microneedle depths considered. Microneedle-based 
delivery at the 1 mm depth was at least as effective as subcutaneous catheter delivery.  
Based on these findings, this depth was used in phase 2 on the second subject to 
determine effect of microneedle insulin delivery on postprandial glucose levels. 
4.3.3. Phase 2: Effect of Microneedle-Based Insulin Delivery on Postprandial Glucose 
Levels (unequal control and microneedle insulin doses) 
To determine if microneedle-based insulin delivery is also effective in reducing 
postprandial glucose levels, insulin delivery was assessed with a bolus infusion 
immediately before a 75-g carbohydrate meal.  Based on the second subject’s insulin-to-
carbohydrate ratio of 1 unit for every 10 g of carbohydrate ingested, insulin delivery 
through the subcutaneous catheter was assessed with a bolus of 7.5 units of 100-U 
Humalog.  Plasma free insulin levels rose over the course of the first hour and then 
steadily declined (Figure 4.21a).  Plasma glucose levels initially increased and eventually 
started to decrease after 1.5 h. Plasma glucose levels approximately returned to the pre-




units of 50-U Humalog at 1 mm through the microneedle device, followed by the 
consumption of an identical standardized meal within 5 min of bolus infusion.  In both 
microneedle experiments, the tmax occurred at 45 min after infusion.  Moreover, plasma 
glucose levels decreased throughout the duration of both experiments.  An evaluation of 
the AUIC over a 1-h and a 2-h period immediately after delivery revealed that the 
pharmacokinetics of the insulin delivery were faster for the microneedle as compared to 
the subcutaneous catheter (Figure 4.22a).  Similarly, measurement of plasma glucose 























7.5 U: Control Catheter
15 U: Microneedle Run1




























Figure 4.21: Microneedle-based insulin delivery at 1 mm insertion depth in 
comparison to 9-mm catheter control following consumption of a standardized meal 
immediately after insulin bolus (Phase 2). a) Postprandial plasma free insulin level 
profile and b) corresponding plasma glucose level response.  Microneedle-based 





















































Figure 4.22: Microneedle-based insulin delivery results for Phase 2.  a) AUIC for 0-1 
h and 0-2 h and b) change in plasma glucose levels from 0 to 2 h. Microneedle (MN)-
based insulin delivery led to an AUIC slightly more than double that of the catheter 
control for both 0-1 h and 0-2 h periods and larger reduction in plasma glucose 
levels. Similarity of results from the two microneedle runs demonstrates 
reproducibility. 
This phase demonstrated that microneedles can be used to effectively reduce 
postprandial glucose levels in a reproducible manner as seen by the two trials on the same 
subject.  The first two test phases of the study involved delivery of insulin doses that 
were 1.5 to two times higher than the subject’s usual dose to ensure that insulin delivered 
via microneedles reached the systemic circulation.  However, the rapid decline in 
postprandial glucose levels and the high AUIC values indicate that the doses 
administered in this study were higher than required.  Guided by the results of these two 
phases and to make a stronger claim that microneedles are more effective than catheters, 
phase 3 of this study was carried out in five subjects with the same insulin doses being 





4.3.4. Phase 3: Effect of Microneedle-Based Insulin Delivery on Postprandial Glucose 
Levels (equal control and microneedle insulin doses) 
 To further strengthen the claim that microneedles lead to faster pharmacokinetics 
and improved postprandial glycaemic control, plasma free insulin (Figure 4.23a-b) and 
change in plasma glucose (Figure 4.23c-d) profiles for equal microneedle and catheter 
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Figure 4.23: Plasma free insulin levels for a) catheter-based and b) microneedle-
based insulin delivery for the five study subjects over 2.5 h.  Change ( ) in plasma 
glucose levels for c) catheter-based and d) microneedle-based insulin delivery for the 
five subjects.  Although the study was carried out over 3.5 h, the data were analyzed 
up to 2.5 h as some trials had to be stopped at this time point due to hypoglycaemia.  
 = subject 1,  age: 44 administered 6 units of lispro insulin;  = subject 2, age: 39, 
administered 10 units;  = subject 3, age: 11, administered 15 units;  = subject 4, 

























































































Using the above insulin profiles, the pharmacokinetic parameters of Cmax, tmax, 
and AUIC (from equation 3.2) were determined.  These values together with the insulin 
profile data from Figure 4.23 and Equations 3.3-3.5) were used to calculate the rate 
constants for absorption (ka) and elimination (kel) for the two treatment methods.  The 
results are summarized in the table below. 
Table 4.2: Pharmacokinetic parameters for phase 3 insulin delivery 
Parameter Catheter Microneedle p-value 
Cmax (µU/mL) 24.6 ± 7.5 32.2 ± 14.0 0.07 
*tmax (min) 57.0 ± 20.0 27.0 ± 13.0 0.01 
AUIC (μU-h/mL) 29.3 ± 18.2 
4.1 10-3± 2.1 10-3 
32.6 ± 14.8 
7.7 10-3± 3.2 10-3 
0.51 
*ka (min-1) 
5.9 10-2± 1.3 10-2 8.1 10-2± 3.3 10-2 
0.03 
kel (min-1) 0.21 
* indicates p < 0.05 via Student’s t-test; data are expressed as mean ± SD; n = 5 
As summarized in Table 4.2 above, intradermal microneedle delivery achieved a 
31% higher peak insulin concentration than subcutaneous catheter delivery in less than 
half the time, in spite of administration of the same insulin dose for both treatments.  This 
significant difference in the PK parameter of tmax indicates that microneedle-based insulin 
delivery had faster pharmacokinetics than the catheter.  The area under the insulin curve 
over a 2.5 h time period was not significantly different between the microneedle and 
catheter deliveries indicating both treatments led to comparable insulin absorption 
overall.  Therefore, although both treatments led to similar relative insulin bioavailability, 
intradermal microneedle-based delivery led to much faster absorption.  This faster 




rate constants (ka) for the two treatments as seen in Table 4.2.  The absorption rate 
constant for intradermal microneedle treatment was significantly higher, being almost 
two times that of the subcutaneous catheter treatment (Student’s t-test; p < 0.05).  This is 
due to rapid uptake of insulin by the dermal vasculature, achieved by targeting 
microneedle-insulin delivery to the papillary dermal region having a rich capillary 
network.  The elimination rate constants for the two treatment methods were not 
significantly different (Student’s t-test; p > 0.05). 
Considering the pharmacodynamic response, as seen in Figure 4.24, three out of 
five subcutaneous catheter treatments did not lead to any blood glucose reduction over 
the entire study period, whereas all intradermal microneedle treatments led to reduction 
either close to or below initial glucose levels.  The average changes in blood glucose 
levels for the microneedle and control treatments over a 2.5 h period were ΔBGmicroneedle = 
-55 ± 49 mg/dL and ΔBGcatheter = + 13 ± 102  mg/dL.  Thus, although subjects were 
administered the same insulin dose and started at similar baseline glucose levels for their 
microneedle and control treatments, intradermal microneedles were much more effective 
than subcutaneous catheters in reducing postprandial glucose levels.   
Overall, intradermal microneedle delivery enabled faster onset, higher peak 
insulin concentration, and faster return/maintenance of normoglycaemia. This suggests 
that intradermal microneedles may provide better glucose control, which is critical to 
reducing diabetic complications, and enable more efficient utilization of insulin, thereby 





























Figure 4.24: Comparison of the net change in plasma glucose levels between the two 
treatment methods, ( ) catheter and ( ) microneedle, for each of the five subjects.  
For the same dose and baseline glucose, microneedles were more effective than 
catheters in reducing plasma glucose levels either to or below the baseline glucose 
levels. 
4.3.5. Assessment of Pain 
In addition to improved pharmacokinetics and pharmacodynamics, we also 
hypothesized that microneedles can improve patient compliance by being less painful 
than catheters.  We therefore asked subjects to score the pain associated with the catheter 
and microneedle insertions as well as with the insulin infusion procedures on a visual 
analog scale ranging from 0 (no pain) to 100 (worst imaginable pain) mm.  The 
microneedle insertion procedure (VASMN-insert = 8 ± 9 mm) was significantly less painful 
than the catheter insertion (VAScath-insert = 40 ± 13 mm) (student’s t-test; p < 0.05).  There 
was no significant difference in the pain scores for the infusion procedures (VASMN-infuse 
= 28 ± 15 mm and VAScath-infuse = 17 ± 16 mm), however, the microneedle infusion score 
can be further reduced by decreasing the infusion flow rate below 1 mL/min as seen in 




preferred microneedle treatment over their catheters.  There were no adverse events 
during the study.  These results suggest that insulin delivery using microneedles could 
increase patient compliance, particularly among children and adolescents, who have the 
tendency to omit insulin injections due to fear, pain, anxiety, and inconvenience 
associated with hypodermic needles and subcutaneous catheters (Hanas and Ludvigsson 
1997; Zambanini, Newson et al. 1999).    
4.3.6. Assessment of Intradermal Delivery and Dermal Irritation 
 Because skin thickness is approximately 3 mm (Bronaugh, Stewart et al. 1982), 
microneedle insertion at 900 µm and 1 mm depths is expected to be intradermal.  To 
confirm that the 900 µm (Phase 3) and 1 mm (Phase 2) insertion depths led to intradermal 
insulin delivery, the skin at the microneedle insertion site was visually observed 
immediately after bolus infusion until the end of the experiment.  Upon observing the 
skin, a raised wheal extending approximately 4-5 mm (depending on the volume 
administered) from the point of insertion was seen, consistent with the appearance of an 
intradermal injection (Figure 4.25a).  In comparison, visual observation of the 
subcutaneous catheter infusion site did not show any skin wheal (Figure 4.25b); however, 
moderate erythema and punctate redness at the catheter insertion site was observed in this 
case.  
 Erythema and edema scores were recorded (using the Dermal Draize scale 
described in section 3.6.8) throughout the study period for both treatments.  The catheter 
sites experienced well-defined to moderate erythema, while the microneedle sites had 





Figure 4.25: Surface view of the abdominal infusion site before, immediately after, 
and at 30-min intervals after insulin delivery in Subject 2 (Phase 2).  a) Insulin 
infusion site for microneedle-based delivery. A raised skin wheal was seen 
immediately after delivery.  Over time, the wheal subsided, and skin returned to 
normal.  Slight erythema was also observed which resolved over time, b) Insulin 
infusion site for catheter-based delivery.  Moderate erythema was seen at the point 
of catheter insertion and well-defined erythema in the vicinity of the insertion site.  
The erythema decreased over time but still remained mild at 2 h. No edema was 
observed for catheter delivery sites. 
Erythema scores gradually decreased for both treatments over time and were 




experienced very slight erythema at the end of the experiment and also had punctate 
redness at the needle insertion site.  With regards to edema, the catheter sites did not 
experience any edema as all insulin was deposited in the hypodermis.  Microneedle sites 
experienced moderate edema which was evident by visualization of a raised skin wheal.  
Overtime the skin wheal became less apparent, gradually subsiding over the course of the 














































Figure 4.26: a) Erythema and b) edema scores for ( ) catheter and ( ) microneedle 
treatment sites using the Dermal Draize scale.  Data are expressed as mean ± SD; n 
= 5. 
4.3.7. Conclusions 
 This study demonstrated for the first time that microneedle-based intradermal 
delivery can lead to faster insulin pharmacokinetics and tighter glucose control than 
subcutaneous catheters while causing significantly less pain in children, adolescents, and 
adults.  The potential clinical significance of these results is that intradermal 
microneedles may enable a more flexible insulin therapy regimen and allow for improved 
postprandial glucose control with improved patient compliance, improved health 




4.4. Local Anesthesia Using Hollow Microneedles in Human Subjects 
4.4.1. Introduction 
Local dermal anesthesia is commonly administered to reduce pain prior to 
procedures involving needlesticks such as venipuncture, intravenous catheterization, 
botulinum toxin injections and lumbar punctures, as well as prior to cutaneous surgical 
procedures such as skin biopsies (Houck and Sethna 2005).  While several methods of 
inducing local anesthesia exist, each of them comes with its own limitations. 
Hypodermic needle injection is the most common means of administering local 
anesthesia and allows for rapid onset with good efficacy; however, hypodermic needles 
can also cause pain, anxiety and distress to the patient and lead to poor patient 
compliance, especially among children (Holmes 1994; Zempsky 2008) and also require 
administration by experienced medical personnel.  Topical anesthetic creams and gels 
provide a painless and simple means of administering anesthesia, however, they have to 
undergo passive diffusion across the skin’s outermost barrier layer (stratum corneum) 
which leads to slow onset times ranging from 30 min to 1.5 h depending on the properties 
of the topical anesthetic agent (Houck and Sethna 2005; Zempsky 2008).  This delayed 
onset is the main barrier to widespread use of topical anesthetics for venous access 
procedures.  Some topical anesthetics also have the tendency to cause vasoconstriction 
and skin irritation (Houck and Sethna 2005) and many patients still experience pain in 
spite of using these anesthetics (Kleiber, Sorenson et al. 2002).   
More recently, several needle-free active drug delivery devices such as 
iontophoresis, sonoporation, jet-injection, laser ablation and thermal energy-based 




corneum barrier.  However, these procedures still require 2-15 min for 
preparation/loading, administration and onset, which is not practical in a busy clinical 
setting and these procedures can also lead to variable anesthesia (Houck and Sethna 
2005; Young 2007; Zempsky 2008).  Moreover, these devices can be cumbersome 
(Zempsky, Sullivan et al. 2004; Benson and Namjoshi 2008) and generally require a 
power source which adds cost and complexity to the device (Prausnitz, Gill et al. 2008).  
Due to these reasons, several such commercialized devices have had poor market 
acceptance (Vyteris Annual Report, 2008) and have been discontinued over the past few 
years (Anesiva Annual Report, 2008).   
An ideal local anesthesia system for use in ambulatory clinical environments 
should be effective, have rapid onset, cause minimal pain, be fast and easy to load and 
administer with minimal user training, be portable without bulky equipment and be cost 
effective (Houck and Sethna 2005).  
Microneedles have the potential to meet these criteria and provide a significant 
advance over current available methods.  This study demonstrates for the first time a) 
microneedle based drug delivery for a local therapeutic effect, b) efficacy of lidocaine 
delivery using microneedles to cause local anesthesia in comparison to hypodermic 
needles, and c) the pain associated with hollow microneedle injection of a drug.  The 
objective of this study was to test the hypothesis that minimally invasive microneedles 
cause less pain during injection of lidocaine but induce local anesthesia in human 
subjects with the same onset and efficacy as intradermal lidocaine injection using 





4.4.2. Study Population 
Fifteen healthy subjects were consented to participate in the study.  Of the 
enrolled subjects, data from 13 (87%) subjects were included in the forearm phase of this 
study.  The other two subjects experienced incomplete lidocaine delivery as determined 
by leakage of fluid from the microneedle prototype device (1 subject) and hypodermic 
needle (1 subject) during the injection procedure.  Data from 11 (73%) subjects were 
analyzed for the dorsum of the hand phase of the study due to leakage from the 
microneedle prototype device. 
4.4.3. Assessment of Pain 
To test the hypothesis that microneedle-based injection is less painful than 
hypodermic needle-based injection, VAS pain scores were measured for the two delivery 
methods (Figure 4.27).  Results indicated that microneedles were significantly less 
painful (Student’s t-test; p < 0.05) than hypodermic needles for both forearm and dorsum 
of the hand lidocaine injection procedures.  The pain scores for the forearm procedures 
were VASMN-forearm = 8.2 ± 10.4 mm for the microneedle and VASH-forearm = 24.6 ± 21.2 
mm for the hypodermic needle while the pain scores for the dorsum of the hand delivery 
were VASMN-dorsum = 4.8 ± 7.9 mm and VASH-dorsum = 22.0 ± 17.2 mm.  Therefore, on 
average, the hypodermic needle was 3 times more painful than the microneedle for the 
forearm injections, and was greater than 4 times more painful than the microneedle for 
the dorsum injections.  Further, upon being asked if they considered the lidocaine 
injection procedures to be painful, 92% of the forearm protocol subjects indicated that 
they did not consider the microneedle procedure to be painful as compared to only 25% 




said they did not consider the microneedle procedure to be painful, while only 27% 






























Figure 4.27: Box plot representation of the visual analog pain scores associated with 
lidocaine injection for the forearm and dorsum of the hand and for the IV catheter 
administration procedure following lidocaine anesthesia on the dorsum of the hand.  
The rectangular box represents the interquartile range (25% to 75%) of the VAS 
pain scores for each treatment procedure for the different study protocols (forearm 
delivery, dorsum delivery, and IV insertion on dorsum of the hand).  The vertical 
lines extend from the upper and lower boundary of the box to the maximum and 
minimum data points.  The hollow square inside the box represents the mean pain 
score for each treatment procedure.  The horizontal line inside each box represents 
the median for the corresponding treatment procedure. (* p < 0.05). 
4.4.4. Area of Numbness 
To determine if microneedle injection was as effective as hypodermic needles in 
inducing anesthesia over a clinically relevant area, the area of numbness was measured 




Figure 4.28 depicts the values for the numb areas extending radially from the injection 













































Figure 4.28: Map of the area of numbness from the injection site (0,0) extending 
along the four axes (T, B, L, R) as described in Figure 3.7 for a) t = 0 min, b) t = 7.5 
min, and c) t = 15 min.  The axes are in millimeters.  The distances from the 
injection site to the point of first sensation felt upon pin-prick testing were measured 
as radii along each axis for each time point, d) total area of numbness for the three 
measurement periods.  The radii for each treatment method at each time point were 
averaged to produce an average radius for each period.  The average radius was 
used to calculate the average numb area using the equation for a circle (πr2, where r 
is the average radius).  Microneedles were as effective as hypodermic needles in 
immediately inducing and maintaining anesthesia for at least 15 min.  = 
microneedle;  = hypodermic needle. 
As seen in Figures 4.28 a-c, uniform anesthesia was achieved in all directions, 
creating a circular area of numbness for both delivery methods.  There were no 




measurements between the two treatment methods (repeated measures three-way 
ANOVA: p > 0.05) for all time points.  The average radii in all directions for the 
microneedle sites were r0min-MN = 11.5 ± 2.7 mm, r7.5min-MN = 11.2 ± 2.3 mm, and r15min-MN 
= 10.1 ± 2.8 mm for times t = 0, 7.5, and 15 min respectively.   The corresponding 
average radii for the hypodermic needle were r0min-H = 10.6 ± 3.1 mm, r7.5min-H = 11.0 ± 
2.5 mm, and r15min-H = 11.9 ± 2.6 mm.   
The areas of numbness calculated as a circle with the average radius at each time 
point are shown in Figure 4.28d.  The average areas over the 15 min measurement period 
were 4.0 ± 1.8 cm2 and 4.3 ± 1.9 cm2 for the microneedle and hypodermic needle treated 
forearm sites respectively.  There were no significant differences (repeated measures two-
way ANOVA: p > 0.05) among the anesthetized areas for both treatment methods at any 
time point over the 15 min time period.  Thus, microneedles were as effective as 
hypodermic needles in inducing anesthesia over a clinically relevant area. 
4.4.5. Depth of Numbness 
To test the depth of anesthesia induced by lidocaine injected using a 500-μm 
microneedle compared to a hypodermic needle, a 26-gauge, 9.5 mm long hypodermic 
needle was inserted into the forearm skin at the site of lidocaine injection until subjects 
indicated they felt a sensation.  This depth was measured at t = 0, 7.5, and 15 min after 
injection and is shown in Figure 4.29.  The depth of numbness for the microneedle sites 
were d0min-MN = 9.1 ± 1.6 mm, d7.5min-MN = 9.1 ± 1.2 mm, and d15min-MN = 8.7 ± 1.8 mm at t 
= 0, 7.5, and 15 min respectively.  The corresponding depth of numbness for the 
hypodermic needle sites were d0min-H = 9.4 ± 1.5 mm, d7.5min-H = 9.5 ± 1.1 mm, and d15min-




two delivery methods across all time points (repeated measures two-way ANOVA: p > 
0.05).  Therefore, microneedles were as effective as hypodermic needles in inducing 

















Figure 4.29: Depth of numbness for each treatment procedure at the three different 
time points after lidocaine delivery on the forearm.  Microneedles were as effective 
as hypodermic needles in immediately inducing deep anesthesia for at least 15 min.  
 = microneedle;  = hypodermic needle. 
4.4.6. Efficacy of Delivery Method Based on Venous Cannulation 
To further test the efficacy of microneedle-based lidocaine delivery for use in 
clinical applications, lidocaine was delivered close to a vein on the dorsum of the hand.  
This was followed immediately by insertion of an IV catheter into the vein and 
measurement of pain.  Figure 4.27 (seen previously) shows the VAS pain scores for the 
IV insertion procedure.  The average VAS pain score for the IV cannulation procedure 
for the microneedle treatment was VASMN-IV = 4.2 ± 4.8 mm and the score was VASH-IV 
= 1.6 ± 2.7 mm for the hypodermic needle.  Statistical analysis indicated that there was 
no significant difference between the pain scores for the two treatment methods 
(Student’s t-test: p > 0.05).  Therefore, microneedles were as effective as hypodermic 




percent (9 out of 11) of the subjects considered the IV insertion post microneedle 
treatment to be painless and 91% (10 out of 11) considered cannulation following 
hypodermic needle treatment to be painless.         
4.4.7. Onset of Anesthesia 
As seen from Figures 4.28 and 4.29, the area and depth of numbness from the 
forearm protocol were the same at t = 0 min for both the microneedle and hypodermic 
needle injections.  Further, there was no significant difference in the IV catheter 
administration pain scores for the two treatment methods immediately after lidocaine 
injection.  These results indicate that microneedle-based lidocaine injection had the same 
rapid onset of anesthesia as hypodermic needles. 
4.4.8. Preference of Treatment Method 
To establish if microneedles would be clinically accepted by patients, at the end 
of each protocol (forearm and dorsum of the hand), subjects were asked which treatment 
method they would prefer (first procedure versus second procedure) to receive in a 
clinical setting.  Seventy-seven percent (10 out of 13) of the subjects from the forearm 
injection protocol said they would prefer microneedles over hypodermic needles.  For the 
dorsum protocol, treatment preference was assessed for the overall procedure (i.e. 
lidocaine injection and IV catheter insertion) with 82% (9 out of 11) of the subjects 
indicating that they would prefer the microneedle delivery system.  Thus, even though the 
subjects were blinded to the treatments, a large majority of the subjects preferred 





4.4.9. Local Skin Reaction and Adverse Events 
To study the effect of microneedles on skin irritation, the treatment sites were 
visually examined for local skin reactions.  Immediately after injection, a distinct raised 
skin wheal confirming intradermal delivery was observed at the treatment site (Figure 
4.30).  In subjects with light skin, very mild erythema and slight skin blanching was also 
observed.  Both the skin wheal and erythema were either reduced or gone within 1 h of 
treatment.  Within 24 h of treatment, subjects self-reported that there were no signs of 
erythema or edema.  Upon treatment with hypodermic needles, a similar raised skin 
wheal was also observed which either reduced or disappeared in 1 h.  In contrast, 
hypodermic needle insertions led to the presence of a drop of blood at the injection site 
immediately after treatment which was never seen after microneedle injection.  Punctate 
redness at the hypodermic needle insertion point also often appeared 1 h after treatment.  
Subjects reported no wheal after 24 h, however, in some cases subjects still observed 
punctate redness at the hypodermic needle injection site 24 h after treatment.  There were 
no adverse events observed or reported during or after the study.  Overall, skin responses 
to microneedle and hypodermic needle injection were similar, although hypodermic 









Figure 4.30: Representative images of the forearm injection sites immediately after 
lidocaine delivery and 1 h after delivery.  a) microneedle: a distinct symmetric skin 
wheal and slight erythema is seen immediately after delivery.  There is no evidence 
of blood.  One hour post injection, there is a faint wheal still present.  hypodermic 
needle: a distinct raised skin wheal with slight blanching of the skin and a drop of 
blood at the needle insertion point is seen immediately after delivery at t = 0.  Very 
slight erythema is also observed.  One hour after delivery, there is slight blanching 
and punctate redness at the injection site.  All sites returned to normal 24 h after the 
injection procedures with the exception of some hypodermic needles sites which still 
had punctate redness. 
4.4.10. Discussion 
This study tested the hypothesis that minimally invasive microneedles cause less 
pain during injection of lidocaine but induce local anesthesia in human subjects with the 
same onset and efficacy as intradermal lidocaine injection using hypodermic needles.  In 
terms of injection pain, microneedles were less painful than hypodermic needles for both 
the forearm and dorsum protocols as indicated by the VAS pain scores.  Previous studies 
have shown that the minimum difference in VAS scores for the results to be considered 
clinically significant is between 9 and 13 mm (Todd, Funk et al. 1996; Kelly 1998).  




pain scores for the two treatment methods for the forearm and hand dorsum delivery 
procedures were also significant from a clinical standpoint. 
Further, both microneedle and hypodermic needle-based lidocaine delivery 
induced anesthesia immediately after injection, indicating rapid onset time as seen from 
the results of area and depth of numbness at t = 0 and from the IV catheter insertion pain 
scores.  The 200 μl hypodermic needle injection on the forearm took approximately 5 s to 
complete while the microneedle injection took approximately 40 s due to the 300 μl/min 
flow rate set on the infusion pump.  The 100 μl hypodermic injection on the back of the 
hand took almost 3 s to complete while the microneedle infusion took 20 s.  While the 
microneedle injection required well under 1 min to perform, it was still significantly 
slower than hypodermic needle injection.  However, it must be noted that the infusion 
rate in this study was set to 300 μl/min.  This flow rate can be increased more than 3 
times to 1 ml/min, thereby, bringing down delivery times almost on par with hypodermic 
needle injection without leading to significant increase in pain for volumes as low as 200 
µl as seen in section 4.2.  From a clinical standpoint, when compared to other minimally 
invasive transdermal device alternatives such as iontophoresis, sonophoresis, and jet-
injectors which have application and onset times varying between 2-15 min, this time on 
the order of seconds is considerably shorter and is still shorter when compared to topical 
creams and gels which can have onset times > 1 h (Zempsky 2008) making microneedles 
attractive for use in busy clinical environments. 
This study also showed that the area of numbness produced by microneedle 
injection was similar to hypodermic needles on the order of 4 – 4.3 cm2.  Although 




microneedle and hypodermic needle injections over time, the visual maps of the areas in 
Figure 4.28 depict a decrease in microneedle numb areas over time while the hypodermic 
needle numb areas are increasing.  This may be due to the fact that in order for the 
lidocaine to have its complete effect, it must be injected in the upper dermis, just below 
the epiderms.  Failure to do so will lead to a delay in the complete effect until the deeper 
injected anesthetic diffuses to the target areas in the dermal-epidermal region (Holmes 
1994).  Since lidocaine injection via hypodermic needles was performed using the 
Mantoux method, whereby the needle depth cannot be controlled, it is likely that some of 
the lidocaine injected through hypodermic needles was delivered into the deeper dermis, 
leading to an increase in numb area over time as lidocaine made its way towards the 
upper skin layers.  By using a single microneedle in this study, we were able to induce 
clinically relevant anesthesia areas for applications in venipuncture, venous cannulation, 
lumbar puncture, port access and dermatologic procedures.  However, we hypothesize 
that by using multiple microneedles assembled as arrays, even larger areas could be 
generated. 
The results of this study indicated no significant difference between the depth of 
anesthesia induced by using microneedles and hypodermic needles.  While the maximum 
depth of numbness for both devices was measured to be ~ 9.5 mm in this study, it is 
possible that the depth of induced anesthesia could be deeper had the measurement 
needle been inserted deeper (> 9.5 mm) into skin.  Nonetheless, this depth of anesthesia is 
almost two times larger than that induced by EMLA (5 mm) (Bjerring and Arendt-




mm to 10 mm (Zempsky 2008).  Thus, by inserting a microneedle 500 mm deep into 
skin, we were able to generate numbness to a depth almost 20 times the needle length. 
With regards to cost, microneedles can be manufactured at low cost expected to 
be just a few cents each in mass production (Prausnitz, Mikszta et al. 2006).  Therefore, 
microneedles are likely to be cost competitive with other disposable/consumable systems 
such hypodermic needles and topical anesthetics which are significantly cheaper than 
some jet-injection systems which are priced on the order of $500 as well as energy based 
methods that require an investment in a controlling device, which can be as high as $5000 
(Young 2007).  Thus, microneedles appear to be a cost effective solution for reducing 
time to anesthesia onset in a minimally invasive and significantly less painful manner.                  
In this experiment, some of the microneedle injections were not completed (1 in 
forearm phase and 4 in dorsum phase) due to fluid leakage from the device.  The four 
leakage events on the dorsum of the hand occurred due to the relatively large ball shaped 
surface of the device which was difficult to optimally place near the raised veins on the 
dorsum of the hand.  It should be noted that the device used in this study was an initial 
lab prototype and that the final clinical device would be designed to eliminate leakage 
events. 
The potential medical significance of this work is that microneedles can provide a 
less painful yet efficacious alternative to current local anesthesia delivery systems.  The 
ability of microneedles to induce significantly less painful and rapid anesthesia prior to 
venous cannulation as shown in this study can have a large impact in reducing pain 
associated with venipuncture and IV cannulation.  This impact can be even more 




common sources of pain in the hospital and the second most common cause of worst pain 
during hospitalization (second only to the patient’s underlying disease) (Wong and C.M. 
1988; Cummings, Reid et al. 1996).  Further, the small size of these needles makes the 
needle visually less apparent to patients and might be a suitable alternative to hypodermic 
needles for patients with needle phobia.  Additionally, the rapid anesthesia onset makes 
microneedles extremely attractive for use in busy clinical settings and the envisioned 
simple device which requires minimal to no user training together with its low cost 
properties has the potential to increase uptake of microneedles among medical 
professionals.  
4.4.11. Conclusions 
This study demonstrated for the first time that minimally invasive microneedles 
cause less pain during injection of lidocaine but induce local anesthesia in human 
subjects with the same onset and efficacy as intradermal lidocaine injection using 
hypodermic needles.  Additionally, a large majority of subjects considered microneedles 
to be painless and preferred microneedle treatment over hypodermic needles.  These 
characteristics combined with the simple, miniature, and easy to use, low-cost, disposable 
device features fulfill the qualities of an ideal local anesthesia system making 






CHAPTER 5: DISCUSSION 
 
While several microneedle delivery systems have been developed over the last 
decade, most studies have been performed in-vitro and in in-vivo animal models.  To 
date, only a limited number of studies have been performed to study the application of 
microneedles in human subjects.  The research in this thesis is translational in nature and 
among some of the first to understand the applications of microneedle treatment in 
human subjects. 
As described in Chapter 1, an ideal transdermal drug delivery system would be 
one that i) is safe by maintaining skin permeability only during the desired period of drug 
delivery, ii) can create sustained or bolus delivery profiles, iii) can deliver therapeutic 
volumes/doses of drug quickly with minimal discomfort, iv) has rapidly responsive 
pharmacokinetics and pharmacodynamics, v) causes minimal pain and irritation, and vi) 
is simple, inexpensive, and well-accepted by patients.  This chapter describes the 
significance of this thesis in determining that microneedles possess these characteristics 
of an ideal transdermal drug delivery system. 
The skin impedance study showed that microneedles can be used to increase 
permeability of skin over timescales ranging from as little as 2 h to as long as 40 h by 
modulating the skin’s occlusive conditions and microneedle geometry.  From an efficacy 
standpoint, piercing the skin with microneedles can allow for increased skin permeability 
to facilitate drug delivery from a transdermal patch for a period of almost 2 days.  From a 
safety standpoint, skin permeability can be quickly resealed in the absence of occlusion 




occlusion following microneedle treatment acts like a switch that can turn drug delivery 
through microneedle-created channels “off” as desired.  This result satisfies the first 
characteristic of an ideal microneedle system described above, i.e., is safe by maintaining 
skin permeability only during the desired period of drug delivery.  Most other 
transdermal delivery systems such as ultrasound, iontophoresis, electrophoresis, and 
ablation do not possess this characteristic as they alter the SC lipid structure or remove 
the SC such that the skin remains permeable for several hours even in the absence of 
occlusion.  For example, Appendix C shows elevated skin permeability after sonication in 
the absence of occlusion for a period of at least 7 h.  This elevated permeability can be a 
safety concern as unwanted absorption of pathogenic substances across the skin may take 
place during this time.  Hence, proper care must be taken to avoid absorption of 
exogenous substances after drug delivery has been completed for these types of 
transdermal systems. 
Further, the skin impedance study also demonstrated that microneedles can 
increase skin permeability to allow for sustained drug delivery for almost 2 days in the 
presence of occlusion.  The naltrexone delivery study carried out with collaborators at the 
University of Kentucky (Appendix B), confirmed this finding by delivering clinically 
relevant doses of naltrexone for 72 h in human subjects.  These findings show that 
microneedle-based poke-and-patch delivery satisfies the characteristic of an ideal 
microneedle system that microneedles can create sustained delivery profiles in human 
subjects.  This study also showed that solid microneedles (≤ 750 in length) caused less 
pain than hypodermic needles.  The study further demonstrated that skin resealing time 




microneedle devices that cause prolonged skin permeability (under occlusion), but still 
cause little or no pain. Results showed that using larger numbers of needles with larger 
cross-sectional area, rather than long needles, can accomplish this goal (e.g., geometry 
E), thereby meeting the characteristic that microneedles should cause minimal pain. 
    Further, two decades ago, Lackermeier et al. (Lackermeier, McAdams et al. 
1999) suggested that measurement of skin impedance may have the potential to 
determine the recovery of skin following treatment with a drug delivery system as well as 
to predict the penetration of drug through the skin.  While a few studies have been 
performed using skin impedance to study recovery of skin following treatment with 
transdermal drug delivery systems such as iontophoresis (Kalia, Nonato et al. 1996; 
Curdy, Kalia et al. 2000; Curdy, Kalia et al. 2002), and in-vitro studies have examined 
and developed relationships between skin impedance and skin permeability (Karande, 
Jain et al. 2005), this thesis applied skin impedance measurements to determine skin 
barrier recovery and also to develop a model to predict the quantity of drug within the 
body following microneedle treatment.  The model (equation 4.5) developed in this study 
used electrical skin impedance measurements to predict in-vivo plasma concentrations of 
naltrexone and yielded results that were well correlated with the experimental naltrexone 
results from Appendix B.  These results provide a promising opportunity for using skin 
impedance measurements to predict transdermal drug delivery in-vivo 
The next study in this thesis was carried out to study the flow conductivity of skin 
during in-vivo microneedle infusion.  Previous studies using hollow microneedles have 
demonstrated that the skin offers significant resistance to flow of fluid, however, the 




been previously quantified in-vivo.  Therefore, the volume of drug that can be delivered 
into skin via microneedles, the pressures associated with it, and the corresponding pain 
were previously unknown.  In order for hollow microneedle delivery to be effective, 
clinically significant volumes of drug need to be delivered into the skin and in order to be 
competitive with hypodermic needles, in addition to having faster PK and PD profiles, 
they should also deliver these volumes with significantly less pain than hypodermic 
needles.  The flow conductivity study in this thesis produced the first set of results 
showing the effect of microneedle insertion, retraction, and infusion parameters on skin 
resistance to flow and associated pain.  By inserting a single microneedle into the dermis, 
volumes up to 1 mL can be delivered at shallow depths or low flow rates and up to 800 µl 
can be delivered at higher flow rates with low levels of pain that are significantly less 
than hypodermic needle insertion pain.  These volumes are clinically significant as most 
intradermal injections are generally indicated to not exceed 500 µl (Lynn and Evans-
Smith 2003).  Further, even most bolus subcutaneous injections do not exceed 1-2 mL 
(Chapman 2003) due to pain, distortion and tearing of the tissue (Bookbinder, Hofer et al. 
2006).  Therefore, microneedles could provide a less painful alternate delivery route for 
drugs that would be typically administered subcutaneously, although the different route 
of administration may affect pharmacokinetics and other parameters.  These results show 
that microneedles fulfill the characteristic of being able to deliver therapeutic 
volumes/doses of drug quickly with minimal discomfort. 
 Further, fabricating hollow microneedles that are strong enough to deliver large 
quantities of fluid into the skin without leakage, breakage, or occlusion, especially 




2006).  The results obtained in this study provide significant information to aid in the 
design of hollow microneedle structures that are strong enough to withstand the pressures 
obtained at higher volumes while being flexible enough to conform to the skin wheal 
formed during injection to prevent leakage.   
The next study in this thesis involved delivery of insulin to Type 1 diabetes 
subjects, which since 1922, has been achieved via the subcutaneous route.  Over the past 
several decades, many different delivery routes such as oral, buccal, nasal, pulmonary, 
and transdermal have been studied to improve the pharmacokinetics and 
pharmacodynamics of insulin.  However, most of these methods have had limited success 
(Cefalu 2004).  Exubera, a form of pulmonary insulin was the first insulin delivery 
system to be approved by the FDA as an alternate to subcutaneous insulin delivery in 
2006.  However, this product was discontinued the following year due to safety and 
usability reasons such as low bioavailability, cumbersome device, unknown adverse 
effects, etc. as described in section 4.3.  Several insulin analogues have also been 
developed to improve insulin pharmacokinetics; however, still faster-acting insulin is 
desired to enable even better glycaemic control (Brange 1997; Hirsch 2005). 
The insulin delivery experiments in this thesis demonstrated for the first-time that 
intradermal insulin delivery via hollow microneedles can lead to a) faster 
pharmacokinetics, b) more stable glycaemic control, and c) less administration pain than 
conventional catheters in children, adolescents, and adults with Type 1 diabetes.  These 
three characteristics provide a significant step forward in the field of diabetes 
management and microneedles.  By targeting the microneedles to the dermis, 




network leading to better insulin PK and PD profiles.  Further, the shallow depth of the 
microneedles reduces stimulation of the sensory nerve endings located in the skin, 
allowing for minimal administration pain.  The potential medical significance of these 
results is that microneedles may reduce healthcare complications associated with diabetes 
due to improved glycaemic control as well as reduce pain and apprehension related with 
insulin delivery.  With pain, anxiety, and fear of needles being the main reason for 
noncompliance among diabetes patients, microneedles may provide a means to increase 
patient compliance.  Further, designing the microneedle device to be a simple, miniature 
integrated patch-like device without any tubing, bulky pumps, or catheter may further 
improve patient compliance by increasing comfort and convenience.  Overall, improved 
patient compliance would ultimately lead to reduced healthcare costs for diabetes patients 
due to potential lower frequency of hypo- and hyperglycaemic events and related 
hospitalizations.  Further, the improved glycaemic control achieved due to faster PK 
would further reduce the hypo- and hyperglycaemic events associated with insulin 
delivery.  The results of this study show that microneedles fulfill the characteristics of 
creating bolus drug delivery profiles, having fast pharmacokinetics and 
pharmacodynamics, and causing minimal pain and irritation as seen in section 4.3.  
The last study performed in this thesis used hollow microneedles to deliver 
lidocaine for administering local anesthesia.  Current methods of administering local 
anesthesia involve hypodermic needles which cause pain, anxiety, and distress leading to 
poor patient compliance, especially among children.  Topical anesthetics are the most 
common alternative, however, these substances have very slow onset times ranging from 




transdermal systems have been developed as described in section 4.4, however, they too 
have relatively slow application/loading and onset times ranging from 2-15 min and have 
cumbersome devices that require user training.  The lidocaine delivery results in this 
thesis demonstrated that microneedles can be used to induce local anesthesia with rapid 
onset immediately after completion of delivery with the same efficacy and less pain as 
hypodermic needles.  This result fits the criteria that microneedles can deliver therapeutic 
volumes/doses of drug quickly with minimal discomfort.  Further, > 77% of the subjects 
preferred microneedle-based lidocaine delivery to hypodermic-needle based delivery 
implying that microneedles are well accepted by patients.  Moreover, > 82% of subjects 
found microneedles to be not painful.  Therefore, the results of this study provide a 
significant advance over current methods available to administer local anesthesia as they 
provide features that are attractive to patients (effective anesthesia with significantly less 
pain) and to physicians (application speed and simplicity).  The reduced pain is especially 
beneficial for children who report pain associated with venipuncture and IV cannulation 
as the second most common cause of worst pain during hospitalization (Wong and C.M. 
1988; Cummings, Reid et al. 1996).  With regards to the criteria of microneedles being 
in-expensive, previous studies have indicated that microneedles can be manufactured 
relatively cheaply on the order of a few cents (Reed and Lye 2004; Prausnitz, Mikszta et 
al. 2006). 
 Thus, while microneedles of various geometries and materials have been 
developed over the last decade, their safety, efficacy, and usability characteristics in 
human subjects which are critical in determining the future clinical application of 




translational research studies to facilitate the transfer of microneedles from the laboratory 




CHAPTER 6: CONCLUSIONS 
 
In conclusion, this thesis presented the first-in-humans microneedle data to 
characterize the skin repair responses to microneedle insertion, characterize the effect of 
microneedle and infusion parameters on flow conductivity of skin, and assess the efficacy 
of systemic and local therapeutic effects via microneedle-based intradermal drug delivery 
of insulin and lidocaine. 
This first aim showed that skin occlusion significantly slowed down skin barrier 
recovery following microneedle treatment.  Results indicated that in the absence of 
occlusion, microneedle treated sites recovered barrier properties within 2 h, while 
occluded sites recovered more slowly, with recovery windows ranging from 3-40 h 
depending on microneedle geometry.  Upon subsequent removal of occlusion, the skin 
barrier recovered rapidly.  Additionally, longer microneedles, increased number of 
needles, and larger cross-sectional area demonstrated slower recovery kinetics under 
occlusion indicating that microneedle geometry played a significant role in the barrier 
recovery process.  Results also showed that skin resealing time and insertion pain were 
not directly correlated, leading to opportunities for designing microneedles that cause 
prolonged skin permeability (under occlusion), while causing little to no pain, by 
increasing the number of microneedles and/or the needle cross-sectional area.  The 
impedance-based pharmacokinetic model (without any fitted parameters) showed that 
impedance spectroscopy following microneedle treatment can be a good predictor of 
transdermal drug delivery across skin in-vivo.  Overall, this study showed for the first 




transdermal patch can increase skin permeability for more than one day, but nonetheless 
allow skin to reseal rapidly after patch removal.  
The second part of this thesis performed the first studies to characterize the effect 
of microneedle insertion and infusion parameters on flow conductivity of skin and 
associated pain during in-vivo hollow microneedle delivery.  Results showed that 
microneedle-based delivery within the dermis led to a decrease in flow conductivity 
regardless of intradermal depth at moderate flow rates.  Microneedle retraction, slow 
delivery flow rates, and the addition of hyaluronidase helped increase flow conductivity, 
while increasing infusion flow rate increased skin’s resistance to flow more rapidly.  
Intradermal microneedle insertion VAS pain scores at all depths were significantly lower 
than that of hypodermic needles.  Analysis of infusion pain scores demonstrated that 
intradermal microneedles can be used to deliver up to 800 µl of fluid at moderate to high 
flow rates with significantly less pain than hypodermic needle insertion.  Delivery of 1 
mL of fluid can be achieved with less pain than hypodermic needles at either low flow 
rates, shallow insertion depths, or through the addition of hyaluronidase.  These results 
are practical for clinical applications since most intradermal injections are indicated to 
not exceed 500 µl.       
The final parts of this thesis determined the clinical feasibility of microneedle-
based drug delivery by studying the efficacy of hollow microneedles for systemic and 
local drug effects by delivering insulin to Type 1 diabetes subjects and lidocaine to 
healthy subjects.  Insulin delivery results demonstrated for the first time that intradermal 
insulin delivery via microneedles leads to improved pharmacokinetics as demonstrated by 




reduction in plasma glucose levels, while causing significantly less pain than 
conventional catheters.  The lidocaine study demonstrated for the first time that 
microneedle-based lidocaine injection can induce local anesthesia in human subjects with 
the same rapid onset and efficacy as intradermal injections using hypodermic needles, 
while being significantly less painful.  Therefore, these results show that microneedle-
based intradermal drug delivery can be used to effectively deliver drugs for systemic and 
local therapeutic effects in a less painful manner than conventional needles. 
As mentioned previously, the research in this thesis is translational in nature and 
among some of the first to address microneedle treatment in human subjects.  The results 
in this thesis provide answers to questions regarding the safety, efficacy, and usability of 
microneedles in a clinical setting and will help enable the transfer of microneedles from 





CHAPTER 7: RECOMMENDATIONS 
 
Based on the results of this thesis, I recommend the following studies to further 
advance this research.  This thesis developed an impedance-based pharmacokinetic 
model for predicting the concentration profile of drug in the body following placement of 
a transdermal patch on microneedle created channels.  Results showed that the predicted 
and experimental naltrexone concentration profiles were in good agreement.  This model 
should be further validated by conducting experiments with other drugs having properties 
that differ from naltrexone (diffusion coefficient, volume of distribution, and clearance).  
Successful validation of this model would allow for a high-throughput method of 
determining plasma concentration of drugs administered via poke-and-patch microneedle 
systems and would aid in determining the appropriate number of needles or cross-
sectional area to achieve target plasma concentrations.   
With regards to the flow conductivity study, this thesis postulated the fate of fluid 
infused into the skin based on pressure, pain, and echographic image data.  In order to 
more accurately determine the fluid path and distribution, studies should be carried out 
whereby a biocompatible dye is delivered to the dermis followed by skin biopsy and 
histology.  The goal of microneedle delivery is to obtain reliable intradermal injections.  
While histological pig studies have been performed to show that 100 µl delivered via 
hollow microneedles remains in the dermis (data not shown), and the ultrasonic imaging 
results in this thesis appear to show that delivery of 1 mL of saline through 500 µm, 750 
µm, and 1 mm long needles remains in the dermis at moderate flow rates, it is possible 




occurs, it is important to determine at what volume the fluid starts to flow deeper beyond 
the target region.  Further, understanding the flow and distribution of drug within the skin 
based on the different infusion and microneedle geometry parameters would help 
determine which conditions best target the papillary dermis (for faster absorption).  
Histological studies would help confirm this result.  Alternatively, a contrast agent 
yielding high echogenicity may also be infused and imaged via ultrasonic imaging, as a 
non-invasive alternative.  However, a suitable contrast agent with low viscosity that can 
be infused via microneedles to volumes as high as 1 mL needs to be identified.  
Additionally, future studies should be carried out to determine the resistance offered by 
skin while using microneedle arrays.  This thesis showed that single needles led to high 
resistances upon delivery of large (> 500 µl) volumes at moderate and high flow rates 
without retraction.  It is likely that multiple needles arranged in arrays will experience 
even higher resistances due to compression of the skin at multiple sites, thereby blocking 
the flow pathways nearby each needle.  Further, the formation of a skin wheal may 
further affect the resistance of the needles in the array.  Studies by others have shown that 
delivery of 100 µl of fluid into skin via four hollow microneedles is more painful than 
intramuscular injection (Van Damme, Oosterhuis-Kafeja et al. 2009).  This may possibly 
be due to higher pressures generated during delivery through arrays which may push the 
fluid deep enough to stimulate dermal nociceptors.  Hence, flow conductivity through 
microneedle arrays and its effect on pain should be further studied.   
The insulin delivery study in this thesis demonstrated that hollow microneedles 
can lead to significantly improved insulin pharmacokinetics and improved glycaemic 




have promising implications for the improvements of diabetes management.  However, 
this thesis only studied bolus insulin delivery which is typically administered at 
mealtimes.  In order for microneedles to be well-accepted by diabetes patients, basal 
insulin delivery whereby low insulin volumes are delivered throughout the day also needs 
to be evaluated.  One of the reasons for the failure of Exubera inhaled insulin was that it 
only provided bolus insulin delivery.  Therefore, since Exubera only provided half the 
solution, patients had to continue to use their subcutaneous needles or catheters to meet 
their basal insulin requirements.  This thesis has shown that microneedle-based bolus 
insulin delivery can lead to improved PK and PD.  Therefore, successful application of 
microneedles for insulin delivery will depend on their ability to provide basal 
pharmacokinetic and pharmacodynamic profiles that are at least as effective as 
subcutaneous delivery systems.  Once successful basal delivery has been achieved, the 
next challenge in the acceptance of microneedles for diabetes management will be the 
development of microneedle patches that are able to strongly adhere to the skin surface 
during normal day-to-day activities.  Further, with regards to safety, it would also be of 
future interest to study if an immune response is elicited via injection of insulin to the 








APPENDIX A: MATLAB CODE FOR PREDICTING PLASMA NALTREXONE 












= 4.3  10-5 sec-1 
dt = 3600 sec 
Code to solve equation 4.5 
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APPENDIX B: MICRONEEDLES PERMIT TRANSDERMAL DELIVERY OF A 
SKIN-IMPERMEANT MEDICATION TO HUMANS3 
 
B.1. Abstract 
Drugs with poor oral bioavailability usually are administered by hypodermic 
injection, which causes pain, poor patient compliance, the need for trained personnel, and 
risk of infectious disease transmission.  Transdermal (TD) delivery provides an excellent 
alternative, but the barrier of skin's outer stratum corneum (SC) prevents delivery of most 
drugs.  Micrometer-scale microneedles (MNs) have been used to pierce animal and 
human cadaver skin and thereby enable TD delivery of small molecules, proteins, DNA, 
and vaccines for systemic action.  Here, we present a clinical study of MN-enhanced 
delivery of a medication to humans.  Naltrexone (NTX) is a potent mu-opioid receptor 
antagonist used to treat opiate and alcohol dependence.  This hydrophilic and skin-
impermeant molecule was delivered from a TD patch to healthy human subjects with and 
without pretreatment of the skin with MNs.  Whereas delivery from a standard NTX TD 
patch over a 72-h period yielded undetectable drug plasma levels, pretreatment of skin 
with MNs achieved steady-state plasma concentrations within 2 h of patch application 
and were maintained for at least 48 h.  The MNs and NTX patch were well tolerated with 
mild systemic and application site side effects.  The MN arrays were painless upon 
administration and not damaged during skin insertion, and no MNs were broken off into 
the skin.  This human proof-of-concept study demonstrates systemic administration of a 
                                                 
3 This work was carried out in collaboration with researchers at the College of Pharmacy and College of 
Medicine at the University of Kentucky.  This work has been published as: Wermeling DP, Banks SL, 
Hudson DA, Gill HS, Gupta J, Prausnitz MR, Stinchcomb AL. Microneedles permit transdermal delivery 




hydrophilic medication by MN-enhanced TD delivery.  These findings set the stage for 
future human studies of skin-impermeant medications and biopharmaceuticals for clinical 
applications. 
B.2. Introduction 
Transdermal (TD) drug delivery has proven to be of great therapeutic utility (Guy 
and Hadgraft 2003; Prausnitz, Mitragotri et al. 2004).  Patient acceptance of the 
technology is evident given the commercial success of products intended for chronic pain 
management, angina and congestive heart failure, and hormone replacement therapies.  A 
TD patch can provide continuous drug administration, minimizing peaks and troughs in 
plasma levels throughout the day. TD systems can take the place of more risky and 
invasive injection-based drug delivery, thus improving regimen compliance.  Moreover, 
they are more efficient, use less medication, and are less variable compared with some 
oral medications that undergo presystemic metabolism.  
Even greater utilization of TD delivery for systemic drug administration is 
inhibited by several key factors.  First, the stratum corneum (SC) outer layer of the skin is 
a very effective barrier at preventing entry of xenobiotics, infectious agents, and other 
substances into the body.  This barrier prevents therapeutic delivery of most drugs other 
than those with high potency (dose in milligrams or less), low molecular mass (<1,000 
Da), and optimal octanol-water partition coefficient (Hampton 2005).  
Design of TD product formulations has attempted to overcome some of these 
limitations and enhance drug permeation (Prausnitz, Mitragotri et al. 2004).  Chemical 
formulation methods may include the use of solvents, surfactants, and other chemical 




enhancers may also disrupt SC structure (Williams and Barry 2004).  Prodrug and codrug 
medicinal chemistry, whereby physicochemical properties are modified through chemical 
synthesis with additional nontherapeutic or therapeutic substrates, has also been 
attempted (Vaddi, Hamad et al. 2005; Kiptoo, Hamad et al. 2006).  
Physical approaches apply energy to enhance permeation, causing disruption of 
the SC, generally on a temporary basis (Cross and Roberts 2004).  Successful methods 
include iontophoresis for polar molecules, electroporation and sonophoresis, the use of 
ultrasound, and even microdermabrasion or laser ablation.  
Microneedles (MNs) represent a unique technological approach to enhance drug 
permeation across the SC (Prausnitz 2004).  MN-based delivery involves micrometer-
scale solid or hollow needles that painlessly pierce the SC.  For example, an array of 
stainless steel, solid MNs produces a grid of holes, or micropores, through which 
medications delivered via a standard patch, may be delivered to the skin for local or 
systemic drug absorption (McAllister, Wang et al. 2003).  Modern microfabrication 
techniques have been used to make MNs by methods suitable for inexpensive mass 
production (Reed and Lye 2004).  In addition to solid, stainless-steel arrays, a number of 
other designs have been created, including hollow needles through which a drug solution 
may be transported, MNs that have been coated with a drug for dissolution upon 
application, and polymer MNs that dissolve upon application (Gardeniers, Luttge et al. 
2003; Ito, Yoshimitsu et al. 2006; Gill and Prausnitz 2007). 
MNs have been used to pierce the skin and thereby enable TD delivery of small 
molecules, proteins, DNA, and vaccines for systemic action, as shown in numerous in-




McAllister, Wang et al. 2003; Cormier, Johnson et al. 2004).  Although there have been a 
number of studies in animals, there is very little scientific literature describing the use of 
MNs on humans.  Kaushik et al. (Kaushik, Hord et al. 2001) reported that blinded healthy 
volunteers could not distinguish a MN array from a smooth surface relative to pain 
sensation.  The same subjects could clearly distinguish a MN array from a 26-gauge 
hypodermic needle.  Mikszta et al. (Mikszta, Alarcon et al. 2002) compared microarrays 
to ECG electrode pads for their ability to disrupt human skin, cause pain, or induce 
inflammation.  MNs of 200 µm in length were successful in breaching the SC as 
measured by transepithelial water loss.  Pain perception was negligible and a minor skin 
irritation lasting to 48-h postapplication was noted in several subjects.  Sivamani et al. 
(Sivamani, Stoeber et al. 2005), in a test of localized drug deposition and effect, found 
greater skin blood flow after injection of 1 µl of methyl nicotinate with MNs as compared 
with topical methyl nicotinate alone.  
To date, there are no published human reports describing MN- enhanced TD 
delivery of a medication to the systemic circulation to our knowledge.  Our article builds 
on previous preclinical publications and describes a study in which MN arrays were 
administered to humans in conjunction with TD systemic delivery of a therapeutic 
molecule.  We selected naltrexone (NTX), which is used to block opioid effects in 
detoxified patients and treat alcohol dependence, as a model drug because it would 
benefit from TD administration and is difficult to deliver across intact skin (Vaddi, 
Hamad et al. 2005; Anton, O’Malley et al. 2006; Kiptoo, Hamad et al. 2006).  NTX is a 
small, hydrophilic molecule that when administered orally undergoes significant first-




marketed 30-day NTX depot injection provides therapeutic levels for 1 month but with a 
10- to 15-fold peak-to-trough variation and in an administration system most patients find 
objectionable (Turncliff, Dunbar et al. 2005).  Relatively constant NTX blood levels, and 
perhaps lower side effects, could be achieved if a TD product was developed that 
provided a relatively constant delivery rate (King, Volpicelli et al. 1997). 
The following study was conducted to determine, in an initial human proof-of-
concept study, whether water-soluble NTX hydrochloride could be successfully 
administered systemically from a TD patch after pretreatment of the SC with MNs.  As 
reported by Vereby et al. (Verebey, Volavka et al. 1976), a 2 ng/ml plasma concentration 
in humans resulted in an 85.6% narcotic blockade in response to a 25-mg i.v. injection of 
heroin.  A study performed in healthy volunteers who were given a single oral dose of 50 
mg NTX showed maximum plasma concentration values ranging from 20 to 25 ng/ml, 
and after 24 h those levels had dropped to ≈3 ng/ml (Licko 1980; Wall, Brine et al. 1981). 
Plasma levels of NTX are in the 2–4 ng/ml range for days 7–28 of the monthly depot 
injection regime (Turncliff, Dunbar et al. 2005) and could be a target concentration range 
for this study.  
Given the preclinical data on MNs and the known pharmacokinetics of NTX 
administered by other routes, our hypotheses are that (i) a modest TD NTX dose of ≈10 
mg per day will produce steady-state plasma levels of 2 ng/ml when the skin is pretreated 
with MNs, (ii) control subjects whose skin is not pretreated with MNs will demonstrate 
no significant systemic absorption of NTX, and (iii) the MNs and NTX TD system will 






B.3.1. NTX Pharmacokinetics in Humans after TD Administration 
The principal question we wanted to address was whether pretreatment of skin 
with MNs, and subsequent placement of a TD patch, would permit rapid attainment of 
pharmacologic, clinically relevant and sustained plasma levels of a hydrophilic molecule 
not normally absorbed across intact skin.  To address this question, our data show that 
MN pretreatment of the skin permitted rapid systemic exposure to NTX.  Measurable 
plasma levels were demonstrable within 15 min after patch placement in three MN-
treated subjects and within 30 min for the remaining three subjects.  The concentration–
time curve (Figure B.1) shows a rapid rise or burst of absorption within the first several 
hours of application.  Maximum concentrations occurred within a range of 1.5 to 18 h.  
 
Figure B.1: Mean (SD) NTX plasma concentrations for 72 h of patch application. 
(Inset) Early sampling points. 
Additional questions regarding our technique relate to the length of time the 




constant rates of drug delivery for systemic absorption, or rapidly undergo healing 
changes that would retard drug absorption?  We demonstrate steady-state or a relatively 
constant plasma concentration of NTX was achieved within hours, to at most 1 day after 
patch placement, which indicates rapid transit, localized diffusion, equilibrium of NTX 
through dermal layers, and absorption into capillary beds (Table B.1).  Approximately 
zero-order delivery appeared to be achieved for 48 h with a steady-state plasma 
concentration of ≈2.5 ng/ml, consistent with levels associated with pharmacologic 
activity.  The maximum concentration obtained was somewhat variable and ranged from 
1.6 to 8.1 ng/ml.  Subjects with the lower concentration profiles tended to have lower 
peak-to-trough differences over the 72-h administration period.  Similarly, the time to 
maximum concentration had a wide range, from as little as 1-2 h in two subjects, to as 
long as 18 h in two other subjects. 
Table B.1: NTX and NTXOL exposure after MN-enhanced TD delivery 
Parameters NTX NTXOL 
Css, ng/ml 2.5 (1.0) 0.6 (0.5) 
Tlag, h 1.8 (1.1) 1.4 (1.4) 
Cmax, ng/ml 4.5 (2.4) 1.9 (1.3) 
T max,h 8.8 (7.6) 37.5 (31.3) 
AUC0-t, ng·h/ml 142.9 (43.9) 39.7 (25.9) 
Clast, ng/ml 1.8 (1.0) 0.4 (0.6) 
 
Results are expressed as means ± SD (in parentheses) for six MN-treated subjects. Css = concentration at 
steady-state condition; Tlag = time to reach steady-state condition; Cmax = maximum concentration achieved; 
Tmax = time to achieve maximum concentration; AUC0-t = area under the concentration-time curve from 
time 0 to 72 h; Clast = concentration at time of patch removal after 72 h of application. 
 
Skin micropores appeared to have remained open for at least 48 h as plasma levels 
appeared to be relatively constant for the first 48 h of administration.  Two subjects had a 




consistent for at least 48 h, with a modest average decline of NTX concentration by 
≈50% at 72 h.  The 72-h time-point average concentration of 1.8 ng/ml was ≈25% of the 
maximum concentration and 50% of the steady-state concentration.  Pharmacologically 
active plasma concentrations were still evident at the last time point, 72 h after patch 
placement.  The apparent plasma clearance of NTX indicates an approximate half-life of 
4.4 h, suggesting that 95% of NTX would be eliminated within 24 h of patch removal.  In 
contrast to the MN-treated subjects, the control subjects had undetectable (<1 ng/ml) 
NTX plasma levels, indicating minimal transfer of drug across the skin.  Average peak 
levels in MN-treated subjects were 4.5 times larger than the assay detection limit.  
Drug delivery systems that avoid presystemic drug clearance have been 
demonstrated to remarkably change the metabolite profile of certain medications. 
Similarly, we wanted to understand whether the TD system would significantly alter, and 
perhaps even reverse the ratio of the parent drug NTX to the metabolite.  Naltrexol 
(NTXOL; primary metabolite of NTX) plasma concentrations were significantly less than 
the parent drug NTX (Figure B.2).  This finding is consistent with avoiding presystemic 
first-pass metabolism of NTX.  In contrast, NTXOL plasma concentrations are 
significantly higher than the parent drug NTX after oral administration (Licko 1980).  
The reversal of parent-to-metabolite ratio is a desirable outcome, because the NTXOL 





Figure B.2: Mean (SD) NTXOL plasma concentrations for 72 h of patch application. 
(Inset) Early sampling points. 
A steady-state concentration of 0.6 ng/ml NTXOL was obtained throughout the 
72-h patch placement.  The time to reach steady state was comparable to NTX, indicating 
a slight delay in presentation to the hepatic system for metabolism.  Maximum NTXOL 
concentrations were also modest and were not obtained until an average of 45 h after 
patch placement.  Thus, the MN-facilitated TD delivery of NTX resulted in generation of 
a much lower quantity of the metabolite (NTXOL) and at a much later time, i.e., 45 h 
after TD administration using MN versus 1 h after administration of a tablet.  The study 
by King et al. (King, Volpicelli et al. 1997) suggests our result could lower the side-effect 
profile of NTX, and improve compliance and retention in treatment, because withdrawal 
from oral drug treatment is associated with subjects who generate high levels of NTXOL.  
B.3.2. Effect of MNs and NTX Patch on Human Skin 
Limited previous studies have been reported on local tolerance of MNs 
themselves in humans.  In our study we wanted to determine the tolerability of the MN 




demonstrates the tolerability of the combined technologies in humans.  MN arrays and 
patches were easy to administer.  Administration of MNs simply required removing their 
protective liner and pressing the MN against the skin by hand.  Application time for MNs 
and TD patches took 1–2 min, which is quite short, given the nature of the prototype MN 
and patch systems.  MN arrays were examined for physical damage after their application 
to each subject.  No MN array had bent or broken needles, and no needles were broken 
off into the subjects' skin.  
The MN-treated subjects tolerated the MN and patch application system well. 
Subjects reported no pain when MNs were applied to their skin.  The sensation of 
placement was described as simply of pressure applied at the site.  Two subjects reported 
mild systemic side effects associated with NTX, such as nausea and lethargy, which are 
believed to be drug-specific and not directly associated with the MN delivery route. 
There was no clinically significant change in vital signs or liver function tests as a result 
of TD NTX administration.  Control subjects also tolerated the patch system and reported 
no systemic-related side effects.  
Four of the six MN-treated subjects did have skin changes observed when the 
patch and occlusive dressing were removed after 72 h of application, such as localized 
irritation and erythema outside of the patch placement site but within the dressing area for 
two of the subjects.  Upon removal of the patch, two of the four subjects demonstrated 
contact dermatitis that exactly outlined the dimensions of the MN arrays insertion grid. 
Inside the raised areas were very small crusts that may represent the insertion points of 
the MNs and the subsequent micropores.  The affected subjects were prescribed 




Subjects were seen in the clinic 4–6 days later and had responded to treatment.  Re-
examination of the skin demonstrated the contact dermatitis was greatly diminished and 
within 1–2 weeks had disappeared.  However, the crusts continued healing throughout the 
2-week observation period, with a faint outline of the MN array insertion points still 
evident. Only one control subject demonstrated any finding on skin examination.  The 
subject complained of itchiness and irritation, which was under the occlusive dressing 
and the patch. The findings disappeared upon removal of the patch.  
To better understand the possible causes of skin irritation seen in this study, we 
carried out an additional study in 10 subjects to assess the effect of just MN insertion 
followed by occlusion of the skin.  No NTX or patch formulation was used.  Immediately 
after insertion, erythema was typically seen at the punctate sites where each MN 
penetrated into the skin (data not shown).  The degree of erythema varied from barely 
visible to moderate, highly localized, submillimeter spots of redness.  Within a few hours, 
erythema disappeared in most cases, such that it was not possible to distinguish between 
MN-treated skin and adjacent skin.  The more dramatic effects of contact dermatitis 
observed in the two patients administered NTX were not seen in any of the subjects 
treated with MNs alone.  We therefore conclude that MNs themselves cause little to no 
skin irritation that is highly transient and that the NTX and/or formulation excipients 
were responsible for the skin irritation observed in some subjects in this study.  Further 
optimization of patch formulation could reduce or eliminate this irritation.  
To better understand the lifetime of TD transport pathways created in the skin by 
MNs, we carried out a supplemental study in which skin electrical resistance was 




Skin electrical resistance has been shown to correlate well with skin permeability to 
various molecules (Karande, Jain et al. 2006).  Average skin resistance dropped from 397 
± 183 kΩ before treatment to 11.7 ± 5.5 kΩ after MN insertion and removal.  After 
covering with an occlusive dressing, skin resistance steadily increased but remained 
significantly less than the resistance of an adjacent control site of untreated skin for 30 h 
(Student's t-test; p < 0.05). These measurements are consistent with the measurements of 
NTX pharmacokinetics, which both show that brief treatment of skin with MNs creates 
long-lived permeability.  There are quantitative differences between the measurements, 
however, because the electrical resistance measurement indicated a permeability lifetime 
of 30 h, whereas the NTX delivery measurement indicated a lifetime up to 72 h.  This 
difference may exist because the electrical measurement assessed the barrier properties of 
skin's SC, whereas the NTX measurement assessed the kinetics of drug delivery into the 
bloodstream, which is influenced not only by the SC barrier, but can also be influenced 
by diffusion, pooling, and possible binding in the skin en route to the bloodstream, which 
can delay the kinetics of drug clearance.  
B.4. Discussion 
B.4.1. Delivery of NTX from the TD Patch 
This study demonstrates MN pretreatment of the skin and subsequent TD delivery 
of a drug to humans.  Previous research to demonstrate TD transport has been conducted 
on human cadaver skin and small animals.  Studies in humans have focused on the 
aesthetic nature of avoiding pain upon administration of the MNs or local action in the 
skin itself.  Thus, this work is a significant advancement by combining the MN 




administration of a drug of clinical significance.  This report provides the scientific basis 
and justification for future studies to test MN technology with skin-impermeant 
medications of different chemistry, such as peptides and proteins, married with a TD drug 
delivery system.  
This proof-of-concept study supports the hypothesis that in-vivo insertion of MNs 
into the skin before placement of a standard TD patch drug delivery system results in 
pharmacologically active and clinically relevant plasma levels of a skin-impermeant 
medication. The MN-facilitated TD delivery was very efficient by providing 
pharmacologically active steady-state plasma levels of 2.5 ng/ml at a very modest 
estimated dose of 12.6 mg per day.  The absorbed TD daily dose is roughly one-quarter 
of the daily dose administered as an oral tablet to achieve similar plasma levels.  This 
observed increase in efficiency is ascribed to the avoidance of gastrointestinal and hepatic 
first-pass metabolism.  
Moreover, as a result of avoiding first-pass metabolism, the ratio of plasma NTX 
to NTXOL at steady state was dramatically different from oral delivery.  TD delivery 
using MNs produced a ratio of 4:1, such that most of the drug remained in the parent 
NTX form.  In contrast, the NTX/NTXOL ratio after oral delivery is 1:5, with NTXOL 
being formed rapidly after gastrointestinal absorption.  Moreover, the NTX depot 
injection also does not achieve the desired metabolic ratio of NTX/NTXOL.  The Cmax 
ratio of NTX to NTXOL is 3:4 on the second day after injection (Licko 1980).  Altering 
this ratio through constant rate TD delivery could result in an improved side-effect profile 
because at least one report (Karande, Jain et al. 2006) suggests the commonly observed 




associated in subjects with more rapid metabolism and greater relative formation of 
NTXOL.  
Variability in pharmacokinetic parameters across subjects was small after TD 
delivery using MNs.  For comparison, bioavailability of the oral NTX tablet has an 8-fold 
variation, from 5% to 40%, and similar variability in pharmacokinetic parameters.  Rate 
and extent of NTX exposure was similar across the subjects, with standard deviations 
being approximately half of the mean, which is a characteristic desirable for drugs and 
delivery systems.  This result is encouraging, given the relatively early proof-of-concept 
prototype design used in this pilot study.  
Of great interest is the observation that most subjects appeared to have an initial 
burst of NTX into the systemic circulation.  The result suggests that there is a loading-
dose phenomenon, in which rapid absorption to therapeutic levels takes place initially 
and then is moderated over the course of the next few days.  Subsequent to the burst, 
steady-state concentrations were achieved in a matter of hours, which is unusually fast for 
a TD delivery system.  For example, conventional clonidine and fentanyl TD delivery 
systems do not achieve steady-state concentrations for 1–2 days (Catapres TTS and 
Duragesic Transdermal System product labels; www.fda.gov).  The rapid and consistent 
achievement of steady-state drug concentrations observed in our study provides a 
pharmacokinetic profile that is ideal for many medication classes.  
The observation of a burst of systemically available medication could potentially 
be explained by the combination of two effects.  The first effects concern the relatively 
hydrophilic nature of NTX. Without the use of MN, or other enhancement techniques, 




hydrophobic environment of the SC (Guy and Hadgraft 2003).  The filling of this depot 
delays drug delivery into the circulation.  The use of MNs created hydrophilic micropores 
across the SC, which bypassed the SC depot and permitted the use of a hydrophilic drug 
(i.e., NTX) that would not form a depot.  This expedited NTX delivery to the circulation.  
The second effect is that micropores close over time.  Our electrical resistance 
measurements indicated that skin conductivity steadily decreased with time after MN 
insertion.  NTX plasma levels also were reduced over time, suggesting a slow return of 
skin barrier properties caused by initiation of the healing process after microinjury to the 
epidermis.  Elastic rebound of the skin back to its original conformation, release of 
cytokines upon skin piercing, closure of the pore by interstitial fluid proteins, 
reepitheliazation initially through cell migration and subsequent regeneration, and 
forming a crust over the pore all may contribute to this resealing process (Clark 1996; 
Martanto, Moore et al. 2006a).  
B.4.2. Tolerability of MNs and NTX Patch 
In general, the subjects tolerated the MN insertion and application of the NTX gel 
patch.  Most subjects had mild erythema underneath the occlusive dressing that was 
added to further secure the prototype patches for several days and protect them from 
water. Several subjects also had skin changes under the patch system, in contact with the 
gel and at the MN insertion sites.  These effects were not seen when applying MNs 
without an NTX patch.  Observation of contact dermatitis could be related to the 
medication, NTX, because opiate structures are known to cause histamine release after 




the use of benzyl alcohol as an antimicrobial preservative.  Another form of asepsis for 
the drug product could eliminate this potential irritant.  
An outline of the MN insertion site grids, along with punctate crusts over the 
insertion sites, was observable to varying degrees in most subjects.  The observation did 
not appear to cause distress or discomfort in any subject.  Disappearance of the outline 
and crusts over the next 1–2 weeks likely represented a continued healing process of the 
skin.  
B.4.3. Implications for MN-Assisted TD Patch Delivery 
This proof-of-concept study in humans demonstrated successful TD delivery of 
NTX, a small hydrophilic molecule.  It is likely that other small hydrophilic molecules 
would be amenable to delivery using methods similar to those in this article.  A 
significant new test would be to demonstrate human delivery of pharmaceuticals with 
significantly larger molecular weight, such as peptides and proteins, as shown in animals 
(Mikszta, Alarcon et al. 2002; Gardeniers, Luttge et al. 2003; McAllister, Wang et al. 
2003; Cormier, Johnson et al. 2004).  Additional challenges may be faced with larger 
molecules relative to formulation, the function of the skin barrier that may inhibit 
delivery such as binding of protein drugs to skin constituents, and exposure to proteases. 
Moreover, preclinical data suggest that TD vaccination via MN-pretreated skin is 
feasible.  
This pilot study has a number of limitations that must be taken into context 
relative to the results.  The systems used are relatively early-stage prototypes as far as TD 
delivery systems are usually designed.  The patch and gel used standard components 




into preparation of 200-needle MN patches and NTX gel patches to deliver the desired 
dose in a more practical integrated delivery system.  Application of MNs with this device 
was an imprecise manual administration process.  Additional engineering is required to 
standardize the force necessary to insert MNs to the appropriate depth.  Results could be 
impacted by other factors such as choice of subjects and condition of their skin, 
anatomical site of MN insertion and patch application, and other well known variables to 
consider for TD drug administration.  
In conclusion, this study reports the systemic delivery of a skin-impermeant 
medication via MN-facilitated TD delivery in humans.  This study supports the 
significant body of preclinical research in animal and human cadaver skin, and in limited 
in-vivo studies, that MN-enhanced TD delivery is feasible, well tolerated, and pain-free. 
Methods to enhance standardization of MN insertion and patch formulation are necessary 
for this application.  The results open the possibility of further studies to examine the 
effect of known variables of TD delivery.  Moreover, this study opens the possibility of 
further research of NTX using a zero-order delivery system in the treatment of various 
substance abuse disorders.  
B.5. Materials and Methods 
B.5.1. Fabrication and Assembly of Solid MNs. 
Using methods described in detail previously, solid MN adhesive patches were 
fabricated for insertion into the skin (Kaushik, Hord et al. 2001).  Briefly, fixed MN 
geometries were cut into 75-μm-thick stainless-steel sheets (Trinity Brand Industries; 
McMaster-Carr) using an infrared laser (Resonetics Maestro) and were then manually 




of patches to the skin, MN arrays were assembled into adhesive patches as described.  
The adhesive served to hold the MNs firmly against the skin by compensating for the 
mechanical mismatch between the flexible skin tissue and the rigid MN substrate.  The 
MN patches were assembled in a laminar flow hood for cleanliness and then ethylene 
oxide-sterilized (AN 74j; Andersen Sterilizers) before use.  
MN arrays were fabricated to produce patches containing 50 MNs arranged in 5 × 
10 arrays of MNs (Figure B.3A).  Each MN measured 620 μm in length, 160 μm in width 
at the base, and <1 μm in radius of curvature at the tip.  To validate that these MNs 
pierced into the skin to increase skin permeability, individual arrays were inserted into 
the forearms of 10 human subjects.  After removing the MN patches, the skin was stained 
with a dye that selectively stains sites of skin barrier perforation.  As shown in Figure 
B.3B, all 50 MNs on the patch inserted into the skin and pierced the skin's SC barrier, as 
indicated by the 5 × 10 array of dyed spots corresponding exactly to the geometry of the 
MN array.  These 10 subjects were also asked immediately after MN insertion and 
removal to score the pain on a 0–100 visual analog pain scale.  The average pain score 
was 6 ± 5 for the MN patch and 24 ± 16 for a 5-mm-deep hypodermic needle insertion 
that served as a positive control.  Comparing the ratio of these scores indicates that the 
subjects felt that insertion of the 50-MN array caused just one-fourth of the pain caused 






Figure B.3: MN patch for TD delivery. (A) Image of a 50-MN patch resting on the 
tip of a human thumb. (B) Image of human skin after insertion of a 50-MN patch 
and staining with gentian violet, a dye that selective stained sites of skin perforation. 
(C) NTX TD patch and covering. 
B.5.2. Dose Estimation for Design of TD Patch 
A method was needed to estimate dosing rate and patch size (area) for the initial 
human study. An initial estimate was derived by simply using the relationship of K0 = Cl 
× Css, where K0 = the dosing rate in mg per day, Cl is the total body clearance of the 
medication in liters/min, and Css is the target plasma concentration at steady state. 
Assuming a target of 2 ng/ml concentration, and a total body clearance for NTX of 3.5 
liters/min, a total daily dose of ≈10 mg was estimated.  
In preliminary in-vitro studies of NTX HCl on human skin treated with MNs, we 
were able to achieve a steady-state flux of 14.7 ± 4.9 μg/cm2 per h at a patch formula 
NTX concentration of 160 mg/ml.  To make an in-vivo correlation for patch size we used 




flux constant.  Thus, the patch surface area, at a NTX formulation concentration of 160 
mg/ml, and providing 2 ng/ml plasma levels at steady state, was estimated at ≈28 cm2. 
The daily dose estimate from four commercially accessible 6.7-cm2 patches (26.8 cm2 
total) was estimated at 9.5 mg, very close to the previous estimation method.  
B.5.3. Preparation of NTX TD Patches 
A 16% NTX hydrochloride (HCl) gel was formulated, prepared, and tested 
according to current good manufacturing practices as outlined by the Food and Drug 
Administration.  The gel formulation composition (% wt/wt) was NTX HCl [16% U.S. 
Pharmacopeia (USP)], sterile water for injection (20.25% USP), propylene glycol 
(60.75% USP), 2% Aerosol (hydroxyethyl cellulose), and 1% benzyl alcohol.  The 16% 
NTX formulation was a clear, colorless gel and had a pH of 4.96 ± 0.03 and a viscosity of 
1.69 ± 0.44 × 104 cP.  
The TD occlusive protective covering patches of NTX HCl (6.7 cm2) were 
fabricated by using commercially accessible components by sandwiching a rubber-ringed 
barrier to create a reservoir between a drug-impermeable backing membrane (Scotchpak 
1109 SPAK 1.34 MIL heat-sealable polyester film; 3M) and an Arcare 7396 adhesive 
(Adhesives Research) around the edge of the rubber spacer (Figure B.3C).  The 
impermeable backing laminate was adhered to the rubber retaining ringed barrier with 
3M double-sided tape. Finally, Arcare 7396 was placed on the bottom of the rubber-
ringed barrier to maintain intimate contact with the skin and prevent evaporation of the 
gel formulations.  The protective patch was placed on a release liner composed of 




treated skin to ensure adequate coverage of the micropores and reduce formulation 
pooling in square TD patches.  
B.5.4. Clinical Study Procedures 
This study was approved by the University of Kentucky Institutional Review 
Board and carried out in compliance with the ethical and scientific principles governing 
clinical research as set out in the World Medical Association Declaration of Helsinki. 
Nine male and female healthy volunteers were medically examined and interviewed to 
determine appropriateness for study.  Inclusion/exclusion criteria to confirm general 
wellness were compared with data collected through a physical examination, blood 
sample (chemistry, cell counts, hepatitis), urine sample (urinalysis, pregnancy test if 
applicable, and drug of abuse screen), and drug and medical history.  Subjects could not 
have a history of opiate use/abuse as indicated by verbal report and a negative urine drug 
screen or hepatitis.  A standardized examination of the patch placement skin site was 
conducted to confirm normal skin.  Subjects with inflammatory diseases of the skin, who 
had recent sunburn, or other conditions that may cause changes in skin physiology, or 
who used skin exfoliant dermatologic products or antibacterials were excluded.  Subjects 
were not taking any medications at the time of study with the exception of stable use of 
oral contraceptives.  Subjects were nonsmokers, did not use tobacco products, and agreed 
to not consume alcoholic beverages during the study.  
The six MN-treated and three control subjects were admitted to the inpatient 
facility of the General Clinical Research Center of the University of Kentucky Hospital. 
Subject's good health was confirmed by interview and brief examination, and urine drug 




subjects were average (SD) age of 25.3 (3.2) years, weight of 74 (13.7) kg, and height of 
175.9 (7.8) cm, and they were split evenly between males and females.  The three control 
subjects were 23.3 (2.1) years of age, 65.8 (11) kg, 173.9 (7.6) cm, and female.  
The morning of NTX gel-patch administration, the subjects had an indwelling i.v. 
catheter placed in an antecubital or forearm vein contralateral to the arm that received 
patch placement.  Before patch administration, a single blood sample was obtained as 
baseline, along with vital signs, and a repeat of the standardized skin examination of the 
test site to document baseline conditions.  Six healthy subjects were treated with two 50 
MN arrays (100 MN insertions per single patch application site) on the hairless 
(nonshaved) upper arm before each patch application (four patch sites and 400 MN 
insertions total per patient).  The same procedure, except omission of MN insertion, was 
used for control subjects.  MN insertion simply means placing the MN array over the skin 
and gently pressing down for a few seconds.  The NTX-gel and patch covering were 
placed over the same area of the skin.  An occlusive dressing was placed over the skin 
site and NTX patches to hold them in place for the study duration.  
After patch administration serial blood samples and vital signs were obtained at 
15, 30, 45, and 60 min and at 1.5, 2, 4, 6, 9, 12, 18, 24, 36, 48, 60, and 72 h after 
administration.  Subjects were queried, using a standardized instrument, regarding any 
pain associated with administration and untoward symptoms from the product.  An 
examination of the skin was conducted when the patch was removed and at 4–6 days 
after administration to detect any irritation, inflammation, discharge, etc., using the 
standardized skin examination format.  A blood chemistry test was repeated to evaluate 




B.5.5. NTX and NTXOL Plasma Assay 
The assay was similar to that published by Valiveti et al. (Valiveti, Nalluri et al. 
2004) The extraction efficiency was 86.0 ± 6.8% for NTX and 78.0 ± 19.6% for NTXOL. 
The limits of quantification for NTX and NTXOL were 1.0 and 0.5 ng/ml, respectively, 
with r 2 > 0.95 for both NTX and NTXOL.  
B.5.6. Assessment of Skin Irritation and Resealing Kinetics 
An additional study was conducted to measure skin irritation and resealing 
kinetics.  Ten human volunteers (seven males, 23–51 years of age) were recruited from 
the Georgia Institute of Technology community.  The protocol was approved by the 
Institutional Review Board at Georgia Institute of Technology and informed consent was 
obtained from the subjects.  
A MN patch (Figure B.3A) was inserted into the volar forearm of the subjects and 
then immediately removed.  Treatment sites were occluded by using an occlusive tape 
(3M Blenderm surgical tape; 3M Healthcare).  The occluded sites were further covered 
with a waterproof dressing (Nexcare absolute waterproof premium adhesive pad; 3M 
Healthcare) and Saran wrap (SC Johnson), which was secured with waterproof tape 
(Nexcare absolute waterproof first aid tape; 3M Healthcare).  
Skin electrical resistance was measured hourly with an impedance meter (EIM-
105 Prep-Check electrode impedance meter; General Devices) modified with a 200-kΩ 
resistor (Ack Electronics) in parallel. Ag/AgCl dry electrodes (Thought Technology T-
3404; Stens) were used as the measurement electrodes for the MN treatment sites.  A 
large electrode with a highly conductive gel (Superior Silver Electrode with PermaGel; 




contribution of the reference site at a negligibly low value.  Resistance measurements 
were made by connecting lead wires to the reference and measurement electrodes, 
respectively.  Immediately after MN insertion and periodically during the study, skin 
irritation was assessed by visually examining the MN-treated sites for erythema, edema, 
and other adverse skin reactions and comparing them with adjacent untreated skin sites.  
B.5.7. Data Analysis 
The pharmacokinetic analysis of NTX and NTXOL plasma-concentration versus 
time profiles after MN treatment and gel patch application was carried out by fitting the 
data to a noncompartmental model with extravascular input (WinNonlin Professional, 
version 4.0; Pharsight).  The data generated after TD application were analyzed by a 
noncompartmental method using WinNonlin.  The steady-state plasma concentration of 
NTX after the application of patches was calculated by using the equation Css = AUC0-
t/time. Clast was the final plasma concentration measured from the 72-h sampling time 
point. The flux constant for human skin was calculated as Js = Css × Cl/A.  The average 
daily dose delivered was calculated as K0 = Css × Cl.  Statistical analysis of the subject 
and pharmacokinetic data obtained after the TD application of the patches was performed 






APPENDIX C: RECOVERY OF SKIN BARRIER PROPERTIES AFTER 
SONICATION IN HUMAN SUBJECTS4 
 
C.1. Abstract 
The SonoPrep ultrasonic skin permeation system is used clinically to increase 
skin permeability for rapid, noninvasive delivery of local anesthetics.  This study tested 
the hypothesis that sonication can generate a long-lived increase of skin permeability for 
continuous transdermal drug delivery and diagnostic metabolite extraction. To 
accomplish this, the volar forearm skin of ten healthy adult subjects was sonicated.  As a 
surrogate measure of skin permeability, skin electrical impedance was measured at 
occluded and nonoccluded sites every hour over a period of 48 h.  Sonication 
dramatically increased skin permeability, as demonstrated by a large drop in skin 
impedance. Under occlusion, sonicated skin remained highly permeable during the entire 
42-h period of occlusion, which was followed by an immediate decrease in permeability 
upon removal of occlusion.  Without occlusion, sonicated skin retained elevated 
permeability throughout the 48-h experiment, but regained its barrier function more 
quickly.  Therefore, sonication can increase skin permeability for prolonged periods of 
time, especially under the effect of occlusion, and has potential to facilitate continuous 
transdermal drug delivery and diagnostic metabolite extraction. 
 
 
                                                 
4 This work is in press as Gupta, J and Prausnitz, MR, “Recovery of skin barrier properties after sonication 





Transdermal drug delivery is severely limited by the low permeability of stratum 
corneum (Prausnitz, Mitragotri et al. 2004).  Although transdermal delivery has grown 
into a multibillion dollar industry over the past 25 years, this industry is based on fewer 
than 20 drugs that can currently be delivered across the skin (Prausnitz, Mitragotri et al. 
2004).  Sonication using low-frequency ultrasound has been shown to create openings in 
the stratum corneum (Wu, Chappelow et al. 1998) and to increase skin permeability for 
transdermal delivery of several classes of drugs including insulin, lidocaine, tetanus 
toxoid antigen and low molecular weight heparin, as well as extraction of interstitial fluid 
metabolites for glucose sensing (Kost, Mitragotri et al. 2000; Katz, Shapiro et al. 2004; 
Mitragotri and Kost 2004).  To further assess the clinical utility of this approach, this 
study tested the hypothesis that sonication can generate a long-lived increase of skin 
permeability for continuous transdermal drug delivery and diagnostic metabolite 
extraction.  This is the first human study to assess permeability of sonicated skin for more 
than one day and the first to compare skin recovery with and without occlusion.  
Sonication was carried out in this study using the SonoPrep ultrasonic skin permeation 
system, which is the only low-frequency ultrasound device that is FDA approved for 
transdermal drug delivery (Farinha, Kellogg et al. 2006).  This device transmits ultrasonic 
energy to the skin through an aqueous medium, which generates cavitation bubbles at the 
skin surface that create transport pathways across the stratum corneum. SonoPrep has 
been approved by the FDA as a pretreatment to premeabilize the skin for rapid delivery 
of local anesthetics.  In this study, skin permeability was monitored after sonication by 




skin’s barrier properties and has been shown to correlate with skin permeability for a 
variety of compounds over a broad range of impedance values (Karande, Jain et al. 
2005). 
C.3. Materials and Methods 
Ten healthy adult human subjects (3 female, 7 male, age 24 to 52 y) with no 
history of dermatological disease provided informed consent to participate in the study, 
which was approved by the Georgia Tech Institutional Review Board.  Two sites were 
identified on the right volar forearm of each subject, one of which was occluded (skin 
made impermeable to air and moisture by covering with surgical tape and dressings) 
during the study and the other was nonoccluded (uncovered skin).  After measuring 
pretreatment skin impedances, the identified sites were sonicated by briefly applying low-
frequency (55 kHz) ultrasound (intensity = 15 W/cm2) until the skin was permeabilized, 
as determined by the inbuilt mechanism in the device (SonoPrep; Sontra Corporation, 
Franklin, MA).  The occluded sites were unoccluded during the sonication procedure 
followed by immediate occlusion after treatment.  Hourly impedance measurements were 
taken at each site over a period of 48 h.  Occluded sites remained covered during the 
impedance measurement process.  After the 42nd hour reading, the occlusive dressings 
were removed and all sites remained nonoccluded for the final 6 h.  Subjects were 
divided into two groups of five individuals each.  The first group provided data for time 
points 1-11 and 23-35 h, and the second group provided data for time points 12-22 and 
36-48 h.  Both groups also provided data for time points –1, –0.5 and 0 h (immediately 
after treatment).  Throughout each data collection period, subjects remained seated in the 




measurements (EIM-105 Prep-Check, 30 Hz, modified with a 200 kΩ resistor in parallel; 
General Devices, Ridgefield, NJ) were made using Ag/AgCl dry electrodes (Thought 
Technology T-3404, Stens Corporation, San Rafael, CA) placed at each treatment site 
with a Ag/AgCl gelled reference electrode (Superior Silver electrode with PermaGel, 
Tyco Healthcare Uni-Patch, Wabasha, MN) placed approximately 5 mm away. 
C.4. Results and Discussion 
Skin on the volar forearm of 10 human subjects was exposed to low-frequency 
ultrasound using a SonoPrep sonication device (Figure C.1a).  Visual inspection of the 
skin immediately before (Figure C.1b) and after (Figure C.1c) sonication showed no 
differences other than formation of a slight circular indentation because of pressing the 
sonication hand piece against the skin.  This indentation disappeared within 1 h and no 
erythema or edema was observed at any time on the skin surface for both occluded and 
nonoccluded skin (Figure C.1d).  There were no adverse events and the treatment was 
well tolerated by all subjects.  As a surrogate measure of skin permeability, the electrical 
impedance of skin was measured before, immediately after and hourly for 48 h after 
sonication.  During this time, the skin was either nonoccluded or was occluded for 42 h 
and then nonoccluded for the remaining 6 h.  Immediately after sonication, skin 
impedance dropped dramatically from pre-treatment values (>200 kΩ-cm2) to less than 
10 kΩ-cm2 (Figure C.2).  This impedance drop signifies a large increase in skin 
permeability.  Although no drugs were delivered in this study, previous studies suggest 
that skin with such a low impedance corresponds to skin permeability increased by orders 
of magnitude that should be sufficient for delivery of hydrophilic molecules and even 





Figure C.1: Sonication of the skin. (a) Sonication was carried out by applying a 
hand piece containing ultrasound coupling medium to the subject’s volar forearm 
skin.  A reference sensor clasped in the subject’s hand helped determine the 
duration of sonication by interacting with the main control console.  Photographs of 
a representative sonicated skin site are shown (b) immediately before sonication, (c) 
immediately after sonication and (d) 24 h after sonication.  No erythema, edema or 
adverse events were associated with sonication at any time.  Only a transient skin 
indentation caused by application of the hand piece was observed immediately after 
sonication (c). 
The primary goal of this study was to assess the longevity of increased skin 
permeability after sonication.  Over the 48-h experiment, skin impedance values steadily 
increased for both the occluded and nonoccluded sites, although the increase was slower 
for the occluded case (Figure C.2).  Statistical analysis at each time point using a paired t-
test with 95% confidence interval revealed that impedance of the occluded sites remained 
indistinguishable from the initial post sonication impedance value for up to 42 h.  These 




sonication as a skin pretreatment for electrophysiology measurements (Farinha, Kellogg 
et al. 2006) and another 24-h study measuring extraction of interstitial glucose after 
sonication (Kost, Mitragotri et al. 2000).  This long-lived effect suggests that transdermal 
delivery from an occlusive patch applied to sonicated skin could persist at high levels for 
at least 42 h. Upon removal of occlusion after the 42nd hour, the impedance jumped and 
was significantly different from the initial post sonication impedance.  This suggests that 
upon removal of an occlusive transdermal patch from sonicated skin, the skin barrier can 
rapidly begin to recover.  We hypothesize that this slow skin barrier recovery under 
occlusion is caused by the reduced transepidermal water loss under occlusive skin 
conditions. Previous studies have shown that stratum corneum barrier repair is mediated 
by the formation of a water gradient in the skin caused by increased transepidermal water 
loss through the compromised skin barrier (Grubauer, Elias et al. 1989).  In this way, 
occluded skin is more slowly repaired and removal of occlusion creates a water gradient, 
allowing normal repair to occur.  In contrast, the nonoccluded sites regained their 
impedance more rapidly and were significantly different from the initial post sonication 
impedance within 7 h.  However, even after the 7-h period, the impedance was still much 
lower than that of intact skin and thus, the sites could potentially be permeable to, for 
example, smaller molecules. Experimental and theoretical studies of transport across 
sonicated cadaver skin indicate that as skin impedance increases, permeability decreases 
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Figure C.2: Average skin impedance for occluded ( ) and nonoccluded ( ) skin 
before and after ultrasound treatment, which was carried out at t = 0.  Nonoccluded 
skin remained nonoccluded throughout the experiment.  Occluded skin remained 
occluded until t = 42 h, after which skin was nonoccluded for the final 6 h.  
Immediately after sonication, skin impedance dropped dramatically from 
pretreatment values (>200 kΩ-cm2) to less than 10 kΩ-cm2, indicating an increase in 
skin permeability.  Skin impedance recovered slowly over time, but the occluded 
sites recovered more slowly than nonoccluded sites.  Upon removal of occlusion at t 
= 42 h, skin impedance rapidly jumped higher.  Data are presented as the average of 
n = 10 samples (t < 0) or n = 5 samples (t ≥ 0) with standard deviation error bars. 
Thus, even though macromolecule delivery may be reduced beyond 7-h post 
sonication, nonoccluded skin could still be used for delivery of small molecules.  This 
presents opportunities for long-term delivery, but also presents safety concerns after 
short-term delivery, because of residual permeability after a transdermal delivery 
procedure is completed.  These results can guide the use of sonication for both short-term 
and long-term transdermal delivery applications.  SonoPrep is currently approved as a 
pretreatment before short-term delivery of local anesthetics over a time course of a few 
minutes under typically nonoccluded conditions, although the anesthetic formulation 




impedance, corresponding to a large increase in skin permeability, are consistent with this 
demonstrated application.  However, the persistence of increased skin permeability for 
hours after delivery of the local anesthetic is complete suggests that patients and clinical 
personnel should take care to prevent unintentional absorption of exogenous materials 
during that time.  For long-term delivery from an occlusive transdermal patch, our data 
suggest that drug delivery can persist at relatively steady levels for at least 42 h.  Animal 
studies have demonstrated delivery of a variety of drugs, including that of insulin 
(Mitragotri and Kost 2004; Park EJ, Werner J et al. 2007), heparin (Mitragotri and Kost 
2004) and tetanus toxoid antigen (Tezel, Paliwal et al. 2005).  Thus, a sonication 
pretreatment could be followed by sustained-release delivery of drugs and vaccines from 
a patch.  Similarly, noninvasive glucose monitoring has been demonstrated in diabetic 
subjects via interstitial glucose extraction from sonicated skin (Kost, Mitragotri et al. 
2000).  Our data suggest that continuous monitoring for at least one day may be possible 
after a single ultrasound pretreatment.  In conclusion, skin impedance measurements in 
this study showed that skin permeability can be dramatically increased by sonication and 
that elevated skin permeability can persist for at least 42 h under occlusion.  Skin 
permeability recovered more rapidly without occlusion. 
This suggests that sonication can be used as a pretreatment to generate a long-
lived increase of skin permeability for continuous transdermal drug delivery and 
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